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AUC	 	 Analytical	Ultracentrifugation	 	
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Staphylococcus	 aureus	 is	 a	 versatile	 and	 potentially	 dangerous	 human	
pathogen.	 One	 of	 the	 traits	 of	 S.	 aureus	 that	 is	 crucial	 for	 its	 survival	 during	
pathogenesis	is	its	ability	to	quickly	adapt	to	changes	in	the	microenvironment,	
including	an	ability	to	adapt	to	the	limited	availability	of	micronutrients	such	as	
biotin.	 Biotin	 is	 a	 co-factor	 required	 for	 important	metabolic	 enzymes	 such	 as	
pyruvate	carboxylase	(PC)	and	acetyl	CoA	carboxylase	(ACC).	In	certain	bacteria	
like	S.	aureus,	the	protein	that	is	responsible	for	managing	biotin	homeostasis	is	
the	biotin	 retention	protein,	BirA	 (also	known	as	biotin	protein	 ligase	or	BPL).	
BirA	 is	 a	 bi-functional	 protein	 that	 serves	 as	 both	 the	 enzyme	 responsible	 for	
protein	 biotinylation	 and	 a	 transcriptional	 repressor	 that	 regulates	 biotin	
biosynthesis	and	import.		
Escherichia	 coli	 BirA	 (EcBirA)	 has	 been	 well	 studied,	 however,	 less	
extensive	studies	have	been	performed	on	S.	aureus	BirA	(SaBirA).	Whilst	EcBirA	
regulates	 transcription	 of	 the	 biotin	 biosynthesis	 operon	 (bioO),	 SaBirA	 has	
multiple	 targets	 including	 bioO,	 the	 biotin	 transporter	 (SabioY)	 and	 genes	
involved	 in	 fatty	 acid	 synthesis	 (SayhfS-SayhfT).	 For	 both	 EcBirA	 and	 SaBirA,	
homodimerization	is	a	pre-requisite	for	DNA	binding	and	subsequent	repressor	
activity.	 In	 the	 absence	 of	 protein	 requiring	 biotinylation,	 and	 when	 cellular	
demand	for	biotin	is	low,	BirA	will	dimerize,	bind	to	its	target	DNA	and	repress	
expression	 of	 biotin	 biosynthetic	 enzymes.	 Previous	 studies	 in	 our	 laboratory	
revealed	clear	differences	between	EcBirA	and	SaBirA.	One	of	these	differences	
is	 that	 dimerization	 and	 DNA	 binding	 of	 EcBirA	 only	 takes	 place	 when	 the	
protein	 is	 in	 complex	 with	 the	 reaction	 intermediate	 biotinyl-5ʹ-AMP	 (i.e.	 the	




I	 hypothesized	 that	 there	 are	 clear	 distinctions	 in	 the	 DNA	 binding	
interaction	between	SaBirA	and	the	well-studied	EcBirA.	These	differences	allow	
S.	aureus	 to	elegantly	orchestrate	biotin	synthesis	and	 transport	 in	response	 to	
external	 biotin	 availability.	 	 This	 study	 aims	 to	 define	 SaBirA-regulated	 gene	
expression	 using	 in	 vitro	 and	 in	 vivo	 methods.	 In	 addition,	 the	 effect	 of	
extracellular	biotin	concentration	on	biotin	uptake	and	gene	expression	in	both	
S.	aureus	and	E.	coli	were	also	investigated	in	this	study.	The	result	showed	that	





difficult	 to	 genetically	 manipulate	 this	 bacteria.	 To	 overcome	 this	 problem,	
reporter	strains	were	constructed	in	E.	coli	containing	chromosomally	integrated	
SaBirA	 and	EcBirA,	 as	 well	 as	 their	 target	 promoters	 fused	 to	 a	 lacZ	 reporter	
gene.	 	 Here	 I	 confirmed	 that	 birA	 from	 both	 bacteria	 are	 biotin-responsive	
transcription	 factors.	 Moreover,	 based	 on	 the	 dimerization	 constant	 of	 	 apo-
SaBirA	 	 (KD2-1	 =	 30	 μM)	 and	 apo-EcBirA	 (KD2-1	 =	 2	 mM),	 and	 the	 predicted	






promoters,	 whereas	 EcBirA	 R119W	 was	 devoid	 of	 repressor	 activity.	 These	
results	were	 confirmed	 in	vitro	 by	 gel-shift	 assays.	Cross-linking	 studies	 added	
further	 evidence	 that	DNA	 promotes	 dimerization	 of	 SaBirA	 F123G,	 but	 not	E.	
coli	 R119W.	 	 In	vitro	 analysis	 also	 revealed	 the	 affinity	 for	DNA	binding	varies	
between	 SaBirA-target	 promoters.	 This	 suggested	 a	 hierarchy	 of	 SaBPL	
regulated	genes,	with	the	biotin	biosynthesis	operon	being	the	most	responsive	
to	 exogenous	 biotin	 concentration.	 Taken	 together,	 the	 outcomes	 from	 in	 vivo	
and	in	vitro	analyses	performed	in	this	study	have	validated	the	hypothesis	that	
SaBirA	 uses	 different	 DNA	 binding	 mechanisms	 to	 EcBirA.	 As	 a	 consequence,	
SaBirA	 provides	 S.	 aureus	 with	 one	 avenue	 to	 adapt	 in	 response	 to	 its	
environment.		
	 Finally,	 this	 study	 also	 investigated	 the	 role	 of	 a	 novel	SaBirA	 inhibitor,	
BPL199,	 as	 a	 co-repressor	 in	DNA	binding	and	 its	 effect	on	gene	 transcription.	
Quantitative	Real-Time	PCR	experiments	revealed	that	BPL199	was	able	to	act	as	
a	 co-repressor	 to	 down-regulate	 expression	 of	 biotin-regulated	 genes	 in	 vivo,	
with	 similar	 kinetics	 as	 biotin.	 EMSA	 analysis	 showed	 that	 the	 affinity	 of	
SaBPL:BPL199	 for	 DNA	 binding	 was	 similar	 to	 that	 of	 the	 natural	 substrate,	
biotinyl-5ʹ-AMP.	 This	 supported	 the	 proposal	 that	BPL199	 successfully	mimics	
the	action	of	biotinyl-5ʹ-AMP	in	initiating	transcriptional	repression.	In	addition,	
a	 BPL199-resistant	 strain	 of	 S.	 aureus	 	 generated	 in	 our	 laboratory,	 was	 also	
investigated.	 DNA	 sequencing	 revealed	 a	 single	 point	 mutation	 in	 SaBirA	
(D200E)	 that	 mapped	 within	 its	 dimerization	 interface.	 The	 ability	 of	 SaBirA	
D200E	 to	 bind	 DNA,	 and	 down	 regulate	 gene	 expression,	 was	 subsequently	
addressed.	 The	 results	 indicated	 that	 SaBirA	 D200E	 was	 compromised	 in	 the	
SaBirA:DNA	 interaction	 in	 vivo.	 The	 most	 susceptible	 target	 was	 the	 	 SabioY	
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The	 thesis	will	be	presented	as	a	 combination	one	published	 literature	 review,	
one	manuscript	to	be	submitted	for	publication	as	well	as	conventional	chapters.	
Each	 manuscript	 will	 be	 a	 chapter	 with	 its	 own	 references.	 A	 general	
introduction	and	discussion	will	also	be	included	to	link	together	all	the	research	
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S.	aureus	 is	 a	member	of	 	micrococcaceae	 family	 of	 bacteria	with	 typical	
gold	pigmentation	as	 their	distinctive	attribute.	As	a	consequence,	 they	are	often	
referred	 to	 as	 “golden	 staph”.	S.	aureus	 is	 one	 of	 the	most	 potentially	 dangerous	
human	 pathogens.	 S.	 aureus	 can	 quickly	 adapt	 to	 changes	 in	 their	 environment,	
allowing	 them	 to	 survive	 in	 a	 wide	 variety	 of	 niche	 microenvironments,	 to	
circumvent	 host	 immune	 responses	 and	 avoid	 antibiotic	 assault.	 	 S.	 aureus	
infection	can	cause	severe	disorders	affecting	skin,	respiratory	organs,	soft	tissues,	
bones,	joints	and	the	endovascular	system.	Life	threatening	S.	aureus	infection	such	
as	 bacteremia,	 toxic	 shock	 syndrome,	 sepsis	 and	 endocarditis	 contribute	 to	 high	
mortality	 rates	 in	 hospitals	 and	 the	wider	 community	 (reviewed	 in	 [1]).	 During	
2014-2015,	 there	were	 1490	 cases	 of	 bacteremia	 infection	 reported	 in	Australia	
[2].	 The	United	 States	 Center	 for	Disease	 Control	 have	 reported	 that	 there	were	
11285	death	and	80461	severe	infections	related	to	S.	aureus	infections	in	2013	in	
the	United	States	[3].	In	addition,	a	study	conducted	on	1000	hospitalized	patients	





nosocomial	 and	 community-acquired	 infection	 that	 has	 developed	 resistance	 to	





Centre	 for	 Disease	 Control	 first	 reported	 vancomycin	 resistant	 MRSA	 in	 US	
patients	 [9].	 Similar	 resistance	 profiles	 were	 also	 identified	 in	 Japan	 [9].	 Since	
these	 first	 reports	 of	 the	 emergence	 of	 vancomycin	 resistance,	 cases	 from	 other	
countries	 such	 as	Thailand	 [10],	 China	 [11]	 and	more	 cases	 in	 the	United	 States	
[12],	have	been	reported.	These	findings	strongly	indicate	the	possibility	of	MRSA	
to	 acquire	 additional	 resistance	 in	 the	 future	 and	 highlight	 the	 need	 for	 new	
antibiotics	to	treat	MRSA	infection.		
	Moreover,	 it	 is	 undeniable	 that	 antibiotic	 resistance	 has	 become	 a	major	
challenge	 for	 our	 public	 health	 care	 systems.	 Increased	 costs,	 longer	
hospitalization,	as	well	as	increased	mortality	rates	are	all	attributed	to	antibiotic	
resistance	 [13].	 One	 prevailing	 approach	 to	 combating	 antibiotic	 resistance	 is	 to	
develop	 new	 antibiotics	 that	 are	 not	 subject	 to	 existing	 resistance	 mechanisms.	
Despite	the	effort	of	major	pharmaceutical	companies	and	academic	researchers	to	
discover	new	classes	of	antibiotics,	only	four	new	classes	of	antibiotics	have	been	
launched	 in	 the	 last	 40	 years	 [14].	 	 Most	 antimicrobials	 in	 the	 development	
pipeline	 are	 next	 generation	 analogues	 of	 existing	 scaffolds	 for	 which	 there	 are	
already	 pre-existing	 resistance	 mechanisms	 [15].	 The	 discovery	 of	 new	
chemotherapies	is	underpinned	by	basic	research	into	unexplored	antibiotic	drug	
targets	 that	 are	 not	 employed	 by	 current	medicines.	 This	 thesis	 investigates	 the	




Biotin	 (also	 known	 as	 vitamin	 H	 or	 B7)	 is	 an	 important	 water-soluble	





the	 first	 committed	step	 in	 fatty	acid	synthesis	 [16].	This	metabolic	pathway	has	
been	shown	to	be	essential	in	a	number	of	microorganisms	(reviewed	in	[17])	and	
has	been	the	subject	to	numerous	antibiotic	discovery	projects	(reviewed	in	[18]).	
As	 well	 as	 possessing	 ACC,	 S.	 aureus	 has	 a	 second	 biotin-dependent	 enzyme,	







A	 study	 conducted	 by	 Gretler	 and	 co-workers	 [26]	 reporter	 that	 38	 out	 of	 46	
coagulase	negative,	clinical	 isolates	of	S.	aureus	 	had	an	absolute	requirement	 for	
biotin	 in	 the	 growth	 media	 whereas	 8	 other	 strains	 failed	 to	 reach	 maximum	
growth	 in	 the	 absence	 of	 biotin.	 In	 addition,	 a	 study	 conducted	 by	Mah	 and	 co-
workers	 [27]	 suggested	 that	 biotin	was	 essential	 in	 supporting	 the	 growth	 of	 S.	
aureus		S-6	strain,	when	glutamic	acid	was	used	as	a	carbon	source	as	opposed	to	
glucose.	This	observation	suggests	 that	 in	 its	natural	environment,	when	glucose	
may	be	 limited,	 the	 ability	of	S.	aureus	 to	maintain	 the	 supply	of	biotin	becomes	
critical	for	survival.	Based	on	the	findings	outlined	above,	 it	 is	evident	that	biotin	
plays	 a	 significant	 role	 in	 S.	 aureus	 growth,	 and	 deprivation	 of	 biotin	 might	 be	
lethal	 to	 certain	 strains	 of	 S.	 aureus.	 The	 biotin	 utilization	 therefore	 serves	 as	
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potential	 targets	 for	 new	 antibiotic	 development	 against	 S.	 aureus.	 In	 addition,	
recent	 studies	 have	 shown	 a	 strong	 correlation	 between	 biotin	 availability	 and	
virulence	 in	 Francisella	 novicida	 [28,	 29]	 and	 E.	 coli	 [30].	 However,	 the	 role	 of	
biotin	in	S.	aureus	virulence	has	not	yet	been	investigated.	
	 Bacteria	 such	 as	E.	 coli	and	 S.	aureus	 satisfy	 their	 biotin	 demand	 through	
two	 alternative	 mechanisms,	 de	 novo	 synthesis	 and	 import	 from	 exogenous	
sources	 through	 the	 action	 of	 a	 biotin	 transport	 system.	 On	 the	 other	 hand,	
humans	 and	 other	mammals	 are	 auxotrophic	 for	 biotin	 due	 to	 the	 absence	 of	 a	
biotin	biosynthesis	pathway	and	rely	solely	on	biotin	uptake	from	dietary	sources.	
This	clear	distinction	between	human	and	microbes	suggests	that	biotin	metabolic	
pathways	 are	 promising	 targets	 for	 new	 antibiotic	 discovery	 [31].	 The	 biotin	
synthesis	pathway	is	well	characterized	in	E.	coli	and	Bacillius	subtilis,	as	described	
by	Lin	and	Cronan	[32].	The	first	stage	involves	the	synthesis	of	a	pimelate	moiety,	
which	provides	most	of	 the	biotin	carbon	atoms.	The	reactions	 leading	up	 to	 the	
production	 of	 pimelate	 are	 catalyzed	 by	 two	 different	 enzymes,	 encoded	 by	 the	
bioC	 and	 bioH.	 The	 second	 stage	 of	 the	 synthesis	 involves	 the	 assembly	 of	 the	
bicyclic	rings	as	illustrated	in	Figure	1.	The	second	stage	of	biotin	synthesis	starts	
with	 the	 conversion	 of	 pimelate	 thioester	 to	 7-keto-8-aminopelargonic	 acid	
(KAPA)	by	the	action	of	KAPA	synthase	that	is	encoded	by	the	bioF	gene.	7-keto-8-
aminopelargonic	 acid	 is	 then	 transformed	 into	 7,8-diamino-pelargonic	 acid	
(DAPA)	 by	 DAPA	 synthase	 encoded	 by	 bioA.	 Next,	 dethiobiotin	 (DTB)	 is	 then	
formed	 from	DAN	and	CO2	 in	 a	 reaction	 catalyzed	by	DTB	 synthase,	 encoded	by	
bioD.	Finally,	the	thiophene	ring	of	biotin	is	closed	using	S-adenosyl	methionine	in	
a	 reaction	 catalyzed	 by	 biotin	 synthase,	 encoded	 by	 bioB.	 In	 bacteria,	 these	
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enzyme-encoding	 genes	 are	 often	 clustered	 into	 an	 operon	 known	 as	 the	 biotin	
Operon	or	bioO.	




onto	 target	 enzymes	 such	 as	 PC	 and	 ACC.	 An	 introduction	 to	 BirA	 and	 BirA-
regulated	 transcriptions	 is	 discussed	 in	 more	 detail	 in	 the	 next	 section	 and	 the	





Biotin	 is	 synthesized	 from	 pimelate	 thioester	 in	 a	 four-enzymes	 catalyzed	







Biotin	 biosynthesis	 is	 an	 expensive	 metabolic	 event.	 At	 least	 4	 gene	
products	 and	 an	 estimated	 20	 ATP	 equivalents	 are	 required	 to	 synthesize	 one	
biotin	 molecule	 [28].	 Therefore,	 biotin	 biosynthesis	 needs	 to	 be	 stringently	
regulated.	As	mentioned	above,	in	S.	aureus	and	E.	coli	biotin	synthesis	is	regulated	
through	 the	 action	 of	 the	 bifunctional	 protein,	 BirA.	 In	 S.	 aureus,	 bioinformatics	
analysis	predicted	that	BirA	also	regulates	the	expression	of	a	biotin	transporter,	
BioY	(SabioY),	as	well	as	two	other	genes	involved	in	fatty	acid	metabolism,	namely	
SayhfS-SayhfT	 (homologs	 of	 acetyl-CoA-acetyl	 transferase	 and	 Fatty	 acid-CoA	
ligase,	 respectively)[33].	 However,	 this	 has	 not	 yet	 been	 demonstrated	
experimentally.		
A	detailed	review	of	the	relevant	literature	discussing	the	different	classes	
of	 BirA,	 the	 bi-functional	 properties	 of	 class	 II	 BirA	 and	 the	 regulatory	 switch	
between	the	two	functions	is	presented	as	a	published	manuscript	and	is	attached	
to	 this	 chapter.	 This	 review	 provides	 the	 background	 literature	 about	 the	 BirA	




Targeting	 essential	 metabolic	 pathways	 present	 in	 bacteria	 is	 one	 well	
accepted	approach	to	the	discovery	of	new	antibiotics	 [34].	 In	particular,	vitamin	
biosynthesis	 pathways	 serve	 as	 attractive	 targets	 for	 new	 antibiotics.	 Vitamins	
such	 as	 thiamine,	 riboflavin	 and	 folic	 acid	 have	 all	 been	 the	 focus	 for	 antibiotic	
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development	 (reviewed	 in	 [35]).	 As	 biotin	 is	 an	 essential	 vitamin,	 targeting	
metabolic	 pathways	 where	 biotin	 is	 utilized	 as	 a	 co-factor	 would	 also	 serve	 as	
promising	targets	for	antibiotic	development.			
	 Recent	 research	 in	 our	 group	 has	 focused	 on	 developing	 new	 antibiotics	
that	 target	 BirA	 from	 S.	 aureus	 [36,	 37].	 Chemical	 analogues	 of	 biotin,	 or	 the	
biotinylation	 reaction	 intermediate,	 biotinyl-5ʹ-AMP	 [36-41],	 provide	 valuable	








The	 role	of	EcBirA	as	 a	 transcriptional	 regulator	has	been	 the	 subject	 of	
many	studies	over	 the	years	 (reviewed	 in	 [42-44]).	The	molecular	mechanism	of	
DNA-binding	 and	 the	 regulatory	 switch	 between	 transcriptional	 repressor	 and	
enzyme	function	of	EcBirA	have	been	well	characterized.	However,	the	function	of	
SaBirA	as	a	transcriptional	regulator	has	not	been	as	well	studied.		Recent	findings	















to	 the	 pathogen’s	 rapid	 ability	 to	 adapt	 and,	 therefore,	 may	 play	 a	 crucial	 role	
during	pathogenesis.	This	hypothesis	warrants	a	more	detail	investigation	into	the	
mechanism	 of	 DNA-binding	 and	 biotin-regulated	 gene	 expression.	 In	 addition,	
understanding	 this	 transcriptional	 regulation	would	 also	 contribute	 positively	 to	
the	future	design	of	antibiotics	targeting	SaBirA	,	as	favourable	compounds	would	
simultaneously	inhibit	BPL	activity	whilst	also	serving	as	co-repressors.		
	 	The	 aim	 of	 this	 study	 is	 to	 characterize	 the	 transcriptional	 repressor	












that	 constrains	 the	 uptake	 of	 foreign	 DNA,	 resulting	 in	 poor	 transformation	
efficiency.	As	an	alternative,	an	E.	coli	reporter	system	was	developed	in	order	to	
facilitate	the	interaction	of	SaBirA	with	DNA	in	an	In	vivo	model.	The	construction	
of	 these	 reporter	 strains	 and	 the	 development	 of	 a	 biotin-regulated	 β–
galactosidase	 expression	assay	are	discussed	 in	chapter	 3.	This	 system	was	also	
utilized	 in	 the	 characterization	 of	 SaBirA	 inhibitor,	 BPL199,	 as	 discussed	 in	
chapter	5.	
	
Aim	 2:	 To	 Investigate	 the	 effect	 of	 biotin	 on	 S.	 aureus	 growth	 and	
characterization	of	SaBirA	as	a	transcriptional	repressor	
	 The	effect	of	biotin	on	the	growth	of	S.	aureus	NCTC	8325,	was	investigated.	
In	 addition,	 characterization	 of	 SaBirA	 as	 a	 transcriptional	 regulator	 was	 also	







	 As	 discussed	 above,	 inhibitors	 designed	 to	 target	 SaBirA	 have	 not	 been	
characterized	with	regards	to	their	effect	on	DNA	binding.	In	this	part	of	the	study,	
lead	compound	BPL199	was	tested	for	its	effect	on	SaBirA’s	DNA	binding	function	
and	consequently,	 its	 impact	on	gene	regulation.	 In	addition,	a	BPL199-	resistant	
mutant	generated	in	our	laboratory	was	characterized.	The	in	vitro	and	in	vivo	DNA	
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binding	 properties	 of	 this	 mutant	 were	 also	 investigated,	 to	 delineate	 the	





























2.	 Bacteraemia	 in	 Australian	 public	 hospitals	 2014-2015.	 2015,	 Australian	
government:	 Australian	 Institute	 of	 Health	 and	 Welfare.	 p.	
http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6012955423
3.	
3.	 Antibiotic	 resistance	 threats	 in	 the	United	 states,	 2013.	 .	 US	 department	 of	
Health	and	Human	services	(Centers	for	Disease	Control	and	prevention).	





6.	 Koyama,	 N.,	 Inokoshi,	 J.,	 Tomoda,	 H.,	 Anti-infectious	 agents	 against	MRSA.	
Molecules,	2012.	18:	p.	204-224.	
7.	 Tomasz,	 A.,	 Multiple-	 Antibiotic-Resistant	 Pathogenic	 Bacteria.	 The	 New	
England	Journal	of	Medicine,	1994.	330:	p.	1247-1251.	
8.	 Responding	to	the	threat	of	antimicrobial	resistance:	Australia’s	first	national	
antimicrobial	 resistance	 strategy	 2015-2019.	 Departments	 of	 Health	 and	
Agriculture,	Australian		Government,		June		2015.	.	
9.	 Hiramatsu,	 K.,	 Hanaki,	 H.,	 Ino,	 H.,	 Yabuta.,	 T.,	 Oguri,	 T.,	 Tenover,	 F.C.,	
Methicillin-resistant	 Staphylococcus	 ausreus	 clinical	 strain	 with	 reduced	
vancomycin	susceptibility.	.	J.	Antimicrob.	Chemother.,	1997.	40:	p.	135-136.	
10.	 Trakulsomboon,	S.,	et	al.,	First	report	of	methicillin-resistant	Staphylococcus	
aureus	 with	 reduced	 susceptibility	 to	 vancomycin	 in	 Thailand.	 J	 Clin	
Microbiol,	2001.	39(2):	p.	591-5.	




Guide	 for	 Health	 Departments	 and	 Infection	 Control	 Personnel.	 	 .	 2015,	
Division	of	Healthcare	Quality	Promotion	Centers	 for	Disease	Control	 and	
Prevention:	Atlanta,	GA.	
13.	 Chakravartty,	 V.	 and	 J.E.	 Cronan,	 The	 wing	 of	 a	 winged	 helix-turn-helix	
transcription	 factor	 organizes	 the	 active	 site	 of	 BirA,	 a	 bifunctional	
repressor/ligase.	J	Biol	Chem,	2013.	288(50):	p.	36029-39.	
14.	 Cooper,	A.,	Shlaes,	D,	Fix	the	antibiotics	pipeline.	Nature,	2011.	472:	p.	32.	
15.	 Payne,	 D.J.,	 Gwynn,	 M.N.,	 Holmes,	 D.J.,	 and	 Pompliano,	 D.I.,	Drugs	 for	 bad	
bugs:	 confronting	 the	 challenges	 of	 antibacterial	 discovery.	 Nature	 reviews	
drug	discovery,	2007.	287(21):	p.	21-40.	
16.	 Thampy,	 K.G.,	Formation	of	malonyl	 coenzyme	A	 in	 rat	heart.	 Identification	
and	purification	of	an	isozyme	of	A	carboxylase	from	rat	heart.	 J	Biol	Chem,	
1989.	264(30):	p.	17631-4.	
17.	 Cronan,	 J.E.,	A	new	pathway	of	exogenous	 fatty	acid	 incorporation	proceeds	
by	 a	 classical	 phosphoryl	 transfer	 reaction.	 Mol	 Microbiol,	 2014.	 92(2):	 p.	
217-21.	
	 13	
18.	 Polyak,	 S.W.,	 et	 al.,	 Structure,	 function	 and	 selective	 inhibition	 of	 bacterial	
acetyl-coa	carboxylase.	Appl	Microbiol	Biotechnol,	2012.	93(3):	p.	983-92.	
19.	 Jitrapakdee,	 S.,	 Booker,	 G.	 W.,	 Cassady,	 A.	 I.	 and	 Wallace,	 J.	 C.,	 Cloning,	
sequencing	and	expression	of	rat	liver	pyruvate	carboxylase.	Biochem	J,	1996.	
316	(	Pt	2):	p.	631-7.	




21.	 Pendini,	 N.R.,	 Bailey,	 L.	 M.,	 Booker,	 G.	 W.,	 Wilce,	 M.	 C.,	 Wallace,	 J.	 C.	 and	
Polyak,	 S.	 W.,	 Microbial	 biotin	 protein	 ligases	 aid	 in	 understanding	
holocarboxylase	synthetase	deficiency.	Biochim	Biophys	Acta,	2008.	1784(7-
8):	p.	973-82.	




24.	 Sevag,	M.G.	 and	M.N.	 Green,	The	Mechanism	of	Resistance	 to	Sulfonamides:	
III.	 Pantothenic	Acid	and	Tryptophane	Metabolism:	The	Role	of	Pantothenic	
Acid	in	the	Synthesis	of	Tryptophane	by	Staphylococcus	aureus	and	the	Effect	





26.	 Gretler,	 A.C.,	 Mucciolo,P.,	 Evans,	 J.B.,	 Niven,	 JR.,	 C.F.,	 Vitamin	 nutrition	 of	
staphylococci	with	 special	 reference	 to	 their	biotin	 requirements.	 Journal	 of	
bacteriology,	1955.	70(1):	p.	44-49.	








the	 large	 intestine	 for	 colonization	and	 infection.	 Nat	 Commun,	 2015.	6:	 p.	
6592.	
31.	 Salaemae,	W.,	Azhar,	A.,	Booker,	G.	W.,	 Polyak,	 S.	W.,	Biotin	biosynthesis	 in	
Mycobacterium	 tuberculosis:	 physiology,	 biochemistry	 and	 molecular	
intervention.	Protein	Cell,	2011.	2(9):	p.	691-5.	
32.	 Brune,	 I.,	 Gotker,	 S.,	 Schneider,	 J.,	 Rodionov,	 D.	 A.	 and	 Tauch,	 A.,	Negative	
transcriptional	control	of	biotin	metabolism	genes	by	the	TetR-type	regulator	
BioQ	 in	 biotin-auxotrophic	 Corynebacterium	 glutamicum	 ATCC	 13032.	 J	
Biotechnol,	2012.	159(3):	p.	225-34.	
33.	 Rodionov,	D.A.,	Mironov,	A.	A.	and	Gelfand,	M.	S.,	Conservation	of	the	biotin	
regulon	and	 the	BirA	regulatory	signal	 in	Eubacteria	and	Archaea.	 Genome	
Res,	2002.	12(10):	p.	1507-16.	
	 14	
34.	 Hughes,	 D.	 and	 A.	 Karlen,	 Discovery	 and	 preclinical	 development	 of	 new	
antibiotics.	Ups	J	Med	Sci,	2014.	119(2):	p.	162-9.	
35.	 Mobegi,	 F.M.,	 et	 al.,	From	microbial	gene	essentiality	 to	novel	antimicrobial	
drug	targets.	BMC	Genomics,	2014.	15:	p.	958.	
36.	 Feng,	 J.,	 et	 al.,	 Biotin	 Protein	 Ligase	 Is	 a	 Target	 for	 New	 Antibacterials.	
Antibiotics	(Basel),	2016.	5(3).	




39.	 Soares	da	Costa,	T.P.,	 et	 al.,	Biotin	analogues	with	antibacterial	activity	are	
potent	inhibitors	of	biotin	protein	ligase.	ACS	Med	Chem	Lett,	2012.	3(6):	p.	
509-14.	
40.	 Tieu,	 W.,	 et	 al.,	 Improved	 Synthesis	 of	 Biotinol-5'-AMP:	 Implications	 for	
Antibacterial	Discovery.	ACS	Med	Chem	Lett,	2015.	6(2):	p.	216-20.	
41.	 Tieu,	 W.,	 et	 al.,	 Heterocyclic	 acyl-phosphate	 bioisostere-based	 inhibitors	 of	
Staphylococcus	 aureus	 biotin	 protein	 ligase.	 Bioorg	 Med	 Chem	 Lett,	 2014.	
24(19):	p.	4689-93.	
42.	 Beckett,	 D.,	 Biotin	 sensing:	 universal	 influence	 of	 biotin	 status	 on	
transcription.	Annu	Rev	Genet,	2007.	41:	p.	443-64.	
43.	 Beckett,	 D.,	The	Escherichia	 coli	 biotin	 regulatory	 system:	 a	 transcriptional	
switch.	J	Nutr	Biochem,	2005.	16(7):	p.	411-5.	
44.	 Satiaputra,	 J.,	 Shearwin,	 K.E.,	 Booker,	 G.W.,	 Polyak,	 S.W.,	 Mechanisms	 of	
biotin-regulated	 gene	 expressions	 in	 microbes.	 Synthetic	 and	 Systems	
Biotechnology,	2016(1):	p.	17-24.	
45.	 Xu,	Y.	and	D.	Beckett,	Evidence	for	interdomain	interaction	in	the	Escherichia	
coli	 repressor	 of	 biotin	 biosynthesis	 from	 studies	 of	 an	 N-terminal	 domain	
deletion	mutant.	Biochemistry,	1996.	35(6):	p.	1783-92.	
46.	 Eisenstein,	 E.	 and	 D.	 Beckett,	 Dimerization	 of	 the	 Escherichia	 coli	 biotin	
repressor:	 corepressor	 function	 in	 protein	 assembly.	 Biochemistry,	 1999.	
38(40):	p.	13077-84.	
47.	 Weaver,	 L.H.,	 et	 al.,	 Corepressor-induced	 organization	 and	 assembly	 of	 the	
biotin	 repressor:	 a	 model	 for	 allosteric	 activation	 of	 a	 transcriptional	
regulator.	Proc	Natl	Acad	Sci	U	S	A,	2001.	98(11):	p.	6045-50.	
48.	 Wood,	 Z.A.,	 et	 al.,	 Co-repressor	 induced	 order	 and	 biotin	 repressor	
dimerization:	 a	 case	 for	 divergent	 followed	 by	 convergent	 evolution.	 J	 Mol	
Biol,	2006.	357(2):	p.	509-23.	
49.	 Kwon,	 K.	 and	 D.	 Beckett,	 Function	 of	 a	 conserved	 sequence	motif	 in	 biotin	
holoenzyme	synthetases.	Protein	Sci,	2000.	9(8):	p.	1530-9.	
50.	 Streaker,	E.D.	and	D.	Beckett,	Coupling	of	site-specific	DNA	binding	to	protein	
dimerization	 in	 assembly	 of	 the	 biotin	 repressor-biotin	 operator	 complex.	
Biochemistry,	1998.	37(9):	p.	3210-9.	
51.	 Soares	da	Costa,	T.P.,	et	al.,	Dual	roles	of	F123	in	protein	homodimerization	
and	 inhibitor	 binding	 to	 biotin	 protein	 ligase	 from	 Staphylococcus	 aureus.	
Mol	Microbiol,	2014.	91(1):	p.	110-20.	
52.	 Henke,	 S.K.	 and	 J.E.	 Cronan,	 The	 Staphylococcus	 auresu	 group	 II	 biotin	
protein	ligase	birA	is	an	effective	regulator	of	biotin	operon	transcription	and	













Mechanisms of biotin-regulated gene expression in microbes
J. Satiaputra a, K.E. Shearwin a, G.W. Booker a,b, S.W. Polyak a,b,*
a Department of Molecular and Cellular Biology, School of Biological Science, University of Adelaide, North Tce, Adelaide, South Australia 5005, Australia
b Centre for Molecular Pathology, University of Adelaide, North Tce, Adelaide, South Australia 5005, Australia
A R T I C L E I N F O
Article history:
Received 17 August 2015
Received in revised form 8 January 2016
Accepted 10 January 2016
Available online
A B S T R A C T
Biotin is an essential micronutrient that acts as a co-factor for biotin-dependent metabolic enzymes. In
bacteria, the supply of biotin can be achieved by de novo synthesis or import from exogenous sources.
Certain bacteria are able to obtain biotin through both mechanisms while others can only fulfill their
biotin requirement through de novo synthesis. Inability to fulfill their cellular demand for biotin can have
detrimental consequences on cell viability and virulence. Therefore understanding the transcriptional
mechanisms that regulate biotin biosynthesis and transport will extend our knowledge about bacterial
survival and metabolic adaptation during pathogenesis when the supply of biotin is limited. The most
extensively characterized protein that regulates biotin synthesis and uptake is BirA. In certain bacteria,
such as Escherichia coli and Staphylococcus aureus, BirA is a bi-functional protein that serves as a tran-
scriptional repressor to regulate biotin biosynthesis genes, as well as acting as a ligase to catalyze the
biotinylation of biotin-dependent enzymes. Recent studies have identified two other proteins that also
regulate biotin synthesis and transport, namely BioQ and BioR. This review summarizes the different tran-
scriptional repressors and their mechanism of action. Moreover, the ability to regulate the expression
of target genes through the activity of a vitamin, such as biotin, may have biotechnological applications
in synthetic biology.
© 2016 Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
1. Introduction
Biotin (vitamin H or B7) is an important micronutrient that func-
tions as a cofactor for biotin-dependent enzymes.1 These include
the biotin-dependent carboxylases, decarboxylases and
transcarboxylases, all of which are found in the microbial world. In
the prototypical bacteria Escherichia coli, there is a single biotin-
dependent enzyme, namely acetyl CoA carboxylase, that catalyzes
the first committed step in the fatty acid biosynthesis pathway.2,3
Other examples of biotin-dependent enzymes commonly found
in prokaryotes include pyruvate carboxylase responsible for
replenishing the TCA cycle with oxaloacetate,4 and propionyl CoA
carboxylase required for the metabolism of certain amino acids and
fatty acids.5 Micro-organisms, plants and some fungi are able to syn-
thesize biotin de novo as well as importing it from their environment
through the action of a biotin transport system. In contrast, humans
and other mammals are biotin auxotrophs and rely solely on uptake
from external sources, such as intestinal microflora or the diet.6 This
genetic difference in biotin metabolism between humans and mi-
crobes provides potential drug targets for new antibiotic discovery
(reviewed7). The biotin synthesis pathway is well characterized in
E. coli and Bacillus subtilis and has recently been reviewed.8 In many
bacteria the genes that encode the biotin biosynthetic enzymes are
often clustered into an operon known as the bio operon.9 Briefly,
the synthetic pathway commences with L-alanine and S-adenosyl-
L- methionine being introduced into pimeloyl-ACP by the activities
of 7-keto-8-aminopelargonic acid synthase (encoded by bioF) and
7,8-diaminopelargonic acid synthase (encoded by bioA), respec-
tively, to generate 7,8-diaminopelargonic acid. Dethiobiotin
synthetase (encoded by bioD) and biotin synthase (encoded by bioB)
then catalyze the closure of the ureido and thiophane hetero-
cycles, respectively, liberating biotin.
The de novo synthesis of biotin is metabolically costly, requir-
ing 20 equivalents of ATP for each molecule of biotin and the
activities of at least 4 metabolic enzymes.10 Therefore, transcrip-
tional regulation of the biotin biosynthetic enzymes needs to be
Abbreviations: BCCP, biotin carboxyl carrier protein; BirA, biotin retention protein
A; BPL, biotin protein ligase; EcBirA, Escherichia coli BirA; SaBirA, Staphylococcus aureus
BirA.
* Corresponding author. Department of Molecular and Cellular Biology, School of
Biological Sciences, University of Adelaide, South Australia 5005, Australia. Tel.: +61
8 8313 6042; fax: +61 8 8313 4362.
E-mail address: steven.polyak@adelaide.edu.au (S.W. Polyak).
Peer review under responsibility of KeAi Communications Co., Ltd.
http://dx.doi.org/10.1016/j.synbio.2016.01.005
2405-805X/© 2016 Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Synthetic and Systems Biotechnology 1 (2016) 17–24
Contents lists available at ScienceDirect
Synthetic and Systems Biotechnology




tightly controlled. In the model bacteria E. coli, the balance of biotin
demand versus supply is maintained through the action of the biotin
retention protein A (BirA); a bi-functional protein that is not only
a transcriptional repressor but also serves as the biotin ligase that
catalyzes the attachment of biotin onto the biotin-dependent car-
boxylases. In other microorganisms, such as Corynebacterium
glutamicum and Agrobacterium tumefaciens, there is no BirA homolog
to regulate biotin synthesis and transport. Instead, alternative DNA-
binding proteins perform this function, namely BioQ and BioR
respectively. The mechanisms by which BirA, BioQ and BioR regu-
late biotin biosynthesis and transport will be discussed in this review.
2. BirA is a bi-functional protein
BirA serves as both a transcriptional repressor and the enzyme
responsible for protein biotinylation (outlined in Fig. 1). As both biotin
ligase and transcriptional repressor activities are intimately linked,
we provide an overview of both functions as background for the
reader to understand the sophistication of this elegant system.
Protein biotinylation is achieved through a conserved, two-step re-
action mechanism that is catalyzed by biotin protein ligase (BPL)
in all organisms. In the first partial reaction biotin and ATP are re-
quired to form biotinyl-5′-AMP that serves as both the reaction
intermediate for protein biotinylation and corepressor for tran-
scriptional regulation. The BirA: biotinyl-5′-AMP (holo) enzyme can
then adopt one of two different fates. When the cellular demand
for biotin is low holo BirA can dimerize and bind DNAwhere it func-
tions as the transcriptional repressor of the biotin biosynthesis
operon, thereby inhibiting the synthesis of more biotin. In con-
trast, in the presence of substrate requiring biotinylation the holo
BirA functions as a biotin ligase. Here BPL recognizes and binds to
a biotin carboxyl carrier protein (BCCP) present in the receiving
enzyme that contains the lysine residue targeted for biotinylation.11
Protein biotinylation is an example of a post-translational modifi-
cation that is performed with exquisite specificity. For example, the
E. coli biotin ligase (BirA) modifies just one of the >4000 different
proteins in the bacterial cell.12 Moreover, the biotin cofactor is co-
valently attached onto the side chain of one single, specific target
lysine residue present in the active site of biotin-dependent enzymes.
BPLs from a wide variety of species are able to modify BCCP from
unrelated organisms,13–15 highlighting how highly conserved both
the catalytic mechanism and the protein:protein interactions
between enzyme and substrate have remained throughout evolu-
tion. The possible mechanisms through which BirA can switch
between its two functions are described later in this review.
All BPLs contain a conserved 2-domain catalytic core responsi-
ble for biotinyl-5′-AMP synthesis and protein biotinylation.16 The
greatest divergence between the BPLs is in their N-terminal regions
(see Fig. 2A). Class I BPLs are composed only of the conserved cata-
lytic module that is required for protein biotinylation. Hence, these
are mono functional enzymes. X-ray crystal structures of Class I BPLs
have been reported forMycobacterium tuberculosis19 and Pyrococcus
horikoshii.21 In contrast, the Class II BPLs are truly bi-functional having
both biotin ligase and transcriptional repressor activities due to an
N-terminal DNA binding domain. BirA from E. coli is the most ex-
tensively studied representative of a Class II BPL, having been the
subject of structural, genetic and biophysical studies (reviewed22,23).
Fig. 1. Bifunctional BirA from Escherichia coli. The schematic shows the two alter-
native functions for the protein. The bioO sequence from the biotin biosynthetic operon
is shown below, with the BirA binding sites in bold text and the −10 and −35 se-
quences boxed.
Fig. 2. Biotin Protein Ligase. (A) The relative sizes of the three structural classes of
BPLs are shown. The conserved catalytic region is depicted in blue, the DNA binding
domain of Class II enzymes in red and the proof reading domain in human BPL is
boxed black.17,18 The structures of BPLs fromM. tuberculosis [PDB 3RUX19] and E. coli
[PDB 2EWN20] are highlighted. (B) Schematic overview showing the single protein
model of protein biotinylation and transcriptional regulation in Class II BPLs.




Several recent reports of the homolog from S. aureus (SaBirA) have
appeared in the literature and provide some interesting points of
difference to the prototypical EcBirA that will be elaborated further
below. Genetic knockout studies performed on both E. coli and
S. aureus, among other bacteria, have demonstrated that BirA is an
essential gene product.19,24–26 Therefore, biotin ligases serve as prom-
ising targets for new antibacterials.27–29 Interestingly, a recent study
reported that Francisella novicida expresses both a Class I and Class
II BPL.30 In this bacterium the Class I enzyme functions as the biotin
ligase whereas the Class II homolog is a transcriptional regulator
essential for virulence in mouse infection models. However, this is
exceptional as most bacteria only possess one BPL equivalent. The
Class III BPLs, such as those found in mammals and certain eukary-
otes, contain an extended N-terminal region making them at least
twice the size of the Class II BPLs (Fig. 2A). This extension bears no
sequence or functional similarity to the Class II DNA binding domain.
Recent mutagenic, genetic and biophysical studies have demon-
strated that the N-terminal extension contains a ‘proof reading’
activity to ensure that only the appropriate enzymes are selected
for protein biotinylation.17,18
3. Structural biology delineates the bifunctional activities of
class II BPLs
The X-ray crystal structures of bifunctional Class II BPLs from
E. coli and S. aureus reveal that the proteins are composed of three
discrete domains. The N-terminal domain is a winged helix-turn-
helix motif required for DNA binding. The central and C-terminal
domains form the catalytic core of the enzyme that share high se-
quence homology with BPLs across all three kingdoms of life. The
central domain of BirA is composed of α-helices and β-strands
whereas the C-terminal domain is composed of antiparallel
β-sheets.31 Although the function of the C-terminal domain has not
been elucidated, it is believed that this region of the enzyme con-
tributes to the binding of the BCCP substrate.32 The catalytic site of
the enzyme is located in the central domain, where biotinyl-5′-
AMP synthesis and biotinyl-transfer occur.33 Structural biology has
provided further insights into the BPL catalyzed reaction. The
adenylation of biotin proceeds in a sequential mannerwhereby biotin
binds first to the enzyme followed by ATP, and its subsequent hy-
drolysis produces biotinyl-5′-AMP.20 Comparisons of the crystal
structures of EcBirA in its unliganded (ie apo) and holo forms show
that important conformational changes accompany ligand binding.
Here the biotin-binding loop (amino acids 110–128) undergoes a
disordered-to-ordered transition that closes over the biotin-
binding pocket. This conformational change positions the side chain
of a key tryptophan residue (Trp123) in the active site necessary
for π–π stacking interactions with the adenylate moiety of ATP.20
Amino acids within this loop are also required for protein dimeriza-
tion and, consequently, DNA binding.
Surprisingly, the N-terminal helix-turn-helix domain of EcBirA
is required for both catalytic function and DNA binding. Removal
of the first 64 amino acids (Δ1–64) resulted in a truncated enzyme
that had reduced affinity for biotin and biotinyl-5′-AMP.34 Hence,
long-range interactions through the protein are believed to help sta-
bilize the conformational changes associated with ligand binding.
This observation was supported by recent studies by Chakravartty
and Cronan that showed an E. coli ‘delta wing’ (Δ48–61) mutant
strain resulted in the accumulation of ADP due to the hydrolysis of
ATP.35 These cells exhibited slow growth under low biotin condi-
tions. When the DNA binding domain from an unrelated protein,
OmpR, was fused onto the N-terminus of EcBirA the chimeric protein
restored growth of the E. coli delta wing strain in minimal media
containing low biotin concentrations. The accumulation of ADP was
also no longer observed. The authors propose that the wing in the
helix-turn-helix structure is needed to stabilize the biotin-binding
loop.35 Interestingly, in a recent study on the BirA from B. subtilis,
deletion of the N-terminal region did not compromise enzyme ac-
tivity in vitro36 suggesting that the role of the N-terminus in assisting
catalysis is not conserved among all Class II BPLs. Indeed the re-
combinant expression of truncated B. subtilis BirA was able to
complement a strain of E. coli expressing the N-terminally deleted
EcBirA (Δ1–64).36
The N-terminal DNA-binding domains of both E. coli and S. aureus
BirAs recognize specific palindromic sequences present in the op-
erator site, bioO, upstream of the biotin biosynthesis operon.
Bioinformatics analysis predicted that SaBirA is also responsible for
regulating expression of the biotin transporter bioY and fatty acid
biosynthetic enzymes yhfT and yhfS in S. aureus (summarized in
Fig. 2B).9 The difference in target gene regulation between E. coli and
S. aureus suggests that SaBirA is solely responsible for maintaining
biotin levels within the bacteria by regulating expression of both
biotin synthesis and transport proteins, as well as contributing to
fatty acid synthesis through the transcriptional regulation of yhfT
and yhfS and activation of acetyl CoA carboxylase. This is in con-
trast to E. coliwhere the BirA recognition sequence is only present
in the promoter of the biotin biosynthesis operon. Consequently,
we propose that BirA regulated gene expression is potentially more
responsive to environmental stimuli in S. aureus than the bacterial
model E. coli.
4. BirA dimerization is intimately linked to DNA binding
Homodimerization of EcBirA is a prerequisite for DNA binding.
The binding of BirA to bioO is a co-operative event involving two
BPL subunits and two bioO operator half-sites (Fig. 1).37,38 The more
stable the homodimer, the greater the affinity for DNA.39,40 Muta-
tion of amino acids that reside in the dimer interface of BirA results
in loss of DNA binding activity.41 Sedimentation equilibrium studies
have revealed the dimerization constant (KD) of apo BirA is greater
than 1mM39 and, thus, apo BirA is not likely to dimerize at the phys-
iological concentrations present inside the bacterial cell which have
been estimated at <10 molecules per cell.42 Similarly, biotin-
bound BirA exhibits weak dimerization with a KD of 0.9 mM.39 In
contrast, biotinyl-5′-AMP enhances dimerization free energy by
−4.0 kcal/mol yielding a KD of 1 – 10 μM,39,43,44 suggesting that the
co-repressor acts as an allosteric activator to dimer assembly and
DNA binding.33
The crystal structures of both EcBirA and SaBirA show the dimers
assemble in a side-by-side anti-parallel arrangement such that the
two N-terminal HTHmotifs are aligned for DNA binding.45,46 An X-ray
structure of any Class II BPL in complex with DNA has not yet been
reported. However, molecular modeling studies propose that the
N-terminal domain from one subunit of EcBirA binds to the major
groove of the double helix while the other subunit binds to theminor
groove.47 Mutation of amino acids Ser-32, Arg-33 and Ala-34 in the
DNA-binding α-helices abolishes DNA binding and results in loss
of repression activity.48 In E. coli, two face-to-face promoters drive
expression of the bio operon. The recognition sequence for EcBirA
(bioO) is an inverted repeat that is located in between the two pro-
moters, at the −35 and −10 sites of the operator sequence (Fig. 1).
Circular permutation analysis suggests that the double stranded DNA
might be bent when in complex with EcBirA.47 On the other hand,
small angle X-ray scattering analysis performed on the SaBirA:SabioO
complex proposed that the DNA does not bend for this species.46
Hence, the footprint observed on the DNA is likely smaller for SaBirA
than EcBirA.
5. Co-repressor induces BPL dimerization
Upon binding of the biotinyl-5′-AMP co-repressor, five loops
located within the central domain of EcBirA undergo a




disorder-to-order transition, with three of these loops (amino acids
110–128, 140–146 and 193–199) located in the dimerization
interface.41 When dimerization occurs, an extended intermolecu-
lar β-sheet is formed involving residues 189–195 in the central
domain.49 Following the structural changes induced by biotin, the
biotin-binding loop encases the co-repressor and is stabilized through
a network of hydrophobic interactions50 as well as direct hydro-
gen bonding interactions involving R118.49 Binding of the co-
repressor leads to the ordering of the ATP-binding loop (residues
212–223) and better packing of the biotin-binding loop, which sup-
ports bonding interactions that stabilizes the dimer.20 Therefore, the
biotin-binding loop must fold before dimerization.49 Direct inter-
actions between the two monomers involve amino acids found in
the loops, namely R118, R119 and D197.49
A recent study involving randommutagenesis to generate super-
repressor mutants in E. coli identified an amino acid substitution
with stronger DNA-binding to bioO than wildtype, namely G154 to
aspartate.40 Interestingly, this amino acid is neither located in the
helix-turn-helix motif nor the dimerization interface. This sug-
gests that other residues within the central domain but located
outside of the dimer interface can participate in long-range inter-
actions that stabilize the dimer, resulting in tighter binding to DNA.
No structural data for this mutant has yet been reported to fully un-
derstand these long-range bonding interactions. Likewise, a recent
study focused on G142 that is present in the dimer interface but
that does not directly contribute to dimerization.51 Substitution of
G142 with alanine altered the structure of the 140–146 loop, and
this in turn prevented the 193–199 loop from undergoing the
disordered-to-ordered transition through long-range interactions.
Together these studies highlight the importance of long-range al-
losteric interactions on dimerization and DNA binding.
In SaBirA, ligand binding induces similar conformational changes
in the loops that are located at the dimerization interface. Like EcBirA,
the biotin-binding loop in this interface (residues 118–129) under-
goes a disorder-to-order transition to facilitate the interaction
between the two-dimer subunits.46 The dimerization interfaces of
biotinyl-5′-AMP bound EcBirA and SaBirA are illustrated in Fig. 3.
The subunits are connected by an analogous intermolecular β-sheet
interaction as observed for EcBirA, but the dimer is stabilized by
additional intersubunit contacts.46 Of particular note is F123 that
forms a hydrophobic interaction with the side chain of D200 from
the opposing monomer (Fig. 3A).52 In EcBirA the homologous amino
acid is R119 that forms a hydrogen bond with D197 on the partner
subunit (Fig. 3B). Interestingly, substitution of R119 with an aro-
matic amino acid (R119W) has been shown to strongly disrupt
homodimerization.44 Analytical ultra centrifugation studies on SaBirA
revealed that replacing the F123with either glycine or arginine abol-
ished dimerization even in the presence of biotin, highlighting a role
for this aromatic residue in homodimer assembly.52
Recent studies on SaBirA dimerization indicate that the non-
liganded form of the enzyme is also able to dimerize at low
concentrations with a KD of 29 ± 1.8 μM. This is a sharp contrast to
apo EcBirA, which only dimerizes at millimolar concentrations.39,43,44
Apo-SaBirA dimer was also shown to bind DNA in an electropho-
retic mobility shift assay with KD = 649 ± 43 nM, which is only 6-fold
weaker than the binding of the holo-enzyme (KD = 108 ± 6.0 nM).52
Hence, allosteric regulation of the BirA switch in S. aureus may be
more complex than originally thought. These data highlight key dif-
ferences between E. coli and S. aureus BirAs that may have important
physiological consequences that impact the bacteria’s ability to sense
their surroundings and adapt to the niche microenvironments they
inhabit.
6. Switching between enzymatic and repressor
functions of BPL
Both the biotin ligase and transcriptional repressor activities of
BPL are critical for cell metabolism and survival. Therefore, con-
trolling the switch between these two mutually exclusive functions
is likely important for virulence. This raises a key question; how does
the enzyme switch between enzymatic and DNA binding modes?
One hypothesis proposed by Weaver and co-workers53 is based on
the observation that EcBirA utilizes the same β sheet for both
homodimerization and the interaction with the substrate BCCP
(Fig. 4). A co-complex of the enzyme with BCCP has not yet been
crystallized with a Class II BPL, but has been achieved with the Class
I enzyme from P. horikoshii.21 The model proposes that when there
is an excess of non-biotinylated substrate, holo-BirA will preferen-
tially bind BCCP, thereby preventing BirA homodimerization.
Alternatively, when the concentration of BCCP is low, holo-BirA will
accumulate and homodimerize, leading to DNA binding and sub-
sequent repression of transcription. Therefore, in this model, the
regulatory switch between the enzymatic and transcriptional re-
pressor functions of BirA is governed by competing protein:protein
Fig. 3. Intersubunit contacts of BirA. The structures of dimeric holo BirA from (A)
S. aureus [PDB 3RIR46] and (B) E. coli [PDB 2EWN20] are shown, with one subunit
colored while the other subunit is in gray ribbon. Key amino acids in the dimeriza-
tion interface are highlighted.
Fig. 4. Competing protein:protein interactions. The structure of holo E. coli BirA is
shown with one subunit in space filled mode and the other in blue ribbon [PDB
2EWN20]. The BCCP substrate bound to BirA (pink ribbon) has been modeled using
the BPL:BCCP complex from P. horikoshii [PDB 2EJG32] with UCSF Chimera software.54
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interactions and the intracellular concentration of non-biotinylated
BCCP.46,53 Recent DNase I footprint studies performed in the pres-
ence of BCCP provide support for this model.55
In contrast, Solbiati and Cronan56 proposed an alternative mech-
anism whereby biotinyl-5′-AMP is the key regulator of alternative
protein:protein interactions. These authors argue that in order to
compete with homodimerization, the BirA:BCCP complex must be
strong and long lived in the cell. However, the enzyme-substrate
interaction is believed to be transient as there has been no evi-
dence to support a stable BirA:BCCP complex. Furthermore, these
authors showed that a small 14 amino acid synthetic peptide was
effective at de-repressing a EcBirA regulated reporter construct in
vivo.56 Given the small size of this biotin-accepting substrate, ex-
tensive protein–protein interactions were not required to effectively
disrupt EcBirA binding to DNA. The authors propose that the reg-
ulatory switch between the two functions is, therefore, the removal
of the biotinyl-5′-AMP co-repressor from the active site of EcBirA
rather than the competing protein-protein interactions.
A study conducted by Pendini and colleagues suggests that the
level of the apo-BCCP is likely to be the key switch between the two
mutually exclusive functions, at least in S. aureus.46 Small-angle X-ray
scattering data showed that in the absence of BCCP, SaBPL formed
a homodimer that was receptive to binding DNA. However, when
apo-BCCP was included in the same reaction mixture, DNA binding
activity was disrupted. These authors highlight that X-ray crystal
structures demonstrated that upon the removal of biotin from the
enzyme’s catalytic site, the dimerization interface is destabilized by
the conformational changes in the biotin-binding loop. Presum-
ably this mechanism allows for the release of BCCP following
biotinylation.
7. Regulation of biotin biosynthesis and biotin transport in
organisms with class I BPL
In organisms containing Class I BPLs and no BirA homolog, such
as α-proteobacteria, the transcriptional regulation of biotin biosyn-
thesis has to be fulfilled by other proteins. A comparative genome
study revealed co-localization of biotin biosynthetic genes with a
recognition sequence for a GntR-type transcription factor called BioR
in many α-proteobacterial genomes.57 Additionally, a protein be-
longing to the TetR family of transcription factors, BioQ, has recently
been identified as the key player in the regulation of biotin bio-
synthesis in Mycobacterium smegmatis58 and biotin transport in
Corynebacterium glutamicum.59 The target genes regulated by BioQ
and BioR are summarized in Fig. 5A. As these two proteins have only
been identified recently, they have not yet been as extensively
studied as BirA. For both BioR and BioQ, the repressor function of
both proteins appears to be independent of biotin, and no ligands
have yet been identified for these transcription factors.58 A two-
protein model involving BPL together with either BioQ or BioR has
been proposed as a possible mechanism for biotin sensing and reg-
ulation in bacteria containing Class I BPLs (Fig. 5B).58 This model
assumes that there is cross talk between the biotin sensor (BPL) and
the transcriptional regulator (BioQ/R). However, themolecular details
supporting this model still require experimental validation.
8. BioR mediated gene expression
Bioinformatic analysis of genomic sequences from
α-proteobacteria suggested that biotin synthesis in these bacteria
is regulated by BioR.57 It was also observed that the DNA recogni-
tion sequence for BioR was found upstream of the bioY gene biotin
transporter in several other α-proteobacteria such asM. loti, B. meli-
tensis, Silicibacter sp. TM1040 and S. pomeroyi. The BioR recognition
sequence also co-localized with bioR genes in certain organisms such
asMesorhizobium loti, Brucella melitensis, Bradyrizhobium japonicum,
Silicibacter pmeroyi and Rhodobacder sphaeroides, suggesting auto-
regulation – a feature not observedwith BirA/BPL. However this auto-
regulation is not completely conserved as the BioR recognition
sequencewas not present upstream of the bioR gene in Agrobacterium
tumefaciens. Moreover, in A. tumefaciens, BioR does not control the
expression of the BioY biotin transporter protein. Fig. 6 outlines the
localization of BioR recognition sequence in differentα-proteobacteria.
Feng and co-workers further investigated the role of BioR in regu-
lating biotin synthesis by conducting a series of electromobility gel
shift assays.10 In addition to binding the recognition sequence in its
own genome, BioR from A. tumefacienswas able to bind DNA probes
with sequences derived from B. japonicum, R. sphaeroides and B. meli-
tensis. In addition, the B. melitensis BioR was able to repress
expression of A. tumefaciens bioB in vivo.10 These data support the
hypothesis that the BioR:operator interaction is well conserved in
α-proteobacteria. It also revealed that the expression of the biotin
operon (bioBFDAZ) in wildtype A. tumefacienswas 10–15 fold lower
relative to a BioR knockout when the bacteria were grown in high
(1 μM) biotin media. This observation further validates the role of
BioR as a transcriptional repressor.10
In B. melitensis, the BioR recognition sequence is located up-
stream of the genes encoding both BioR and the BioY biotin
transporter (Fig. 6). Two BioR sites are also present in the bioBFDAZ
operon, indicating a complex regulatory network of biotin metab-
olism involving BioR.10 Electromobility gel shift assays also confirmed
that B. melitensis BioR was able to bind to a DNA probe containing
the BioY promoter sequence, providing the first evidence that BioR
can mediate expression of the biotin transporter in these bacteria.10
In contrast, A. tumefaciens BioR does not regulate biotin transport
and only binds weakly to the recognition site present within the
coding region of bioB, in vivo.10 As a consequence, the amount of
biotin produced by A. tumefaciens is greater than their minimum
growth requirement, which presumably is beneficial for survival in
their environment.10
A search for a ligand and co-repressor of BioR concluded that
biotin is not the natural ligand.10 Complete removal of biotin from
the protein preparations had no effect upon DNA-binding in vitro.
Conversely, the hypothesis that biotin can serve as a dissociation
factor that disrupts DNA-BioR complex was also tested. Again, the
Fig. 5. Summary of BioR and BioQ transcriptional regulation. (A) The genes andmet-
abolic pathways regulated by BioR (blue boxes) and BioQ (red boxes) are shown. Each
box represents an individual operator. (B) Schematic overview showing the two-
protein model of protein biotinylation and transcriptional regulation in Class I BPLs.
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addition or removal of biotin had no effect on DNA-binding activ-
ity. Various biotin metabolites were also tested and none showed
evidence of being a ligand for BioR. Hence, further studies are re-
quired to define the links between biotin sensing by BPL and
downstream control by BioR in the two protein model of biotin-
regulated gene expression.
9. BioQ mediated gene expression
In Corynebacterium glutamicum, the biotin synthesis pathway is
incomplete, thereby rendering the bacteria biotin auxotrophic.
However, the expression of the bio genes is proposed to be con-
trolled by a transcription factor belonging to the TetR protein family,
namely BioQ. Although the TetR family of regulators has been well
characterized, none have previously been shown to regulate biotin
synthesis.60 Bioinformatic analysis of the C. glutamicum genome re-
vealed co-localization of the bioQ coding region with the biotin
biosynthetic genes (Fig. 6).59 The presence of the BioQ recognition
sequence in the promoter of the bioQ gene suggests auto-regulation
of the transcription factor (Fig. 6). In addition, the same regulato-
ry sequence is also found upstream of the bioY biotin transporter,
suggesting BioQ regulates its expression. This is crucial for biotin
auxotrophic C. glutamicum that relies on supply of the micronutri-
ent from the external environment. In addition, the study showed
that increasing the biotin concentration in the growth media only
had modest repression on the transcription of the biotin operon in
this organism.59
In contrast to C. glutamicum, BioQ is believed to regulate ex-
pression of the transporter genes inMycobacterium smegmatis. The
recognition sites are also localized upstream of the bioF and bioQ/B
genes suggesting regulation of biotin biosynthesis and auto-
regulation by BioQ in this species (Fig. 6).58 Tang et al. also showed
that BioQ binding sites are also found in othermycobacterium species
such as M. abcessus, M. gilvum, M.JLS, M. massiliense, M. rhodesiae
andM. vanbaalenii, but not in the clinically important human patho-
genM. tuberculosis.58 The same study also confirmed the role of BioQ
as a functional repressor. Increased mRNA levels of bioF, bioB and
bioDwere measured in a ΔbioQmutant strain ofM. smegmatis com-
pared to the wildtype parent. LacZ-based reporter assays using the
bioFD promoter also showed expression was highly increased in
ΔbioQ strain whereas no LacZ activity was observed in the wildtype
strain.58 In addition, increasing levels of biotin in the growth media
resulted in decreasing expression of biotin biosynthesis genes bioF,
bioD and bioB for the wildtype bacteria whereas there was no sig-
nificant change in the ΔbioQ strain. These findings underline the
biotin sensing ability of BioQ.
10. Potential biotechnological applications
Synthetic biology facilitates us to better understand life through
the dissection then reconstruction of complex biological systems.61
At the heart of this endeavor are engineered genetic circuits that
allow us to dissect the interplay between genes, proteins, cells and
systems. Synthetic biology is currently used to deliver valuable bio-
products and therapeutic molecules, such as fine chemicals, peptides,
proteins and antibodies. For example, most monoclonal antibod-
ies are produced recombinantly using genetically engineered Chinese
hamster ovary cells as bio-factories.62 Many of the reagents that have
been developed by industry are becoming valuable tools in aca-
demia. Underpinning synthetic biology are well-characterized
transcriptional regulators required to engineer the genetic circuits
and tightly control bio-production. The TetR inducible expression
system is an example that is widely employed due to its high speci-
ficity toward its recognition system and the high affinity to
tetracycline, a well characterized antibiotic.63 There is now a need
fill our discovery toolbox with a greater variety of well-characterized
transcriptional regulators with utility in systems biology. In this
review, the mechanisms of BirA, BioQ and BioR in regulating their
target genes are discussed. The high specificity of BirA to its target
operator, as well its ability to regulate gene expression in re-
sponse to external biotin, provides an attractive approach to
developing novel ligand-regulated gene expression systems for use
in bacteria, yeast plants and animal systems. To date this ap-
proach has not yet been exploited. Biotin provides a highly attractive
ligand to regulate transcription due to its low cost, solubility in
aqueous solutions, low toxicity to many cell types and has no reg-
ulatory issues. While the well-studied Class II BirA enzyme/
repressor from E. coli provides one useful example for generating
a controllable genetic switch, the emergence of other biotin re-
sponsive transcription factors extends our repertoire of potential
systems. Other Class II BPLs may be more responsive to environ-
mental biotin levels, such as that from S. aureus. The BioR and BioQ
proteins provide alternative repressors with distinctive mecha-
nisms of action to BirA/BPL. These may potentially be advantageous
when generating new genetic circuits that are highly responsive to
Fig. 6. BioR and BioQ. Sequences of the binding sites for BioR and BioQ are shown.
Transcription start sites are boxed, and −35 and −10 sequences are underlined. Se-
quences of the binding sites for BioR (blue) and BioQ (red) are colored.
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DNAseI	(RNAse	free)		 Life	 technology,	 Carlsbad,	
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Antibodies	 were	 reconstituted	 and	 stored	 according	 to	 manufacturer’s	






























































































Luria	 Broth	 (LB):	 1%	 (w/v)	 tryptone,	 0.5%	 (w/v)	 yeast	 extract,	 1%	 NaCL,	
adjusted	to	pH	7.0	with	5M	NaOH.		
























pGEM®-T	 vector	 (Addgene):	 3000	 bp	 cloning	 vector,	 used	 to	 clone	 particular	
gene	 or	 construct	 required.	 This	 vector	 had	 been	 modified	 previously	 in	 our	
laboratory;	 modifications	 include	 the	 presence	 of	 6xHis-tag	 and	 additional	
restriction	sites	at	its	multiple	cloning	sites.	
2.1.9	Buffers	and	solutions	


































ApE-A	 plasmid	 Editor	 version	 1.17	 (by	 M.	 Wayne	 Davis)	 and	 SnapGene	 viewer	
(GSL	Biotech,	www.snapgene.com)	was	used	 to	 generate	 constructs	 and	plasmid	
maps	as	well	as	sequencing	chromatogram	viewings.	USCF	Chimera	version	1.8.1	
(UCSF,	CA,	USA)	was	used	for	viewing	and	analysis	of	PDB	files.	Imaging	of	agarose	
gel	 and	 western	 blotting	 membrane	 were	 done	 using	 Chemidoc™	 -MP	 system	
imager	 and	 analysed	 using	 Image	 lab	 software	 (Bio-rad	 laboratory,	 California,	
USA)	
2.11	Web	resources	
	Sequence	 alignments	 were	 done	 using	 Clustal	 Omega	 (EMBL-EBI,	
www.ebi.ac.uk/Tools/msa/clustalo/).	 NCBI	 (http://www.ncbi.nlm.nih.gov/)	 was	
used	 to	 access	 protein	 and	 nucleotide	 reference	 sequences	 as	 well	 as	 Pubmed	
databases	 and	Basic	 Local	Alignment	Tool	 (BLAST).	 Protein	 translation	 and	ORF	
prediction	was	obtained	from	Https://www.expasy.org.	Softberry-BProm	bacteria	










For	 purification	 of	 small	 (<10	 μg)	 amounts	 of	 plasmid	 DNA,	 Pellet	 from	 5mL	 of	
overnight	 bacterial	 culture	 harboring	 the	 desired	 plasmid	 was	 used.	 QIAGEN	
QIAprep	 Miniprep	 kit	 was	 employed	 following	 the	 manufacturer’s	 instructions,	





Two	 genomic	 DNA	 methods	 were	 employed,	 for	 colony	 screening,	 the	 genomic	













Genomic	 DNA	 extraction	was	 performed	 according	 to	 the	manufacturer’s	
instructions,	 with	 the	 exception	 of	 the	 overnight	 culture	 volume.	 The	 overnight	
cultures	 used	 for	 extraction	 was	 5mL	 instead	 of	 1mL	 as	 recommended	 by	
manufacturer.	 The	 resulting	 purified	 DNA	 was	 quantified	 by	 measuring	








incubated	 at	 37°C	 for	 15	 minutes	 with	 frequent	 mixing	 by	 inversion,	 every	 5	
minutes.	 350μl	 of	 RLT	 buffer	 solution	 from	 RNeasy	 RNA	 extraction	 mini	 kit	
containing	 1%	 Beta-mercaptoethanol	 was	 then	 added	 to	 the	 lysed	 solution	 and	
vortexed	 for	20	seconds.	200μL	of	100%	ethanol	solution	was	added	tubes	were	













Step 1:  98°C, 0:30 
 
Step 2: 98°C, 0:10 
            55°C, 0:30 
            72°C, 1:00 (0.5Kb / min extension) 
 
Step 3: 72°C, 5:00 
 
Step 4:  hold at 4°C 
The	reaction	was	carried	out	on	a	MJ	Research	PTC	2000	Thermal	Cycler	(GMI	Inc.,	
MN,	 USA)	 The	 resulting	 PCR	 product	 was	 then	 purified	 using	 Qiaquick	 PCR	
purification	kit	(Qiagen).	
2.2.5	Agarose	gel	electrophoresis	
Analysis	 of	 DNA	 and	 separation	 of	 DNA	 fragments	 was	 performed	 using	











20μL	 -50μL	of	PCR	reaction	was	added	 to	5X	PB	buffer	provided	 in	 the	Qiaquick	
PCR	Clean	up	kit	(Qiagen)	and	transferred	into	the	purification	column	followed	by	
centrifugation	 at	 17500	 x	 g	 as	 per	 manufacturer’s	 instruction.	 The	 column	 was	
then	 washed	 with	 650μL	 of	 PE	 Buffer	 and	 centrifuged	 for	 1	 minute	 to	 remove	
excess	 ethanol,	 at	 17500	x	 g.	 The	purified	PCR	product	was	 then	 eluted	 in	35μL	
elution	buffer.	
2.2.7	DNA	extraction	from	agarose	gel		
DNA	 was	 excised	 from	 the	 gel	 using	 a	 clean	 blade	 and	 weighed	 in	 1.5	 mL	




NEB	buffer	 for	 2	 hours	 at	 37	 °C.	 For	 cloning,	DNA	 fragments	were	 separated	 by	










mutagenesis	 according	 to	 the	 manufacturer’s	 recommendation.	 Complementary	
strands	of	synthetic	oligonucleotide	primers	containing	the	desired	mutation	were	
extended	by	the	activity	of	Phusion®	DNA	polymerase	during	thermo	cycling.	The	
50μL	 reaction	mixture	was	 comprised	of	1x	 reaction	buffer,	50ng	DNA	 template,	
1mM	 dNTPs,	 2.5ng/μl	 each	 primer	 and	 5	 units	 of	 Pfu	 DNA	 polymerase.	 The	
reaction	was	carried	out	on	a	MJ	Research	PTC	2000	Thermal	Cycler	(GMI	Inc.,	MN,	








	 E.	coli	 cells	were	grown	 in	 the	appropriate	media	with	antibiotic	selection	
overnight	 and	 sub-cultured	 into	 1L	 of	media	 the	 next	 day,	with	 starting	OD600	 =	
0.05.	Once	the	cells	have	reached	mid-log	phase	(OD600	=	0.4-0.6)	cells	were	cooled	
on	 ice	 for	30	minutes	 followed	by	centrifugation	at	3200	x	g	 ,	4°C	 for	5	minutes.	
Cell	pellet	was	then	resuspended	in	10	mL	of	transformation	buffer	I	(15%	glycerol	
(v/v),	 10mM	 Potassium	 Acetate	 (CH3CO2K),	 100mM	 RbCL,	 10mM	 CaCL2,	 50mM	
MnCL2)	and	cooled	on	ice	for	10	minutes.	The	cells	were	then	centrifuged	at	3200	x	
g,	 4°C	 for	 5	 minutes.	 The	 cell	 pellet	 was	 then	 resuspended	 in	 1mL	 of	
	 38	
transformation	 buffer	 II	 (10mM	MOPS,	 10mM	 RbCL,	 15%	 (v/v)	 glycerol,	 75mM	
CaCL2)	and	aliquoted	into	10x	100μL	before	storage	at	-80°C.	 	
2.2.11b	Heat	shock	method:	









E.	coli	 cells	were	grown	 in	 the	appropriate	media	with	antibiotic	selection	





(v/v)	 glycerol,	 followed	 by	 centrifugation	 at	 3200	 x	 g,	 4°C	 for	 5	 minutes.	






then	 transferred	 the	 mixture	 to	 pre-cooled	 1mm	 electroporation	 cuvettes.	 Cells	
were	 transformed	 using	 a	 Bio-Rad	 MicroPulser™,	 following	 the	 manufacturer’s	
recommended	setting	 for	E.	coli,	pre-set	Ec1	program	(1.8	kV).	SOC	medium	was	






plated	 onto	 fresh	 agar	 plate	 containing	 the	 appropriate	 media	 and	 antibiotic	
selection,	by	gently	touching	the	tip	of	the	toothpick	onto	the	fresh	agar	plate.	The	
toothpick	 was	 then	 dipped	 into	 PCR	 mixture	 containing	 0.25μL	 of	 100ng/μL	
forward	and	reverse	primer,	0.25μL	of	10mM	dNTP	mix,	1X	taq	polymerase	buffer	
(NEB),	 0.2μL	 of	 taq	 polymerase	 (NEB)	 in	 a	 total	 of	 20μL	 reaction.	 The	 following	
program	was	then	used	to	amplify	the	specific	region	within	the	clones:	
Step 1:  98°C, 3:00 
 
Step 2: 98°C, 0:10 
            55°C, 0:30 
            72°C, 1:00 (1Kb / min extension) 
Step 3: 72°C, 5:00 
 










recombinant	 plasmid	was	 prepared	 at	 37	 °C.	 An	 equal	 volumes	 of	 the	 overnight	
culture	and	80%	glycerol	were	mixed	and	stored	at	-80	°C.	
2.2.15	Sequencing	












MN,	 USA).	 The	 sequencing	 product	 was	 then	 mixed	 with	 80μL	 of	 75%	 (v/v)	
isopropanol,	 incubated	 at	 room	 temperature	 for	 15	 minutes	 followed	 by	
centrifugation	 at	 17500	 x	 g	 for	 30	min	 and	 then	washed	 once	 in	 250μL	 of	 75%	








buffer	 (300mM	 KCL,	 50mM	 KPO4	 pH	 8.0,	 5mM	 imidazole)	 and	 added	 300μL	 of	
300mM	 PMSF.	 The	 cells	 were	 then	 passed	 through	 cell	 disruptor	 (M110L	
homogenizer,	Microfluidics,	USA)	set	at	18000	psi,	for	5-6	times.	The	homogenized	
solution	was	then	centrifuged	at	20000	x	g	for	10	minutes	at	4°C	using	Avanti	J26-
XPI	 centrifuge	 (Beckman-coulter).	 Supernatant	was	 then	passed	 through	0.45μM	
filter	disc	(Sartorius)	before	loaded	into	the	purification	column.		
2.2.17	6xHis-tag	purification		
His-tagged	 proteins	 were	 purified	 by	 immobilized	 nickel	 affinity	
chromatography	using	 a	5mL	Bio-ScaleTM	Mini	Profinity™	 IMAC	 cartridge,	 in	 an	
FPLC-based	 purification	 using	 AKTA	 FPLC	 (Amersham	 Pharmacia	 Biotech).	 All	
buffers	and	 solution	used	 in	 this	purification	were	 filtered	 through	0.45μM	 filter	
disc	 (Sartorius).	The	 flow	was	set	at	5mL/min,	making	sure	no	air	bubbles	were	
introduced	 to	 the	column	at	any	stage	of	purification.	For	each	wash,	 samples	of	
the	 flow	 through	were	 collected	and	 ran	on	SDS-PAGE	 for	 analysis.	 	 The	 column	
was	washed	 first	 with	 5x	 column	 volume	 of	 20%	 (v/v)	 ethanol,	 followed	 by	 5x	
column	wash	with	H20.	6x	 column	volume	of	wash	buffer	 I	 (300mM	KCL,	50mM	
KPO4	pH	8.0,	5mM	imidazole)	was	then	loaded	to	equilibrate	the	column.	Bacteria	






purified	protein	was	 then	dialysed	overnight	 in	4L	of	 storage	buffer	 (50mM	Tris	
pH	8.0,	100mM	KCL,	1mM	EDTA	pH	8.0,	5%	(v/v)	glycerol,	1mM	DTT)	at	4	°C.	
2.2.18	Cartridge	clean	up	and	maintenance.		
At	 the	 end	 of	 each	 purification,	 the	 column	 was	 cleaned	 by	 running	 10x	
column	volumes	of	cleaning	solution	I	(500mM	NaCL,	50mM	Tris	pH8.0),	followed	
by	 10x	 column	 volumes	 of	 cleaning	 solution	 II	 (500mM	 NaCL,	 100mM	 sodium	
acetate).	 10x	 column	 volumes	 of	 filtered	 distilled	H20	was	 then	 run	 through	 the	
column	and	finally,	10x	column	volume	of	20%	(v/v)	ethanol	was	run	through	the	
column	and	stored	at	4°C.		
A	 thorough	 clean	 up	 and	 recharging	 procedure	 for	 the	 column	 was	 also	
conducted	 for	maintenance,	by	 running	10x	column	volume	of	50mM	EDTA,	10x	
column	 volume	 of	 H20,	 10x	 column	 volume	 of	 Guanidine	 Hydrochloride,	 10x	




or	 -15	 centrifugal	 filter	 devices	 (10000	 MWCO)	 (Millipore,	 MA,	 USA)	 following	
manufacturer’s	 instruction	 manual.	 The	 columns	 were	 rinsed	 with	 MilliQ	 water	
and	then	equilibrated	in	storage	buffer	by	centrifugation	at	5000	x	g	at	4	°C	for	30	
min	 or	 until	 reaching	 a	 required	 retentate	 volume.	 The	 storage	 buffer	 was	
discarded	 prior	 adding	 protein	 sample	 into	 the	 spin-	 column.	 Likewise,	 protein	
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was	concentrated	by	centrifugation	at	5000	x	g	at	4	 °C	until	 reaching	a	 required	
retentate	 volume.	 For	 retentate	 recovery,	 the	 concentrate	 was	 collected	 using	 a	
pipette	with	200μL	tip	to	new	pre-cold	microcentrifuge	tube.	The	protein	was	kept	
at	-80	°C	until	needed.	For	storage	of	the	Amicon®	Ultra-50	or	-15	centrifugal	filter	
devices,	 the	 centrifuge	 tube	was	washed	with	distilled	water	 to	 remove	 residual	
buffer	components	and	kept	in	MilliQ	water	at	4	°C.	
2.2.20	Bradford	assay	for	protein	concentration	determination	
Protein	 concentration	 was	 assayed	 using	 the	 Bradford	 Reagent	 (Bio-Rad	
Laboratories	 Inc.,	 CA,	 USA)	 assay	 method.	 A	 standard	 curve	 of	 bovine	 serum	
albumin	 (BSA)	was	 generated	 from	 0	 to	 1	mg/ml.	 A	 10μL	 of	 sample	was	mixed	
with	200μL	of	Bradford	reagent	in	a	96	well	plate	(Falcon).	Absorbance	at	620	nm	










PAGE	 Coomassie	 Blue	 staining	 solution.	 The	 gel	 was	 first	 soaked	 in	 staining	
solution	 (0.2%	 Coomassie	 Blue,	 50%	 ethanol	 and	 10%	 acetic	 acid)	 at	 room	
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For	 3H-biotin	 incorporation	 assay,	 lysate	 was	 collected	 and	 total	 protein	
concentration	was	 then	determined	using	Bradford	assay.	For	blotting,	 following	
bradford	assay,	 samples	were	diluted	 to	obtain	uniform	concentration	 for	all	 the	
samples	 and	 was	 then	 mixed	 1:1	 with	 2x	 protein	 loading	 buffer.	 Samples	 were	
heated	 at	 98°C	 for	 5	minutes	 following	 centrifugation	 at	 full	 speed	 for	 5	minute	
prior	to	gel	loading.	
2.2.23	Western	blotting	
Proteins	 fractioned	 by	 PAGE	 were	 transferred	 onto	 a	 PVDF	 membrane	 using	 a	
semi-	dry	transfer	unit	(Hoefer	SemiPhor,	Amersham	Pharmacia	Biotech,	CA,	USA).	
Six	 sheets	of	Whatman	 filter	paper	and	 the	PVDF	membrane	were	pre-soaked	 in	
western	transfer	buffer	prior	 to	assembly	of	 the	3	 :	1	 :	1:	3	ratio	of	 	paper	 :	gel	 :	
membrane	 :	paper	 sandwich.	Proteins	were	 transferred	 for	1	hour	at	80	mA	per	
gel.	The	membrane	was	then	blocked	in	1%	(w/v)	skim	milk	blocking	buffer	for	1	
hour	at	room	temperature	or	at	4	°C	overnight.	The	membrane	was	then	washed	
three	 times	 with	 PBS-Tween	 before	 being	 probed	 with	 a	 6xHis	 Monoclonal	
Antibody	(diluted	in	1:10000)	for	1	hour	at	room	temperature.	The	membrane	was	
then	washed	 three	 times	 in	 PBS-Tween	 before	 addition	 of	 a	 CyTM	3-conjugated	
	 45	
AffiniPure	 Donkey	 Anti-mouse	 IgG	 (diluted	 in	 1:5000)	 for	 1	 hour	 at	 room	
temperature.	 Finally	 the	 membrane	 was	 washed	 three	 times	 with	 PBS-Tween	
before	being	visualized	using	Chemidoc-MP	system	 imager	 (Bio-rad	 laboratories,	
California,	USA).	
2.2.24	Chromosomal	integration	of	vector	containing	promoter	construct	





100μg/mL	 ampicillin	 followed	 by	 overnight	 incubation	 at	 30°C.	 The	 resulting	
colonies	 were	 then	 made	 chemically	 competent	 and	 transformed	 with	 the	
integration	 plasmid	 containing	 promoter∷lacZ	 construct.	 Transformation	 was	
recovered	 for	 1	 hour	 at	 37°C	 and	 plated	 onto	 LB	 agar	 containing	 30μg/mL	
spectinomycin	 followed	 by	 overnight	 incubation	 at	 37°C.	 The	 resulting	 colonies	
were	screened	using	HK022	screening	primers.		
2.2.25	Chromosomal	integration	of	vector	containing	repressor	construct	




were	 recovered	 for	 one	 hour	 at	 30°C	 and	 then	 plated	 onto	 LB	 agar	 containing	
100μg/mL	 ampicillin	 followed	 by	 overnight	 incubation	 at	 30°C.	 The	 resulting	
	 46	
colonies	 were	 then	 made	 chemically	 competent	 and	 transformed	 with	 the	
integration	 plasmid	 containing	 the	 promoter	 construct	 (pIT4_plac_repressor)	 .	
Transformation	 was	 recovered	 for	 1	 hour	 at	 37°C	 and	 plated	 onto	 LB	 agar	








































	 E.	 coli	 	 reporter	 strains	 were	 streaked	 onto	 minimal	 media	 agar	 containing	
100nM	biotin	and	30	μg/mL	spectinomycin	and	grown	overnight	at	37°C.	The	next	day,	
a	 single	 colony	was	 used	 to	 inoculate	 2	mL	 of	 the	minimal	media	 containing	 100nM	
biotin	 and	 grown	 overnight	 at	 37°C.	 The	 next	 day,	 the	 overnight	 culture	 was	
centrifuged	and	washed	3x	times	in	5	mL	minimal	media	without	any	biotin	to	remove	
excess	 biotin.	 The	 culture	was	 then	 resuspended	 in	 1	mL	of	minimal	media	 (without	
biotin)	 and	 OD600	was	measured.	 	 For	 a	 standard	 assay,	 the	 concentrations	 of	 biotin	
tested	 were	 0.5nM,	 1nM,	 3nM,	 5nM,	 10nM,	 50nM,	 100nM	 and	 500nM	 and	 therefore	
these	amount	of	biotin	were	added	to	the	minimal	media.	Growth	plate	was	set	up	by	
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S.	aureus	 is	 challenging,	due	 to	 the	genetic	make	up	of	 the	bacteria.	 It	 is	known	
that	S.	aureus	possess	a	complex	restriction	modification	barrier,	which	consists	
of	 type	 I,	 type	 II	 and	 type	 IV	 modification	 systems,	 that	 reduce	 the	 natural	
competency	 of	 this	 species	 [1].	 Type	 I	 encodes	 for	 host-specificity	 proteins	 [2]	
and	type	II	encodes	for	restriction	endonucleases	 .	Type	IV	is	believed	to	be	the	
dominant	barrier	in	preventing	DNA	uptake,	and	encodes	for	proteins	that	detect	
methylation	of	DNA	and	cleaves	 foreign	DNA	[3,	4].	These	barriers	result	 in	 the	
genetic	 manipulation	 of	 S.	 aureus	 being	 very	 difficult	 and	 time-consuming	 to	
perform	 [5].	 On	 the	 other	 hand,	 in	 the	 prototypical	 bacteria	 E.	 coli,	 genetic	
manipulations	 and	 in	 vivo	 experiments	 are	 relatively	 easy	 to	 perform	 due	 to	
advanced	 knowledge	 of	 the	 bacteria	 and	 resources	 available	 to	 genetically	
manipulate	this	species	[6-11].	
	 One	 way	 to	 avoid	 the	 need	 to	 manipulate	 S.	 aureus,	 is	 to	 re-construct	






		 In	 this	 chapter,	 a	 bacterial	 reporter	 system	 was	 generated	 in	 a	 biotin	
auxotroph	E.	coli	strain	by	engineering	constructs	into	the	bacterial	chromosome.	
The	 assembly	 of	 the	 reporter	 strain	 involved	 an	 established	 method	 of	 site	
specific	chromosomal	 integration	[16].	First,	 the	birA	gene	of	 interest	under	the	
control	of	a	lac	promoter	was	integrated	into	the	attB-	λ	phage	attachment	site	of	
the	 E.	 coli	 chromosome.	 A	 second	 construct	 containing	 the	 test	 promoter	
sequence	fused	to	the	lacZ	gene	was	subsequently	integrated	into	the	attB-HK022	
phage	 attachment	 site.	 The	 interaction	 between	 repressor	 and	 promoter	 was	
then	 analyzed	 by	 quantifying	 the	 amount	 of	 LacZ	 expression	 using	 a	 β-
galactosidase	 assay.	 As	 the	 overall	 aim	 of	 this	 study	 was	 to	 compare	 the	
mechanism	 of	 action	 of	 SaBirA	 with	 the	 well-studied	 EcBirA	 transcriptional	
repressor,	 both	 repressors	 were	 investigated.	 In	 addition,	 mutants	 of	 these	
repressors	that	were	shown	to	be	monomeric	in	solution	were	also	investigated,	
namely	SaBirA	F123G	 [17]	and	EcBirA	R119W	[18-20].	To	 facilitate	 this	 in	vivo	
analysis,	 any	 repression	 generated	 by	 the	 endogenous	 EcBirA	 has	 to	 be	
prevented,	in	order	to	ensure	that	any	repression	observed	in	the	assay	was	due	
to	 the	 integrated	 repressor.	 Therefore,	 the	 endogenous	 E.	 coli	 birA	 gene	 was	
modified	such	that	the	protein	retained	its	catalytic	function	to	maintain	viability,	
but	the	DNA	binding	activity	was	abolished.	As	biotin	is	an	allosteric	activator	of	
DNA	 binding	 [21],	 hence	 the	 ability	 to	 control	 the	 level	 of	 biotin	 in	 the	 β	 –
galactosidase	assay	was	crucial.	Therefore,	in	addition	to	using	a	biotin	auxotroph	
strain,	 0.1%	 casamino	 acid	minimal	media	was	 chosen	 as	 the	 growth	media	 in	




3.1.1	Overview	 of	 stages	 involved	 in	 reporter	 strain	 assembly	 and	 in	vivo	
assay	development		
	
	 In	 this	 chapter,	 the	 construction	 of	 an	 E.	 coli	 reporter	 strain	 and	 the	
development	 of	 in	 vivo	 β-galactosidase	 assays	 to	 measure	 biotin-inducible	
repression	 will	 be	 described.	 	 An	 overview	 of	 the	 steps	 involved	 in	 strain	
construction	 and	 in	vivo	 assay	 is	 presented	 in	Figure	 3.1.	E.	coli	 	 JD26186	was	
used	as	 the	parent	 strain	 in	 this	 study,	 as	 this	 strain	 is	unable	 to	 synthesize	 its	
own	biotin	due	 to	 the	disruption	of	 the	biotin	biosynthesis	gene,	bioC.	The	 first	
stage	 of	 the	 strain	 construction	 involved	 the	 disruption	 of	 the	N-terminal	 DNA	
binding	domain	of	the	endogenous	EcBirA	of	the	parental	strain,	by	insertion	of	a	
chloramphenicol	cassette	(CAT)	into	the	5ʹ	region	of	the	birA	gene.	This	resulted	
in	 a	 new	 strain	 expressing	 EcBirA	 lacking	 DNA	 binding	 activity,	
JD26186_birA∷CAT.	 The	 precise	 disruption	 of	 the	 endogenous	 birA	 gene	 was	
confirmed	 by	DNA	 sequencing	 and	 β–galactosidase	 assay.	 This	 strain	was	 then	
used	for	the	assembly	of	a	series	of	reporter	strains	for	use	in	this	study.			
	 The	second	stage	of	 the	 reporter	 strain	construction	 involved	cloning	a	
series	of	integration	vectors	suitable	for	chromosomal	integration	into	the	E.	coli	
genome	 at	 specific	 phage	 attachment	 sites.	 The	 final	 step	 of	 the	 strain	
construction	 involved	 integrating	 these	 vectors	 chromosomally	 into	 JD26186-
birA∷CAT	 using	 methods	 previously	 described	 [16].	 The	 resulting	 reporter	
strains	were	 then	 used	 in	 β-galactosidase	 assays	 to	 assess	 repression	 of	 target	
promoters,	following	changes	in	extracellular	biotin	concentrations.	The	outcome	












and	 In	 vivo	 assay	 establishment.	 E.	 coli	 	 JD26186	 with	 disrupted	 bioC	 was	
chosen	as	the	parent	strain	to	generate	the	reporter	strain.	N-terminal	domain	of	
the	 endogenous	 EcBirA	 was	 disrupted	 by	 the	 insertion	 of	 chloramphenicol	
cassette.	 A	 series	 of	 integration	 vectors	 containing	 the	promoter	 and	 repressor	
genes	of	interest	were	constructed	and	chromosomally	integrated	into	JD26186_	











Japan).	 	This	strain	 is	not	able	 to	synthesize	biotin,	due	 to	 the	disruption	of	 the	
bioC	 gene	by	a	kanamycin	resistance	gene	 (KanR)	 [22].	Consequently,	 the	strain	





are	 presented	 in	 chapter	 2.	 Specific	 methods	 involved	 in	 the	 assembly	 of	 the	
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Top strand of double stranded EcBioO
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3.3.1.1	 Cloning	 of	Hsbpl	 gene	 into	 pKD46	 plasmid	 to	 complement	 the	 catalytic	
activity	of	the	endogenous	EcBirA	
	
	 As	 mentioned	 in	 the	 introduction,	 for	 the	 assay	 to	 function,	 any	
background	 repression	 caused	 by	 endogenous	 EcBirA	 should	 be	 avoided.	 This	
was	 done	 by	 insertion	 of	 CAT	 cassette	 in	 a	 specific	 region	 of	 the	 N-terminal	
domain	of	EcBirA.	Previous	studies	have	indicated	that	EcBirA	is	an	essential	gene	
in	 E.	 coli	 and	 deletion	 of	 the	 N-terminal	 region	 of	 EcBirA	 resulted	 in	 reduced	
affinity	 to	 biotin	 [23,	 24].	 Based	 on	 these	 reports,	 it	 was	 possible	 that	 any	
modification	 performed	 on	 the	 N-terminal	 domain	 of	 the	 endogenous	 EcBirA	
could	result	in	less	efficient	biotinylation	activity,	which	could	be	detrimental	to	
the	bacteria’s	growth.	To	prevent	any	viability	issue,	another	functional	BPL	gene	
(Human	 BPL	 or	 Hsbpl)	 was	 transformed	 into	 the	 parent	 strain,	 in	 order	 to	
complement	the	compromised	endogenous	EcBirA	catalytic	activity.	
	 The	 Hsbpl	 gene	 was	 isolated	 from	 pK(Hsbpl)	 [25]	 as	 a	 ClaI	 fragment,	
using	B391-B392	primers	and	cloned	into	the	same	helper	plasmid		(pKD46)	that	
encodes	 the	 λ-red	 genes	 (β,	 exo	 and	 gam),	 essential	 for	 recombineering	 [26,	










helper	 plasmid	 pKD46.	 This	 plasmid	 also	 encodes	 for	 genes	 required	 in	
recombineering	process	(β,	exo	and	gam)	and	a	temperature	sensitive	replication	




	 The	 chloramphenicol	 resistance	 gene	 (CamR)	 and	 its	 promoter	 (CAT	
promoter)	was	isolated	from	pCY216	plasmid	[28]	using	a	set	of	oligonucleotides	
(B395	and	B396)	 that	contained	a	 flanking	sequence	homologous	 to	 that	of	 the	
EcBirA	 N-terminal	 region.	 The	 specific	 sequence	 of	 the	 CAT	 cassette	 insertion	
point	within	the	EcBirA	gene	and	the	flanking	homologous	sequence	incorporated	
into	the	oligonucleotides	is	outlined	in	Figure	3.3.	Deep	vent	polymerase	(NEB)	
was	 used	 to	 amplify	 the	 cassette,	 according	 to	 the	manufacturer’s	 instructions.	





endogenous	 EcBirA	 gene.	 The	 gene	 encoding	 for	 endogenous	 EcBirA	 of	 the	
parent	strain	E.	coli	JD26186	is	outlined.	The	translation	initiation	codon	(Met)	is	
underlined.	 Blue	 shading	 indicates	 the	 homologous	 sequence	 that	 was	
engineered	in	the	B395-B396	oligonucleotides	to	target	EcBirA	gene.	Red	letters	
indicate	 the	 sequence	 targeted	 for	 replacement	 by	 CAT	 cassette	 during	 the	
recombineering	process.	
	
3.3.1.3	 Insertion	 of	 CAT	 cassette	 into	 E.	 coli	 JD26186	 endogenous	 EcBirA	 N-
terminal	domain.		
	 Electrocompetent	 JD26186	 cells	 carrying	 the	 temperature	 sensitive	
pKD46-Hsbpl	 plasmid	 were	 prepared	 at	 30°C	 in	 the	 presence	 of	 100	 μg/mL	
ampicillin	to	maintain	the	plasmid	and	10mM	arabinose	to	induce	the	expression	
of	 the	 λ-red	 genes.	 The	 PCR	 product	 containing	 a	 CAT	 cassette	 flanked	 by	













antibiotic	 selection.	 However,	 it	 is	 known	 that	 at	 low	 concentrations,	
chloramphenicol	 is	 bacteriostatic	 against	 Enterobacteriaceae	 family	 of	 bacteria	
[30]	 and	 it	 has	 been	 shown	 that	 chloramphenicol	 concentrations	 as	 high	 as	 80	
μg/mL	was	needed	 for	a	bactericidal	effect	against	E.	coli	 [31].	As	a	 result,	PCR	
screening	 showed	 that	 the	 first	 generation	 of	 colonies	 grown	 on	 10	 μg/mL	
chloramphenicol	 plate	 exhibited	 a	 mixed	 population	 of	 wild-type	 and																																	
N-terminally	 disrupted	 colonies,	 as	 detected	 by	 PCR	 (Figure	 3.4a).	 Therefore,	
more	stringent	enrichment	of	 the	mutant	strain	was	needed.	This	was	achieved	







antibiotic	 selection	 and	 LB	 agar	 containing	 ampicillin,	 followed	 by	 overnight	
incubation	 at	 40	 °C.	 Incubation	 at	 this	 high	 temperature	 should	 eliminate	 the	




to	 grow	 on	 the	 media	 without	 ampicillin	 but	 failed	 to	 grow	 on	 media	 with	








Figure	 3.4:	 JD26186	birA::CAT	mutant	 PCR	 screening	 and	 growth	 test.	 (a.)	
Low	concentrations	of	 chloramphenicol	 result	 in	mixed	population	of	wild-type	
and	N-terminal	disruption	mutants	as	shown	by	amplified	fragments	of	~	826	bp	
and	 ~1.6	 Kb	 fragment,	 respectively.	 (b.)	 After	 re-plating	 onto	 LB	 media	
containing	 higher	 chloramphenicol	 concentration,	 single	 colony	 of	 the	 mutant,	






3.3.2	Bioinformatics	prediction	of	 frame	 shift	 created	by	 the	CAT	 cassette	
insertion	into	the	specific	target	site	of	birA	N-terminal	domain.		
	 In	 the	 genome,	 EcBirA	 is	 located	 in	 the	 same	 operon	 as	 another	 gene,	
murB	that	encodes	for	UDP-N-acetylenolpyruvoyl	glucosamine	reductase	(Figure	
3.5a).	 This	 enzyme	 is	 essential	 for	 the	 bacterial	 cell	 wall	 synthesis	 [32]	 and,	
consequently,	cell	growth.	The	promoter	that	drives	the	expression	of	both	murB	
and	EcBirA	 is	not	known.	The	open	reading	frame	(ORF)	of	these	genes	and	the	
ORF	 resulting	 from	 the	 disrupted	 N-terminal	 domain	 of	 EcBirA	 was	 predicted	
using	 bioinformatics	 analysis;	 ORF	 prediction	 tool	 (Https://www.	 expasy.org).	
The	result	showed	that	in	the	genome,	the	coding	sequence	of	murB	and	EcBirA	




134)	 resulted	 in	 a	 shift	within	 these	 two	ORFs	 as	 shown	 in	 (Figure	 3.5b).	The	
first	 ORF	 encodes	 for	murB	 and	 chloramphenicol	 resistance	 gene,	 respectively,	
whereas	 the	 second	 ORF	 encodes	 for	 EcBirA	 with	 the	 disrupted	 N-terminal	
domain	 but	 an	 intact	 C-terminal	 (amino	 acid	 274-317)	 and	 central	 domains	
(amino	 acid	 68-269)	 [33].	 This	 result	 suggests	 that	 the	 insertion	 of	 the	 CAT	
cassette	within	the	specific	targeted	site,	should	result	in	an	endogenous	EcBirA	
with	 abolished	 DNA	 binding	 capability,	 but	 the	 protein	 should	 remain	
functionally	active	as	a	catalyst.	The	transformed	colonies	resulting	 from	the	N-
terminal	 domain	 disruption	 were	 indeed	 viable	 ,	 which	 suggests	 that	 the	 CAT	










prediction	 tool.	 (a)	 In	 the	 genome,	 EcBirA	 is	 located	 in	 the	 same	 operon	 as	
another	essential	gene,	murB.	One	ORF	represent	the	translation	of	murB	and	the	
second	ORF	encodes	 for	EcBirA(denote	as	birA	 in	 the	diagram)	(b)	 Insertion	of	
CAT	cassette	result	in	a	shift	within	these	two	ORFs.	The	expression	of	murB	and	
Chloramphenicol	 resistance	 gene	 (CmR)	 corresponds	 to	 ORF1	 whereas	 the	
disrupted	 N-terminal	 domain	 of	 EcBirA	 with	 conserved	 C-terminal	 domain	
corresponds	to	ORF2.	Oligonucleotides	B409-B411	used	in	the	template	isolation	








sequencing	 from	 the	 genomic	 template.	 	 A	 set	 of	 oligonucleotides	 (B409-B410)	
were	designed	and	utilized	to	amplify	the	disrupted	EcBirA	sequence	by	PCR	from	
the	genomic	DNA	preparations	and	 then	 sequenced	using	oligonucleotide	B411	
and	 B398	 (Figure	 3.5b,	 purple	 text).	 The	 PCR	 analysis	 with	 B409	 and	 B410	
yielded	a	1.6	Kb	fragment,	as	expected.		
	 Furthermore,	DNA	sequencing	results	confirmed	the	insertion	of	the	CAT	
cassette	 on	 the	 N-terminal	 domain	 of	 EcBirA,	 as	 predicted	 (Figure	 3.6).	
Alignment	 of	 the	 amino	 acid	 sequence	 resulting	 from	 translation	 of	 these	
sequences	 against	 the	 wild-type	 EcBirA	 amino	 acid	 sequence	 showed	 a	
mismatched	 in	 alignment	 of	 amino	 acids	 1-45,	 which	 corresponds	 to	 the	 N-
terminal	 domain,	 but	 perfect	 alignment	 from	 amino	 acid	 45-321,	 which	
corresponds	 to	 central	 domain	 and	 C-terminal	 domain,	 as	 predicted	 in	
bioinformatics	 analysis	 (Figure	 3.7a).	 The	 mismatched	 alignment	 between	
amino	 acid	 1-45	 validated	 the	 disruption	 of	 the	 helix-turn-helix	 DNA	 binding	
domain	of	EcBirA,	as	illustrated	in	(Figure	3.7b,	red	shading)	and	therefore,	it	is	







































       EcbirA homologous sequenceà 
ref             --------------ATGGAAGGATAACACCGTGCCACTGAAATTGATTGCCCTGTTAGCGA 44 
clone17         GTGGAGACAATTTCATGGAAGGATAACACCGTGCCACTGAAATTGATTGCCCTGTTAGCGA 240 
                                ******************************************** 
                               CAT promoterà 
ref             ACGGTGAATTTCACGGCAGCATCACCCGACGCACTTTGCGCCGAATAAATACCTGTGACG 104 
clone17         ACGGTGAATTTCACGGCAGCATCACCCGACGCACTTTGCGCCGAATAAATACCTGTGACG 300 
                ************************************************************ 
 
ref             GAAGATCACTTCGCAGAATAAATAAATCCTGGTGTCCCTGTTGATACCGGGAAGCCCTGG 164 
clone17         GAAGATCACTTCGCAGAATAAATAAATCCTGGTGTCCCTGTTGATACCGGGAAGCCCTGG 360 
                ************************************************************ 
           
ref             GCCAACTTTTGGCGAAAATGAGACGTTGATCGGCACGTAAGAGGTTCCAACTTTCACCAT 224 
clone17         GCCAACTTTTGGCGAAAATGAGACGTTGATCGGCACGTAAGAGGTTCCAACTTTCACCAT 420 
                ************************************************************ 
 
ref             AATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAG 284 
clone17         AATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAG 480 
                ************************************************************ 
      CamRà 
ref             GAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCAT 344 
clone17         GAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCAT 540 
                ************************************************************ 
 
ref             CGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTT 404 
clone17         CGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTT 600 
                ************************************************************ 
 
ref             CAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCG 464 
clone17         CAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCG 660 
                ************************************************************ 
 
ref             GCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATG 524 
clone17         GCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATG 720 
                ************************************************************ 
 
ref             AAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAG 584 
clone17         AAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAG 780 
                ************************************************************ 
 
ref             CAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTA 644 
clone17         CAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTA 840 
                ************************************************************ 
 
ref             TCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAG 713 
clone17         TCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAG 715 
                ************************************************************ 
 
ref             AATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTG 773 
clone17         AATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTG 775 
                ************************************************************ 
 
ref             GCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGC 833 
clone17         GCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGC 835 
                ************************************************************ 
 
ref             GACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTCTGTGATGGCTTCCAT 893 
clone17         GACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTCTGTGATGGCTTCCAT 895 
                ************************************************************ 
 
ref             GTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA 953 
clone17         GTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA 955 
                ************************************************************ 
 EcbirA homologous sequenceà 
ref             CTGGGGCGTTGATGTCTTTACCGTTCCGGGTAAAGGATACAGCCTGCCTGAGCCTATCC 1012 
clone17         CTGGGGCGAACTACAG-------------------------------------------  963 
                ****************                                                    
 
Figure	3.6:	Sequence	alignment	to	confirm	the	disrupted	N-terminal	domain	
of	 EcBirA.	 A	 reference	 sequence	 of	EcBirA	 containing	 N-terminal	 CAT	 cassette	
insertion	 (birA::CAT)	was	aligned	with	 the	 sequencing	 result	obtained	 from	 the	
isolated	 clone	 containing	 the	 disrupted	N-terminal	 domain.	EcBirA	 homologous	
sequence	 is	 highlighted	 in	 blue,	 yellow	 highlight	 represents	 CAT	 promoter	












type.	 (a.)	 Altered	 sequence	 of	 amino	 acid	 1-45	 are	 shown	 in	 red	 box.	 The	









3.3.4	 In	 vivo	 validation	 of	 the	 loss	 of	 EcBirA	 repressor	 activity	 in	 E.	 coli	
JD26186	birA::CAT	
	 In	 vivo	 analysis	 to	 validate	 the	 loss	 of	 DNA	 binding	 activity	 of	 the	
JD26186_birA∷CAT,	 was	 performed	 by	 conducting	 β-galactosidase	 assays	 on	
JD26186_birA∷CAT	 strain	 harboring	 a	EcbioO	promoter.	 In	vivo	 assay	 using	 the	
parent	 strain,	 JD26186,	 containing	 the	 same	 promoter	 was	 also	 performed	
alongside	the	mutant	strain,	to	serve	as	a	control.	Reduced	affinity	for	biotin	as	a	
result	 of	 N-terminal	 disruption	 of	 endogenous	EcBirA,	 in	 combination	with	 the	
biotin	auxotroph	background	of	the	parental	strain,	caused	the	mutant	strain	to	
require	higher	biotin	concentrations	to	grow.		
	 The	 use	 of	 rich	 media	 such	 as	 LB	 should	 provide	 a	 high	 biotin	
environment	 that	 is	 sufficient	 to	 support	 the	 growth	of	 JD26186_birA∷CAT	and	
any	 repression	 capability	 of	 this	 mutant	 strain	 should	 be	 apparent	 under	 this	
high	biotin	condition.	However,	the	concentration	of	biotin	in	LB	media	will	vary,	





	 The	 result	 showed	 that	 the	mutant	 strain	was	 able	 to	 grow	 in	 both	 LB	
media	with	and	without	additional	biotin,	indicating	there	was	sufficient	biotin	in	
the	 LB	 media	 to	 support	 growth,	 without	 the	 need	 to	 supplement	 biotin.	 β-
galactosidase	 assay	 showed	 that	 in	 LB	 with	 additional	 biotin,	 the	 EcbioO	
promoter	in	JD26186_birA∷CAT	strain	was	not	repressed,	with	activity	measured	
at	 150	±	 3.6	 units,	whereas	 the	 parental	 strain	with	 an	 unmodified	N-terminal	
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domain	 showed	 11-fold	 lower	 β-galactosidase	 expression	 (13.7	 ±	 3.7	 unit,	 p	<	
0.0001),	 suggesting	 repression	 of	 EcbioO.	 Interestingly,	 similar	 results	 were	
observed	in	LB	media	without	additional	biotin,	where	JD26186_birA∷CAT	strain	
also	exhibited	high	β-galactosidase	expression	(140	±	5.9	unit),	whereas	JD26186	
exhibited	 15.7-fold	 lower	 β-galactosidase	 expression	 (8.3	 ±	 1.8	 unit13,	 p	 <	
0.0001).	 These	 results	 confirmed	 that	 the	 ability	 of	 the	modified	EcBirA	 in	 the	
JD26186_birA∷CAT	 strain	 to	 repress	 EcbioO	 promoter	 has	 been	 successfully	
abolished,	as	indicated	by	the	high	expression	of	β-galactosidase	in	both	of	the	LB	
media	[Figure	3.8a].		
	 Moreover,	 the	 aim	of	 the	 assay	 development	 is	 to	 create	 a	 system	 that	
would	 facilitate	 measurable	 repression	 of	 target	 promoters,	 in	 response	 to	
varying	external	biotin	concentrations.	Development	of	the	β-galactosidase	assay	
in	 LB	 media	 was	 therefore	 not	 feasible,	 as	 a	 substantial	 repression	 of	 EcbioO	
promoter	was	observed	in	LB	media	without	any	additional	biotin,	indicating	that	
the	 level	 of	 biotin	 in	 LB	 media	 was	 too	 high	 to	 allow	 measurable	 biotin-









were	 grown	 overnight	 in	 100nM	 biotin-supplemented	minimal	media	 (refer	 to	
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materials	 and	methods,	Chapter	 2),	 it	 was	 predicted	 that	 during	 this	 time	 the	
cells	 were	 able	 to	 accumulate	 biotinylated	 proteins	 and	 were	 able	 to	 pass	 on	
these	 biotinylated	 proteins	 to	 the	 daughter	 cells	 during	 replication,	which	was	
enough	 to	 sustain	 growth	 over	 a	 short	 period	 of	 time,	 prior	 to	 lysis.	 Multiple	
passage	of	this	overnight	culture	in	low	biotin	media	showed	the	inability	of	the	
cells	to	grow	(data	not	shown).		
	 Overall,	 it	 is	 clear	 that	 the	 insertion	 of	 the	 CAT	 cassette	 into	 the	




strain	 should	 be	 due	 to	 the	 particular	 integrated	 repressor.	 In	 addition,	 dose-












Figure	 3.8:	 Validation	 of	 E.	 coli	 JD26186_birA∷CAT	 DNA	 binding	 property	
impairment.	β-galactosidase	assay	was	employed	to	determine	the	DNA	binding	
ability	 of	 the	 disrupted	N-terminal	mutant	within	 the	 JD26186_birA::CAT	 strain	
compared	 to	 the	 wild-type	 EcBirA	 within	 the	 JD26186	 strain.	 (a.)	 Assay	 was	
performed	initially	in	LB	media	(-/+)	500nM	biotin,	to	ensure	there	was	enough	
biotin	to	support	the	growth	of	the	mutant	strain.	Error	bars	denote	S.E.M,	n	=	3	
(b.)	 Assay	 was	 repeated	 in	 minimal	 media	 with	 varying	 biotin	 concentrations.	
Both	wild-type	 and	mutant	 strains	were	 able	 to	 grow	 in	 this	media.	Wild-type	
strain	 (black)	 was	 responsive	 to	 the	 increased	 biotin	 concentration,	 whereas	
repression	 in	 JD26186_birA::CAT	 strain	 (red)	 was	 not	 responsive	 to	 biotin	




3.3.5.	 N-terminal	 disruption	 result	 in	 lower	 biotinylation	 efficiency	 of	
EcBirA		









described	 in	 chapter	 2.	 An	 assay	 to	 measure	 the	 ligase	 activity	 of	 JD26186	
birA::CAT	was	performed	as	described	previously	by	Polyak	et	al	 [34].	Briefly,	a	




hours.	 	20	μL	of	 the	reaction	was	 then	spotted	onto	 filter	papers	 that	had	been	
treated	with	biotin	and	trichloroacetic	acid	(TCA).	Filter	papers	were	then	dried	
and	washed	2x	 in	10%	 ice	cold	TCA	and	1x	 in	100%	ethanol.	Filters	were	 then	
dried	 and	 submerged	 in	 Optiphase	 supermix	 scintillation	 fluid	 (Perkin	 Elmer,	
USA)	 and	 radioactivity	 was	 measured	 using	 1214	 Racbetta	 liquid	 scintillation	
counter	(LKB	instrument,	Australia).			




a	CAT	 cassette	 in	 this	 study	 is	 in	 agreement	with	 the	previous	 study	described	
above,	concluding	that	disruption	of	the	N-terminal	domain	of	EcBirA	also	affects	
















Figure	3.9:	Activity	assay	of	 JD26186_birA::CAT	 vs.	wild-type.	 3H-biotin	was	
used	 in	 an	 in	 vitro	 activity	 assay	 of	 wild-type	 JD26186	 and	 the	 N-terminal	
disrupted	 mutant,	 JD26186	 birA::CAT.	 Approximately	 4-fold	 less	 activity	 was	
observed	in	the	mutant	compared	to	wild-type.	Assay	was	performed	using	4	μg	
whole	cell	 lysates	as	described	 in	materials	and	methods,	 and	no	 lysate	 sample	











BirA	 binding	 site,	 in	 order	 to	 allow	 regulation	 by	 BirA.	 This	 integration	 vector	
was	constructed	by	digesting	pIT3_CLlacZ	_Trim	vector	[36],	(Figure	3.10a)	with	
BspHI	 and	NheI	 restriction	 enzyme	 to	 remove	 the	 CamR	 gene	 and	 replacing	 it	




































Double-stranded	 oligonucleotide	 containing	 promoter	 sequence	 (EcbioO,	
SabioO,	SabioY	and	SayhfS-SayhfT,	respectively)	was	ligated	upstream	of	the	lacZ	
gene	 in	 the	 placZSH-Trim	 vector,	 as	 KpnI	 and	 SphI	 fragments.	 These	
oligonucleotides	 were	 designed	 to	 include	 BirA	 binding	 sites.	 It	 is	 known	 that	
EcBirA	 binds	 to	 the	 bioO	 operator	 site	 and	 occupies	 the	 -35	 and	 -10	 of	 the	
operator	 region	 [37,	 38]	 (Figure	 3.11a).	 Therefore,	 oligonucleotides	 were	
designed	 to	 comprise	 the	 -50	bp	 to	+20bp	of	 the	 transcription	 start	 site.	 For	S.	
aureus,	 it	 is	 not	 known	 if	 SaBirA	 also	 occupies	 the	 -35	 and	 -10	 region	 of	 the	
operator	region	of	all	three	target	promoters.	Therefore,	the	S.	aureus	promoters	
were	 designed	 to	 include	 -50	 bp	 of	 the	 transcription	 start	 site,	 to	 the	 ATG	
translation	 start	 codon	 	 (Figure	 3.11b-	 3.11d).	 Vector	 transformation	 was	

































Figure	 3.10.	 Parent	 vectors	 of	 pLacZSH_Trim.	 Integration	 vector	
pLacZSH_Trim	 was	 created	 using	 the	 parent	 vector	 (a.)	 pIT3_CLlacZtrim	








and	 bases	 upstream	 and	 down	 stream	 of	 this	 binding	 site,	 comprising	 the	
promoter.	 Blue	 highlighted	 sequences	 are	 the	 overhang	 of	 the	 restriction	
























Figure	 3.12:	 Integration	 vector	 pLacZSH_Trim.	 Promoter	 constructs	 (orange	
boxes,	 representing	 sequences	 outlined	 in	 Figure	 3.11)	 were	 designed	 to	 be	
ligated	 upstream	 of	 LacZ	 gene	 as	 KpnI	 and	 SphI	 fragment.	 Chromosomal	
integration	 of	 construct	 assemble	 in	 this	 vector	 is	 targeted	 for	 HK022	 phage	
attachment	 site	 (green	 box).	 Spectinomycin	 selection	 of	 positive	 integrant	 is	








engineered	 for	 IPTG-inducible	 protein	 expression.	 Double-stranded	
oligonucleotide	 containing	plac	 promoter	 sequence	 flanked	with	BsphI	 and	PciI	
flanking	 sequences	 on	 the	 5ʹ-	 and	 3ʹ-	 end	 of	 the	 oligonucleotide,	 respectively	
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(Figure	3.13a),	was	first	ligated	upstream	of	the	SaBirA	gene	in	the	PciI-treated	
pGEMT-SaBirA(6x	 his)	 vector	 [39]	 (Figure	 3.13b).	 The	 BspHI	 overhang	 is	
compatible	with	the	PciI	overhang,	but	ligation	of	these	overhangs	will	eliminate	
both	 restriction	 sites.	 The	 plac-SaBirA	 construct	 was	 then	 excised	 from	 the	
purified	 pGEMT_plac_SaBirA	 (Figure	 3.13c)	 using	 KpnI	 and	 SphI	 restriction	
enzymes	 and	 sub-cloned	 into	 pIT4_TL_152002	 vector	 carrying	 attP-λ	 phage	
attachment	 site	 [40],	 to	 generate	 a	 new	 integration	 vector	 pIT4_pLac_SaBirA	
(6xhis)	(Figure	3.14).	Sequence	manipulation	in	the	pGEMT	cloning	vector	was	
preferred,	as	this	vector	 is	a	high	copy	vector	that	yielded	suitable	quantities	of	
plasmid	 for	 cloning,	 as	 opposed	 to	 the	 low	 copy	 integration	 vector	
pIT4_TL_152002.		
For	 the	 monomeric	 repressor	 (SaBirA	 F123G)	 construct,	 the	 same	 pLac	
oligonucleotide	was	 ligated	upstream	of	previously	 constructed	vector,	pGEMT-
SaBirA	F123G	(6x	his)[17].	The	resulting	fusion	of	pLac-	SaBirA	(F123G)	construct	
was	 then	 sub-cloned	 into	 pIT4_TL152002	 as	 a	KpnI/SphI	 fragment,	 generating	
integration	vector	construct	pIT4_pLac_SaBirA	F123G	(6xhis).		
For	 the	 integration	 vector	 carrying	 the	 monomeric	 EcBirA	 repressor	
(EcBirA	R119W)	construct,	site-directed	mutagenesis	was	performed	on	pGEMT-




SphI	 restriction	 site	 on	 the	 3ʹ	 end.	 This	 fragment	 was	 then	 digested	 with	 the	
respective	 restriction	 enzymes	 and	 ligated	 to	 a	 vector	 backbone	 pIT4-plac,	
prepared	 by	 digesting	 pIT4-plac-SaBirA	 vector	 with	 PciI	 and	 SpHI	 restriction	
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integration	 plasmid	 were	 not	 successful.	 Therefore,	 another	 strategy	 was	
employed	 in	 order	 to	 generate	 a	 reporter	 strain	 containing	 wild-type	 EcBirA	




Strains	 containing	 pLacZSH-Trim	 (i.e.	 no-promoter	 construct)	 and	 pIT4-
TL-empty	(i.e.	no-repressor	construct)	were	required	to	act	as	controls	in	the	 in	
vivo	 β-galactosidase	 assay.	 As	 pIT4_TL_152002	 vector	 contained	 the	 ccdB	gene	
encoding	a	toxic	protein	[41-43],	direct	transformation	of	this	plasmid	would	not	
result	in	viable	colonies.	Therefore,	the	ccdB	gene	was	removed	from	this	vector	
prior	 to	 transformation,	 by	 digesting	 the	 vector	with	BamHI	 /	BglII	 restriction	
enzymes	 followed	 by	 self-ligation	 to	 generate	 a	 new	 vector,	 pIT4_TL_Empty.	




















Figure	 3.13:	 Construction	 of	 integration	 vector	 carrying	 the	 repressor	
genes.	 (a.)	Double	stranded	oligonucleotide	containing	plac	promoter	sequence	
was	 ligated	 upstream	 of	 the	 repressor	 gene	 in	 the	 parent	 vector,	 (b.)	 pGEMT-
SaBirA(6x	his)	vector.	(c.)	The	resulting	construct	of	pGEMT-plac-SaBirA(6x	his)	












Fusion	 of	 plac::repressor	 (plac::SaBirA)	 extracted	 from	 pGEMT-plac-SaBirA(6x	
















Figure	 3.15:	 Integration	 vector	 to	 be	 used	 in	 assembly	 of	 control	 strain	
containing	 “no-promoter”	 construct.	 placZSH_Trim	 with	 no-promoter	 was	
used	to	transform	the	background	strain	in	order	to	generate	a	 	“no-promoter	“	


















Figure	 3.16:	 Integration	 vector	 to	 be	 used	 in	 assembly	 of	 control	 strain	
containing	 “no-repressor”	 construct.	 pIT4_TL_152002	 was	 modified	 by	
removing	 the	 toxic	 ccdB	 gene	 followed	by	 self-ligation,	 	 no	 repressor	 gene	was	






These	 integration	vectors	were	 subsequently	 employed	 to	 transform	 the	
background	strain	JD26186_	birA::CAT	in	order	to	integrate	a	single	copy	of	each	
construct,	site	specifically	into	the	E.	coli	chromosome	using	the	designated	phage	
attachment	 site.	 Firstly,	 the	 strain	 was	 transformed	 with	 the	 pLacZSH_Trim-
ΔccdB	,		no	repressor	
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derived	 integration	 vectors	 containing	 the	 promoter	 construct.	 Transformants	
were	screened	using	PCR	and	positive	colonies	were	subsequently	selected	and	
transformed	 with	 the	 pIT4-TL-152002	 -derived	 integration	 vectors	 containing	
the	 repressor	 construct.	 The	 protocol	 of	 the	 chromosomal	 integration	 and	 PCR	





integration	 vector	 was	 not	 successful.	 Previous	 study	 revealed	 that	 the	 over-
expression	 of	 EcBirA	 affects	 cell	 viability	 due	 to	 a	 toxicity	 effect	 [44,	 45].	 It	 is	
likely	that	in	the	host	strain,	E.	coli	E2878	(pir+),	the	production	of	lac	repressor	
was	insufficient	to	create	a	complete	suppression	of	the	toxic	gene	product,	which	
resulted	 in	 non-viable	 colonies	 during	 the	 cloning	 process.	 This	 hypothesis,	
however,	was	not	 investigated	 further	 and	 cloning	of	 the	wild-type	EcBirA	 into	
the	integration	vector	was	aborted.	As	an	alternative,	the	parent	strain	JD26186	














Figure	 3.17:	 Diagram	 of	 reporter	 strains	 generated	 in	 this	 study.	 (a.)	 A	
modified	 version	 of	 the	 parent	 strain,	 JD26186_birA∷CAT	was	 used	 to	 generate	
reporter	 strain	 containing	 BirA	 constructs	 and	 the	 respective	 promoter.	
Expression	of	the	repressor	gene	is	driven	by	a	leaky	pLac	promoter,	as	discussed	
in	section	3.3.8	(b.)	For	wild-type	EcBirA	construct,	parent	strain	JD26186	was	
used	 as	 the	 background	 strain	 and	 EcBirA	 production	 were	 sourced	 from	 the	
endogenous	gene.	Biotin	levels	could	be	controlled	by	adding	them	directly	to	the	
media,	 due	 to	 the	 biotin	 auxotroph	nature	 of	 the	 strain.	 In	vivo	 β-galactosidase	










Figure	 3.18:	 Control	 strains	 containing	 “no-promoter”	 and	 “no-repressor“	
constructs.	 (a.)	no-promoter	control	strain	and	(b.)	no-repressor	control	strain	









	 Following	 the	 completion	 of	 reporter	 strain	 construction,	 these	 strains	
were	then	tested	in	β-galactosidase	assays	for	their	ability	to	generate	repression	
of	 target	 promoters	 in	 vivo.	 The	 expression	 of	 repressor	 genes	 in	 the	 reporter	
strain	were	 driven	 by	 the	 lac	 promoter,	 therefore,	 the	 addition	 of	 IPTG	 should	
induce	 the	 production	 of	 these	 repressors	 which	 will	 then	 interact	 with	 their	
respective	promoter,	in	the	manner	that	is	dictated	by	the	introduced	biotin	level.	




	 In	 order	 to	 determine	 the	 optimal	 IPTG	 concentration	 in	 this	 assay,	 a	
strain	 containing	 SaBirA	 repressor	 and	 SabioO	 promoter	 was	 tested	 for	
repression	in	the	presence	of	0.01	mM	IPTG	and	no	IPTG.	In	addition,	to	ensure	
that	 SaBirA	 F123G	 could	 be	 expressed	 in	 this	 system	 and	 that	 the	 mutation	
created	 does	 not	 interfere	 with	 the	 expression	 of	 this	 monomeric	 mutant,	 the	
reporter	strain	with	integrated	SaBirA	F123G	construct	was	also	included	in	the	
test.		
	 It	 was	 expected	 that	 without	 IPTG,	 the	 β-galactosidase	 activity	 would	
remain	 high,	 as	 no	 repressor	 should	 be	 produced	 without	 induction.	
Unexpectedly,	 the	 result	 showed	 that	 in	 the	 absence	 of	 IPTG,	 biotin-responsive	
repression	of	SabioO	promoter	was	still	observed	(Figure	3.19a),	which	suggests	
the	possibility	 that	SaBirA	was	 still	 being	produced.	 In	 addition,	 the	 result	 also	
showed	that	when	the	strains	were	induced	with	0.01mM	IPTG,	no	expression	of	
β–galactosidase	was	observed	at	 any	biotin	 concentration	 (Figure	 3.19b).	 This	
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result	 indicated	 that	 the	addition	of	 IPTG	at	 this	concentration	did	not	result	 in	
biotin-responsive	 repression,	 but	 instead,	 complete	 repression	 of	 the	 promoter	
was	observed.	This	was	probably	due	to	the	high	level	of	SaBirA	expression,	as	a	
result	of	 the	0.01	mM	IPTG	induction.	Based	on	this	data,	 it	was	concluded	that	
the	 addition	 of	 IPTG	 was	 not	 necessary	 as	 biotin-responsive	 repression	 of	 the	
promoter	was	achieved	without	any	addition	of	IPTG,	most	likely	due	to	the	leaky	
pLac	promoter.		
	 Additionally,	 in	order	 to	verify	 this	 leaky	promoter,	 a	western	blot	was	
performed	to	detect	the	production	of	SaBirA	in	the	absence	and	presence	of	0.01	
mM	and	0.1mM	IPTG.	Each	of	the	reporter	constructs	were	engineered	to	express	





derived	 from	E.	coli	 BW25113,	 a	 strain	 known	 to	possess	 lacI+	 lacZ-	phenotype.	
Therefore,	this	strain	should	produce	lac	repressor.	However,	in	this	instance,	it	is	
likely	that	this	strain	might	not	produce	enough	lac	repressor	to	fully	repress	the	
strong	 activity	 of	 the	 lac	 promoter,	 which	 resulted	 in	 basal	 expression	 of	 the	
repressor	 protein.	 The	 response	 generated	 from	 this	 “leaky”	 lac	 promoter	








(a.)	Repression	profile	of	 the	reporter	strains	 in	 the	absence	of	 IPTG	and	(b)	 in	
the	presence	of	0.01mM	IPTG;	blue	line	represents	no-repressor	control,	red	line	
represents	no-promoter	control,	black	line	represents	repressor	strain	containing	
repressor	monomeric	mutant	 (SaBirA	F123G)	and	brown	 line	 represents	 strain	
with	 wild-type	 SaBirA.	 β-galactosidase	 assay	 was	 performed	 to	 test	 the	
repression	 pattern	 in	 response	 to	 the	 increasing	 amount	 of	 biotin.	 Error	 bars	
denote	S.E.M.	of	n	=	9.	 (c.)	Leaky	expression	of	SaBirA	was	detected	 in	western	












	 In	 this	 study,	 a	 series	 of	 E.	 coli	 reporter	 strains	 were	 successfully	
generated.	Firstly,	the	repressor	ability	of	the	endogenous	EcBirA	in	the	parental	
strain,	E.	coli	JD26186,	was	abolished	by	insertion	of	CAT	cassette	into	a	specific	
site	 in	 the	 N-terminal	 domain,	 as	 confirmed	 in	 β-galactosidase	 assay.	 This	
modified	 strain	 was	 then	 used	 as	 the	 background	 strain	 in	 generating	 various	
reporter	strains.	Each	strain	contained	a	particular	repressor	of	interest	(SaBirA	
wild-type,	SaBirA	F123G,	or	EcBirA	R119W)	and	their	respective	promoter.		Due	
to	 unsuccessful	 attempts	 to	 clone	 the	 wild-type	 EcBirA	 into	 the	 integration	
vector,	endogenous	EcBirA	of	the	parental	strain	was	used	in	the	reporter	strain	
containing	wild-type	EcBirA.		







lacZ	 by	 the	 EcBirA	 repressor,	 the	 generation	 of	 this	 strain	 involved	 many	
experimental	stages,	and	would	have	taken	a	long	time	to	complete.		
	 The	general	protocol	for	P1	phage	transduction	required	up	to	five	days	
to	 complete	 [47,	48]	 as	opposed	 to	 two	days	 required	 to	 generate	 the	 reporter	
strain	described	in	this	chapter.	In	addition,	the	fact	that	the	endogenous	EcBirA	









authors	 was	 limited	 to	 analysis	 involving	 EcbioO	 promoter	 and	 EcBirA,	 as	
opposed	to	the	assay	developed	in	this	study	where	the	system	can	be	applied	to	
analyze	 the	 interactions	 of	 other	 transcription	 factors	 with	 their	 respective	
promoters.		
	 Additionally,	 another	 reporter	 assay	was	 developed	 in	Bacillus	 subtillis	
by	Henke	et	al	 [49]	 to	 assess	 the	 ability	of	wild-type	and	mutants	with	deleted	
DNA	 binding	 domain	 of	 B.	 subtillis	 BPL	 to	 regulate	 biotin	 biosynthesis.	 These	




as	 SaBirA,	 using	 gene	 replacement	method	 as	 demonstrated	 in	 the	 subsequent	
work	from	these	same	authors	[50],	this	system	only	allowed	analysis	 involving	
Bs-bioO.	Modification	of	 the	promoter	 in	 this	 system	would	be	difficult	 and	has	
not	 been	 demonstrated.	 In	 contrast,	 the	 in	 vivo	 system	 described	 in	 this	 study	
allowed	analysis	of	more	than	just	one	type	of	promoter	to	be	performed.	
	 The	 reporter	 strains	generated	 in	 this	 study	were	 then	used	 to	analyze	
the	 binding	 of	 SaBirA	 to	 the	 three	 different	 S.	 aureus	 promoters	 in	 vivo,	 and	
comparing	the	interaction	to	the	well	established	binding	mechanism	of	EcBirA	to	
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the	EcbioO	 promoter,	 as	 discussed	 in	chapter	 4.	 In	 addition,	 this	 platform	was	
also	used	to	analyze	the	interaction	of	a	SaBirA	mutant	(SaBirA	D200E),	isolated	
from	advanced	resistance	studies,	with	SabioO	and	SabioY	promoters,	as	detailed	
in	chapter	 5.	Finally,	 the	 integration	vectors	generated	 in	 this	 study	have	been	
designed	 in	 such	 a	way	 that	 cloning	 of	 other	 promoter	 or	 repressor	 constructs	
should	be	relatively	straight	forward,	therefore	allowing	this	reporter	strain	to	be	
applied	 to	 other	 transcription	 factors	 involved	 in	 biotin	 synthesis	 in	 organism	
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 Chapter 4: 
Characterization of SaBirA transcriptional 
repressor function and investigation into the 
























Biotin-regulated	 gene	 expression	 in	 Staphylococcus	 aureus	 is	 more	
responsive	to	environmental	biotin	than	Escherichia	coli.			
	











For	Staphylococcus	aureus,	 an	adequate	supply	of	biotin	 is	vital	 for	 the	bacteria’s	
survival	 and	 pathogenesis.	 The	 key	 protein	 responsible	 for	 maintaining	 biotin	
homeostasis	 in	 bacteria	 is	 the	 biotin	 retention	 protein	 A	 (BirA,	 also	 known	 as	
biotin	protein	ligase).		BirA	is	a	bi-functional	protein	that	serves	both	as	a	ligase	to	
catalyze	 the	 biotinylation	 of	 important	 metabolic	 enzymes,	 as	 well	 as	 a	
transcriptional	 repressor	 that	 regulates	 biotin	 biosynthesis,	 biotin	 transport	 and	
fatty	 acid	 elongation.	 The	 mechanism	 of	 BirA	 regulated	 transcription	 has	 been	
extensively	characterized	in	Escherichia	coli,	but	not	other	bacteria.	In	E.	coli,	biotin	
is	the	co-repressor	that	induces	homodimerization	of	E.	coli	BirA	(EcBirA),	which	is	
a	prerequisite	 for	DNA	binding.	EcBirA	 is	unable	 to	dimerize,	or	bind	DNA,	 in	 its	
non-liganded	form.	In	contrast,	S.	aureus	BirA	(SaBirA)	can	dimerize	in	the	absence	
of	 biotin	 and	 bind	 DNA.	 We	 propose	 that	 this	 activity	 permits	 SaBirA	 greater	
control	of	gene	expression	than	EcBirA.	In	this	study	we	show	that	SaBirA	senses	
varying	biotin	levels	in	the	environment,	and	displays	a	more	rapid	repression	of	
biotin	 biosynthesis	 than	 EcBirA.	 Our	 data	 also	 show	 that	 a	 mutant	 SaBirA	 with	
impaired	dimerization	ability	was	able	 to	bind	DNA,	 in	contrast	 to	 the	analogous	
EcBirA	 mutant.	 Based	 on	 these	 data,	 we	 proposed	 an	 alternative	 DNA	 binding	
mechanism	for	SaBirA	that	is	not	employed	by	EcBirA.	This	alternative	mechanism	
would	 potentially	 allow	 SaBirA	 more	 intricate	 gene	 regulation	 in	 response	 to	







	 Staphylococcus	 aureus	 is	 a	 highly	 adaptable	 bacterial	 pathogen	 with	 an	
extraordinary	 ability	 to	 colonize	 a	 wide	 range	 of	 niche	 microenvironments.	 	 S.	
aureus	 	 infection	 	 is	 	 responsible	 	 for	 	 various	 	 disorders	 	 affecting	 	 the	 skin,	
respiratory	 organs,	 	 soft	 	 tissues,	 	 bones,	 	 joints	 and	 endovascular	 system.	 The	
bacterium	 can	 also	 rapidly	 evolve	 resistance	 to	 host	 immune	 responses	 and	
antibiotic	therapies.	To	establish	a	successful	infection,	S.	aureus	must	co-ordinate	
its	 metabolism	 in	 response	 to	 its	 immediate	 environment.	 If	 the	 bacterium	 is	
unable	 to	 fulfill	 its	 requirements	 for	 certain	 micronutrients	 through	 scavenging	
exogenous	 material	 then	 it	 must	 commit	 to	 the	 synthesis	 of	 these	 factors.	 One	
example	 of	 this	 is	 biotin	 (also	 known	 as	 vitamin	 H	 or	 B7).	 Biotin	 serves	 as	 a	
cofactor	 for	 two	 important	biotin-dependent	enzymes	 in	S.	aureus,	namely	acetyl	
CoA	carboxylase	(ACC)	and	pyruvate	carboxylase	(PC)	[1].	These	enzymes	play	key	
roles	 in	 important	 metabolic	 pathways	 required	 for	 growth	 and	 virulence,	
respectively	[1-4].	ACC	catalyzes	the	first	committed	step	in	the	fatty	acid	synthesis	
pathway	 necessary	 for	 biogenesis	 and	 maintenance	 of	 cell	 membranes	 [5].	 PC	
catalyzes	 the	 production	 of	 oxaloacetate	 that	 is	 fed	 into	 metabolic	 pathways	
required	for	virulence,	such	as	the	TCA	cycle	and	aspartate	biosynthesis	[6,	7].	As	
ACC	 and	PC	 share	 the	 same	 requirement	 for	 protein	 biotinylation,	 balancing	 the	
cellular	demand	for	biotin	with	its	supply	is	critical.		
	 Certain	bacteria,	such	as	Lactococcus	lactis	[8]	and	Streptococcus	suis	[9],	rely	









the	 activity	 of	 a	 high-affinity	 transporter,	 BioY	 [13].	 The	 synthesis	 of	 biotin	 is	
metabolically	costly	requiring	at	least	four	gene	products	and	20	ATP	equivalents	
for	each	molecule	of	biotin	[14].	Therefore,	uptake	of	 the	micronutrient	 from	the	
immediate	 environment	 is	 likely	 to	 be	 preferred	 as	 it	will	 allow	 resources	 to	 be	
diverted	 to	 alternative	 fates.	 However,	 the	 concentration	 of	 biotin	 in	 the	 niche	
microenvironments	 that	 the	 bacteria	 colonize	 is	 likely	 to	 be	 limiting,	 given	 that	
mammalian	cells	have	no	equivalent	biosynthetic	pathway	for	de	novo	synthesis	of	
the	 vitamin.	 The	 concentration	 of	 biotin	 in	 human	 serum	 has	 been	measured	 at	
between	0.5	–	3.0	nM	[15,	16].	
In	both	E.	coli	and	S.	aureus,	biotin	retention	A	protein	(BirA,	also	known	as	
Biotin	 Protein	 Ligase	 or	 BPL)	 is	 the	 protein	 responsible	 for	 maintaining	 biotin	
homeostasis.	 BirA	 is	 a	 bi-functional	 protein	 capable	 of	 both	 enzymatic	
biotinylation	 of	 ACC	 and	 PC,	 as	 well	 as	 transcriptional	 repression	 of	 biotin	
biosynthesis.	 By	 combining	 both	 activities	 in	 a	 single	 protein,	 BirA	 is	 uniquely	
placed	 as	 the	 key	 regulator	 of	 biotin	 metabolism.	 BirA	 from	 the	 prototypical	





biotinyl-5ʹ-AMP	 that	 serves	as	both	a	 reaction	 intermediate	 for	biotin	 ligation	as	
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well	 as	 a	 co-repressor.	 BirA:biotinyl-AMP	 complex,	 known	 as	 the	 holo	 enzyme	
complex,	 then	 has	 one	 of	 two	 fates:	 to	 function	 as	 a	 biotin	 protein	 ligase	 or	
homodimerize	and	serve	as	a	transcriptional	repressor.		
The	 transcriptional	 repressor	 function	 of	 EcBirA	 involves	 a	 co-operative	
interaction	 between	 two	 EcBirA	 subunits	 and	 an	 inverted	 palindromic	 repeat	
sequence	 present	 in	 the	 promoter	 of	 the	 biotin	 biosynthetic	 operon	 (bioO).	
Homodimerization	 of	 the	 holo	 enzyme	 complex	 (KD2-1	 =	 1.5	 x	 10-6	M)	 is	 a	 pre-
requisite	for	DNA	binding	[26,	27].	The	unliganded	enzyme	(i.e.	apo-EcBirA)	does	
not	 dimerize	 at	 physiological	 concentrations	 (KD2-1	 =	 1.4	 x	 10-3	M)	 [28]	 and	 is	




S.	 aureus	 BirA	 (SaBirA)	 shares	 many	 features	 with	 its	 E.	 coli	 equivalent.	
X-ray	crystallography	has	revealed	the	two	proteins	share	homologous	structures,	
and	both	undergo	 the	analogous	conformational	changes	 that	define	 the	ordered	
ligand	 binding	mechanism	 [30,	 31].	 SaBirA	 binding	 to	 the	 bioO	 target	 sequence	
within	 the	 promoter	 of	 the	 biotin	 biosynthetic	 operon	 has	 been	 validated	
experimentally	by	us	and	others	[30-32].	Bioinformatic	studies	have	predicted	the	
presence	 of	 two	 additional	 BirA	 binding	 sites	 in	 the	 S.	 aureus	 genome	 [33],	
suggesting	biotin-regulated	expression	of	the	BioY	biotin	transporter	(encoded	by	
SabioY),	as	well	as	an	operon	containing	SayhfS	and	SayhfT	genes	that	encodes	for	
homologs	 of	 acetyl-CoA	 acetyl	 transferase	 and	 long-chain	 fatty	 acid-CoA	 ligase,	
respectively.	 However,	 transcriptional	 regulation	 of	 these	 genes	 by	 BirA	 has	 not	
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yet	 been	 validated	 experimentally.	 It	 is	 also	 not	 known	 if	 SaBirA	 discriminates	
between	 the	 three	 promoters,	 thereby	 producing	 a	 hierarchy	 of	 regulation.	
Another	 distinction	 between	 S.	 aureus	 and	E.	 coli	 is	 the	 ability	 of	 apo-SaBirA	 to	
dimerize	and	bind	DNA.	Analytical	ultracentrifugation	studies	have	revealed	 that	
SaBirA	can	dimerize	at	significantly	lower	protein	concentrations	(KD2-1	=	29	x	10-6	
M)	 than	EcBirA,	 in	 vitro	 [25].	 Furthermore,	we	 and	 others	 have	 shown	 that	 apo	
SaBirA	 is	 competent	 to	 bind	 DNA,	 as	 evidenced	 by	 small	 angle	 X-ray	 scattering	
analysis	 and	 in	vitro	DNA	binding	 experiments	 [25,	 31,	 32].	Again,	 it	 is	 not	 clear	
whether	 the	 findings	 from	 these	 biophysical	 and	 structural	 studies	 are	
physiologically	important.		
	 In	this	study,	we	analyze	the	effect	of	biotin	on	S.	aureus	growth	and	SaBirA-
regulated	 transcription.	 We	 probe	 the	 repressor	 activity	 of	 SaBirA	 and	 EcBirA		
both	 in	 vitro	 and	 in	 vivo	 using	 an	 E.	 coli	 reporter	 strain.	 Wild-type	 and	
dimerization-defective	mutants	(EcBirA	R119W	and	the	SaBirA	equivalent	F123G)	
were	also	employed	to	understand	the	monomer:dimer	state	and	its	requirement	
for	 repression.	 EMSA	 analysis,	 in	 solution	 crosslinking	 and	 native	 mass	













	 S.	 aureus	 and	 E.	 coli	 strains	 used	 in	 this	 study	 were	 purchased	 from	 the	
American	 Tissue	 Culture	 Collection	 except	 the	 biotin	 auxotroph	 E.	 coli	 strain	
JD26186	(bioC∷Kan)	that	was	obtained	from	National	BioResource	Project	(Japan).	
Unless	otherwise	stated,	all	bacteria	were	cultured	at	37°C	with	vigorous	shaking	
in	 cation-adjusted	 Mueller-Hinton	 II	 broth	 (Becton	 Dickinson	 Company)	 media	
containing	 the	 appropriate	 antibiotic.	 Plasmid	 extractions	were	 performed	using	
the	Plasmid	Mini	Kit	(Qiagen)	and	genomic	extractions	were	performed	using	the	
Wizard®	Genomic	DNA	purification	kit	(Promega).	All	molecular	biology	enzymes	
(DNA	 polymerase	 and	 restriction	 enzymes)	 and	 buffers	 were	 supplied	 by	 New	
England	Biolabs.	 Chemically	 competent	E.	coli	 DH5α	was	 prepared	 in-house	 and	
used	 as	 general	 cloning	 strain,	 unless	 otherwise	 specified.	 Oligonucleotides,	
purchased	 from	Geneworks	Ptd	Ltd,	are	 shown	 in	Supplementary	Table	4	and	5.	




	 Biotin	 depletion	 of	 bacterial	 growth	 media	 was	 performed	 following	
methods	established	previously	 [34].	Briefly,	 slurry	of	 streptavidin-agarose	 resin	







																	S.	 aureus	 NCTC	 8325	 and	 E.	 coli	 strain	 ATCC	 25922	 were	 prepared	 in	
triplicate	 and	 	 grown	 overnight	 at	 37°C	 in	 5	 mL	 Mueller-Hinton	 media	 with	
medium	agitation.	Each	culture	was	washed	three	times	in	5	mL	of	sterile	PBS	and	
re-suspended	 in	2	mL	of	 sterile	PBS.	The	absorbance	of	 each	 culture	OD600	was	
measured	 and	 the	 cell	 suspension	 diluted	 to	 a	 final	 OD600	 of	 0.04	 in	 fresh	with	
culture	media	 containing	 varying	 concentrations	 of	 biotin,	 from	0	 to	 100	nM.	A	
final	volume	of	200	μl	per	well	was	plated	into	96	well	flat-bottom	plates	(Costar)	
in	 triplicate	 and	 the	 sealed	 using	 Breathe-easy®	 gas	 permeable	 membrane	
(Diversified	 biotech,	 BEM-1).	 Cultures	 were	 grown	 for	 24	 hours	 with	 OD600	
measured	every	30	minutes	using	a	Fluostar	Omega	plate	reader	(BMG	labtech).	
Growth	 was	 normalized	 against	 the	 control	 (i.e.	 non-inoculated	 wells)	 and	 the	




	 Overnight	 cultures	 of	 S.	 aureus	 NCTC	 8325	 or	 E.	 coli	 ATCC	 25922	 were	
grown	in	Mueller-Hinton	media.		Each	culture	was	then	centrifuged	at	3200	x	g	for	
10	minutes	 (4°C)	 and	 the	 pellet	was	washed	 three	 times	 in	 5	mL	 of	 sterile	 PBS	




biotin	 and	 20%	 (v/v)	 3H-biotin	 (d-8,9-3H-biotin,	 Perkin	 Elmer).	 Samples	 of	 each	
culture,	200	μL,	were	taken	at	various	time	up	to	90	minutes	post-biotin	treatment.	
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3H-Biotin	 uptake	was	measured	 using	 a	MicroBeta2®	microplate	 counter	 (Perkin	
Elmer).	OD600	 at	 each	 time	point	was	 also	measured	 and	 the	 rate	 of	 uptake	was	
expressed	as	a	measure	of	counts	per	minute/	OD600.	As	a	control,	bacteria	were	
subcultured	 into	10	nM	 	 	 3H-biotin	supplemented	media	and	grown	continuously	
for	 the	 same	 duration	 as	 the	 biotin-treated	 cultures.	 Samples	were	 taken	 at	 the	





	 Biotin-treatment	 was	 performed	 using	 the	 same	 method	 as	 described	 in	
biotin	 uptake	 assay	 except	 10	 nM	 of	 non-labeled	 biotin	 was	 used.	 Cells	 were	
harvested	 at	 relevant	 time	 points	 and	 treated	with	 RNAprotect	 bacteria	 reagent	
(Qiagen),	 following	 the	 manufacturer’s	 protocol.	 The	 bacterial	 cell	 pellet	 was	
resuspended	in	100	μL	of	TE	buffer	containing	1	mg/mL	lysozyme.	For	S.	aureus,	1	
μL	of	10	mg/mL	of	 lysostaphin	 (Sigma	Aldrich)	was	 added	 to	 the	 solution.	 Lysis	
was	 performed	 by	 incubating	 the	 solution	 at	 37°C	 for	 30	minutes	with	 frequent	
mixing	 by	 inverting	 the	 tubes,	 until	 the	 solution	 became	 clear.	 RNA	 extractions	
were	 performed	 using	 RNAeasy	 mini	 kit	 (Qiagen),	 following	 the	 manufacturer’s	
instructions.	 Total	 RNA	 was	 measured	 using	 a	 Nanodrop	 spectrophotometer	
(Thermo	fisher	scientific).	Two	micrograms	of	total	RNA	was	treated	with	20	units	
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of	 DNAse1	 at	 37oC	 for	 1	 hour	 using	 a	 DNAseI	 kit	 (Life	 technology),	 followed	 by	





and	 data	 analysis	 were	 performed	 using	 the	 QuantstudioTM-Dx	 real-time	 PCR	
instrument	 and	 software	 (Thermofisher).	 Relative	 expression	 was	 normalized	
against	 16s	 rRNA	 and	 corrected	 to	 t	 =	 0.	 For	 each	 experiment,	 at	 least	 3	




Reporter	strains	were	constructed	 in	 the	biotin	auxotroph	E.	coli	 JD26186	
(bioC::KanR).	The	DNA	binding	activity	of	 the	endogenous	EcBirA	was	eliminated	
by	inserting	a	chloramphenicol	cassette	(CAT	cassette)	into	the	N-terminal	region	
of	 the	 EcBirA	 gene,	 as	 described	 in	 supplementary	 material	 section	 SE.2.	 	 The	
resulting	E.	coli	strain,	JD26186	birA∷CAT	was	used	as	the	parent	for	all	reporter	
strains	constructed	in	this	study.		
	 Chromosomal	 integration	 vectors	 containing	 either	 the	 birA	 gene	 or	 the	
target	 promoter	 fused	 to	 a	 lacZ	 gene	 were	 constructed	 and	 site	 specifically	
introduced	into	the	chromosome	of	E.	coli	 JD26186	birA∷CAT.	Coding	regions	for	
the	 repressors,	 SaBirA	 and	EcbirA,	 as	 well	 as	mutants	 SabirA	 F123G	 and	EcbirA	
R119W,	 were	 fused	 to	 the	 plac-UV5	 promoter	 and	 ligated	 into	 the	 integration	
vector	 pIT4_TL_15002.	 Sequences	 of	 the	 target	 promoters	 (SabioO,	 SabioY	 and	
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SayhfS-SayhfT	 and	EcbioO)	were	 ligated	 upstream	 of	 a	 lacZ	 reporter	 gene	 in	 the	
integration	vector	pIT3_SH_LacZTrim.	Chromosomal	integration	of	repressor	gene	
and	target	promoter	sequence	of	interest	was	performed	using	the	clonetegration	
method	 [35].	 Positive	 integrants	were	 screened	 by	 PCR,	 as	 previously	 described	
[35].	 Detailed	 cloning	 procedures	 for	 all	 the	 constructs	 can	 be	 found	 in	 the	
supporting	 experimental	 procedures.	 The	 plac-UV5∷SaBirA	 construct	 integrated	
into	the	reporter	strain	indicated	leaky	expression	as	SaBirA	was	obtained	without	








and	 100	 nM	 biotin.	 The	 overnight	 culture	was	 pelleted	 and	washed	 three	 times	
with	minimal	media	containing	no	biotin	and	used	to	inoculate	each	well	of	the	96-
well	growth	plate	containing	minimal	media	supplemented	with	0.5	nM	-	500	nM	
biotin.	 Cells	 were	 grown	 at	 37°C	 with	 gentle	 agitation	 until	 the	 optical	 density	
reached	OD600	=	0.50-0.60,	at	which	point	the	OD600	was	recorded,		cells	lysed	and	
β-galactosidase	 activity	 measured	 as	 described	 previously	 [35].	 The	 β-






Expression	and	purification	of	 apo-	SaBirA	and	apo-EcBirA,	 as	well	 as	 the	
Western	 blot	 procedure	 to	 detect	 the	 purified	 apo-protein,	 were	 performed	 as	
described	in	[25].	Purified	proteins	were	dialyzed	overnight	in	4	L	of	storage	buffer	
(50mM	Tris	pH	8.0,	100	mM	KCl,	1	mM	DTT,	5%	glycerol)	and	stored	at	-80°C	until	








analysis	 by	 nano-electrospray	 ionization-mass	 spectrometry	 (nESI-MS).	 MS	
measurements	were	performed	on	a	Synapt	HDMS	system	(Waters,	UK)	with	the	
sample	introduced	by	nano-electrospray	ionisation	in	positive	ion	MS	mode	from	
platinum-coated	 borosilicate	 capillaries	 prepared	 in-house.	 Instrument	
parameters	 were	 optimized	 to	 remove	 adducts	 while	 preserving	 non-covalent	
interactions,	and	were	as	follows;	capillary	voltage,	1.5	kV;	cone	voltage,	60	V;	trap	








HPLC-purified	 double	 stranded	 oligonucleotides	 containing	 the	 operator	
sequence	of	interest	were	purchased	from	Integrated	DNA	Technology	(USA).	The	
binding	 reactions	 were	 performed	 at	 room	 temperature	 for	 30	 minutes	 using	
EMSA	buffer	(50	mM	Tris	pH	8.0,	50	mM	NaCl,	1	mM	ATP,	1	mM	MgCl2	and	10%	
(v/v)	 glycerol)	 together	with	 10	 nM	 of	 the	 double	 stranded	 oligonucleotide	 and	
varying	 concentrations	of	BirA.	For	analysis	of	holo-enzyme	binding	 reaction	0.1	
mM	biotin	was	 added	 to	 the	EMSA.	Gel	 retardation	was	performed	using	4-12%	







SaBirA	 (13.5	 μM)	 was	 pre-incubated	 with	 26	 µM	 double	 stranded	
oligonucleotide,	0.1	mM	biotin,	10	mM	ATP	and	10	mM	MgCl2	in	PBS,	100	mM	KCl,	
5%	glycerol	and	0.1	mM	EDTA	pH	8.0	at	room	temperature	for	15	min.		A	30-fold	
molar	 excess	 of	 dithiobis	 succinimidyl	 propionate	 (DSP)	 cross	 linker	
(ThermoFisher)	 solubilised	 in	 PBS	 containing	 10%	 DMSO	 was	 added	 to	 the	
reaction,	 such	 that	 the	 final	 DMSO	 content	 was	 1(v/v)%.	 The	 reaction	 was	








	 EcBirA	 binding	 to	 its	 target	 sequence	 bioO	 has	 been	 the	 subject	 of	
numerous	 studies	 [23,	 36-38],	 and	 the	 architecture	 of	 its	 binding	 site	 in	 the	
promoter	 of	 the	 biotin	 biosynthetic	 operon	 is	 well	 characterized	 (Fig.1a).	 The	
EcBirA	 binding	 sites	 are	 composed	 of	 two	 inverted	 palindromic	 sequences	
separated	 by	 16	 bp	 of	 A	 and	 T	 rich	 nucleotides.	 Each	 half	 site	 accommodates	 a	
single	EcBirA	monomer,	the	transcriptional	repressor	functioning	as	a	homodimer.	
EcBirA	regulates	 two	face-to-face	promoters	 located	between	two	coding	regions	
required	 for	 biotin	 biosynthesis,	 namely	 a	 single	 gene	 for	 bioA	 and	 the	 biotin	
biosynthesis	 operon	 containing	 bioB,	 bioF,	 bioC	 and	 bioD.	 The	 BirA	 binding	 site	
directly	 overlaps	 with	 -35	 and	 -10	 sequences	 in	 the	 bioB	 promoter,	 thereby	
directly	competing	with	RNA	polymerase	for	DNA	binding	[36,	39].	Occupation	of	
this	 binding	 site	 allows	 simultaneous	 repression	 of	 bioA	 and	 the	 biotin	 operon.	
SaBirA	target	promoters	have	not	been	the	subjects	of	such	detailed	studies.		
	 Figure	 1b-1d	 shows	 the	 proposed	 biotin-regulated	 promoter	 sequences	
from	 the	 prototypical	 S.	 aureus	 strain	 NCTC	 8325.	 	 Highlighted	 are	 the	 SaBirA	
binding	sites,	predicted	from	previous	bioinformatics	studies	[33].	We,	and	others,	
have	confirmed	that	SaBirA	binds	to	the	bioO	promoter	sequence	through	gel-shift	
and	 solution	 based	 DNA	 binding	 assays,	 as	 well	 as	 small	 angle	 X-ray	 scattering	
experiments	[25,	32].	SaBirA	binding	to	the	SabioY	and	SayhfS-SayhfT	was	verified	
for	 the	 first	 time	 in	 this	 study	(vide	 infra).	All	 three	SaBirA	binding	sites	contain	
two	conserved	palindromic	sequences	separated	by	15	base	pairs.	Like	the	EcBirA	
binding	 element,	 this	 spacer	 is	 rich	 in	 A	 and	 T	 nucleotides	 with	 the	 SabioO	
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S.	 aureus	 growth	 is	 affected	 by	 biotin	 and	 biotin	 uptake	 rate	 is	 increased	
following	changes	in	biotin	levels	in	the	environment.	
To	mimic	the	low	biotin	conditions	experienced	in	vivo,	E.	coli	and	S.	aureus	
were	 grown	 in	Mueller-Hinton	broth	pre-treated	with	 streptavidin-agarose	 resin	
to	remove	biotin.	Using	radio-labeled	biotin,	we	have	demonstrated	this	approach	






to	 reach	 half-maximum	 OD600	 in	 depleted	 media	 was	 longer	 (5.5	 ±	 0.3	 hours)	
compared	 to	 biotin-supplemented	 media.	 The	 addition	 of	 10	 –	 100	 nM	 biotin	
improved	 the	 growth	 of	 S.	 aureus	 (Fig.	 2b),	 with	 10	 nM	 being	 sufficient	 to	
accelerate	the	time	to	reach	half-maximum	OD600	(4.9	±	0.3	hours,	p	=	0.0058,	10	
nM	 vs	 depleted).	 This	 biotin	 concentration	was	 subsequently	 used	 in	 all	 further	




next	 analyzed.	 Both	E.	 coli	 and	 S.	 aureus	 were	 sub-cultured	 into	 biotin-depleted	
media	such	that	the	cells	were	starved	of	exogenous	biotin	and	became	dependent	
upon	de	novo	biotin	synthesis.	At	mid-log	phase,	10	nM	of	3H-biotin	was	introduced	
into	 the	media	 and	 biotin	 uptake	 quantitated	 by	 liquid	 scintillation.	 Cell	 growth	
was	monitored	at	 this	stage	by	both	spectroscopy	and	viable	cell	counts.	Parallel	
cultures	 were	 prepared	 as	 controls,	 where	 bacteria	 were	 subjected	 to	 an	
environment	where	biotin	was	readily	available,	by	growing	continuously	in	10	nM	
3H-biotin	supplemented	media.	The	amount	of	radioactivity	imported	into	the	cells	




3H-biotin	 accumulation	 increased	 in	 S.	 aureus	 for	 the	 first	 30	 minutes	 post	
treatment.	This	data	was	consistent	with	S.	aureus	possessing	a	high-affinity,	active	
transport	 system	 that	 is	 responsive	 to	 environmental	 biotin	 [42-44].	 After	 30	
minutes,	 the	 amount	 of	 tracer	 accumulated	 in	 the	 cells	 decreased	 through	
mechanisms	that	are	not	understood	(Fig.	3b,	solid	black	line).	Viable	cell	counts	
throughout	the	time	course	demonstrated	that	this	was	not	due	to	cell	lysis.	Hence,	
the	 observed	 decrease	 is	most	 likely	 the	 result	 of	 inhibited	 import	 or	 increased	
efflux	 once	 sufficient	 intracellular	 concentrations	 of	 biotin	 are	 obtained.	 In	
contrast	to	biotin-treated	S.	aureus,	the	control	S.	aureus	grown	continuously	with	
10	nM	3H-biotin	showed	a	lower	and	constant	uptake	rate	compared	to	the	biotin-
treated	S.	aureus	 (Fig	 3b,	grey	 line).	The	data	suggests	 that	S.	aureus	was	able	 to	
finely	tune	biotin	import	according	to	cellular	demand	and	the	availability	of	biotin	
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S.	 aureus	 NCTC	 8325	 was	 grown	 until	 mid-log	 phase	 in	 either	 non-depleted	




SabioY	 and	 SayhfS	 were	 all	 up	 regulated	 in	 biotin-depleted	 media	 compared	 to	
non-depleted	 media	 (p	 ≤	 0.001).	 Consistent	 with	 its	 co-repressor	 function,	 the	
addition	 of	 10	 nM	 biotin	 in	 the	 growth	media	 repressed	 expression	 of	 all	 three	
target-genes	 to	 the	 same	 low	 levels	 observed	 in	 the	 non-depleted	 conditions.	 In	
contrast,	the	SaBirA	transcript	showed	no	change	in	any	of	the	conditions	analyzed	
(Fig.	 4d).	 This	 lack	 of	 biotin-controlled	 regulation	 was	 expected,	 as	 the	 birA	
promoter	is	devoid	of	any	potential	binding	sites	for	SaBirA	[33].	
	
Biotin-regulated	 gene	 expression	 in	 S.	 aureus	 and	 E.	 coli	 in	 response	 to	
changing	environmental		biotin	levels.	
	 To	 further	 investigate	 the	 kinetics	 of	 biotin-regulated	 repression,	
transcription	 of	 SabioD	 (the	 first	 gene	 in	 S.	 aureus	 biotin	 biosynthesis	 operon),	
SabioY	 and	 SayhfS	 were	 quantitated	 alongside	 E.	 coli	 bioA	 (EcbioA)	 and	 bioB	
(EcbioB).	Here	cells	were	again	grown	to	mid-log	phase	 in	biotin-depleted	media	
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highly	 responsive	 to	 exogenous	 biotin	 with	 111-fold	 repression	 observed	 at	 15	
minute	post-treatment	(p		=	0.0001,	t	=	0	vs	15	mins).	This	strong	repression	was	
maintained	throughput	the	time	course	(Fig.	5c).	Repression	of	SabioY	and	SayhfS	
was	 not	 as	 pronounced	 as	 for	 SabioD,	 and	 similar	 to	 the	 kinetics	 observed	 for	
EcbioA	and	EcbioB.	Abundance	of	the	SabioY	transcript	was	reduced	by	2.5-fold	at	
15	minutes	(p	=	0.0003,	t=0	vs	15	min),	4.2-fold	at	30	minutes	(p	=	0.0001,	t=0	vs	
30	mins)	 and	 6.0-fold	 at	 90	minutes	 (p	 	 =	0.0001,	 t	 =	 0	 vs	 90	mins)	 (Fig.	 5d).		
Similarly,	SayhfS	repression	was	reduced	by	1.8-fold	at	15	minutes	(	p	=	0.0001,	t	=	
0	vs	15	mins),	4.9-fold	at	30	minutes	(p		=	0.0001,	t	=	0	vs	30	mins)	and	9.0-fold	at	
time	90	minutes	 (p	 	 =	0.0001,	 t	 =	 0	 vs	 90	mins)	 (Fig.	 5e).	As	 controls,	S.	aureus	
grown	in	parallel	in	depleted	media	showed	no	change	in	transcript	levels	between	
the	 0	 and	 90	 minute	 time	 points	 (Sup.	 Fig.	 S3),	 implying	 that	 the	 repression	
observed	 was	 specifically	 due	 to	 biotin.	 	 Together	 these	 data	 highlight	 a	 key	
difference	between	E.	coli	and	S.	aureus,	namely	that	the	latter	is	highly	effective	at	
repressing	 the	 biotin	 biosynthetic	 operon	 when	 exposed	 to	 sufficient	
concentrations	 of	 environmental	 biotin.	While	 some	 of	 the	 differences	 observed	
here	 might	 be,	 in	 part,	 due	 to	 the	 differences	 in	 RNA	 stability,	 the	 data	 clearly	
suggest	a	hierarchy	of	control	between	the	three	target	genes	of	SaBirA,		with	the	
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bacterial	 reporter	 system	was	 constructed	 in	 the	 genome	 of	 a	 biotin	 auxotroph	
strain	of	E.	coli.	These	experiments	permitted	the	study	of	both	EcBirA	and	SaBirA	
in	 a	 homogenous	 genetic	 background,	 thereby	 eliminating	 species-specific	
differences	 that	 complicate	 a	direct	 comparison	of	 the	 two	bacteria	 in	 the	 initial	
series	 of	 cellular	 assays	 already	 described.	 Here,	 a	 birA	 gene	 (either	 SaBirA	 or	
EcBirA)	 under	 the	 control	 of	 pLac-UV5	promoter	was	 site	 specifically	 integrated	
into	 the	 Lambda	 attB	 phage	 attachment	 site	 present	 in	 the	E.	 coli	 chromosome.	
Likewise,	 a	 second	 construct	 containing	 a	 BirA-target	 promoter	 fused	 to	 a	 lacZ	
reporter	gene	was	integrated	into	the	HK022	attB	phage	attachment	site	(Fig.	6a).	
This	approach	 facilitated	 in	vivo	 studies	of	biotin-mediated	gene	control	using	β-
galactosidase	 activity	 as	 a	 convenient	 readout	 for	 gene	 expression.	 Importantly,	
the	 effect	 of	 exogenous	 biotin	 on	 these	 engineered	 genetic	 circuits	 could	 be	
measured	by	simply	adding	appropriate	concentrations	of	 the	micronutrient	 into	
the	growth	media.	To	eliminate	the	DNA-binding	activity	of	endogenous	BirA	in	the	
host	E.	coli	 strain	 JD26186,	 a	 chloramphenicol	 resistance	 gene	was	 inserted	 into	
the	5ʹ	region	of	the	birA	gene	encoding	the	DNA	binding-domain.	The	loss	of	DNA-
binding	 activity	 in	 the	 resulting	 strain,	 JD26186	 birA∷CAT,	 was	 confirmed	
following	integration	of	an	EcbioO-lacZ	reporter.	Whilst	increasing	concentrations	
of	 biotin	 in	 the	 growth	media	 repressed	 β-galactosidase	 expression	 in	 JD26186,	
	 119	
repression	 was	 abolished	 in	 JD26186	 birA∷CAT	 (Fig.	 6b).	 JD26186	 birA∷CAT,	
served	as	the	parent	strain	for	all	reporter	constructs	in	this	study.	
For	 construction	 of	 the	 E.	 coli	 bioO	 promoter,	 the	 DNA	 sequence	
encompassing	-50	to	+20	of	the	promoter	region	was	cloned	upstream	of	the	lacZ	
reporter	 gene	 (Fig.	 1a).	 	 For	 the	 three	S.	aureus	 promoters,	 the	 region	 spanning	










implying	 that	 both	 BPLs	 have	 similar	 repressor	 activities	 in	 vivo.	 In	 all	 cases	
500nM	biotin	was	sufficient	to	completely	repress	β-galactosidase	expression.		
A	 previous	 study	 revealed	 that	 un-liganded	 (apo)	 SaBirA	 was	 able	 to	
dimerize	and	bind	DNA,	with	a	dimerization	constant	of	30	μM	[25].	Considering	
this	high	dimerization	 constant,	 it	 is	 therefore	 expected	 that	under	physiological	
condition,	apo-SaBirA	is	primarily	monomeric.	 	As	it	is	not	possible	to	investigate	
the	apo-form	of	BirA	in	these	in	vivo	assays,	mutant	proteins	with	properties	that	
mimic	 the	 apo	 state	 were	 employed,	 namely	 EcBirA	 R119W	 [26]	 and	 its	




6c,	 grey)	 yielding	 similar	 levels	 of	 β-galactosidase	 activity	 as	 the	 no-repressor	
control	 (Fig.	 6c,	 blue).	 Unexpectedly,	 SaBirA	 F123G	 was	 a	 functional,															
biotin-regulated	repressor	that	reduced	β-galactosidase	activity	for	all	three	target	
promoters	(Fig	6d	–6f,	grey).	For	SayhfS-SayhfT,	the	KR	values	were	2-fold	higher	
for	 SaBirA	 F123G,	 relative	 to	 the	wild-type	 protein	 (p	 =	 0.0009,	WT	 vs	mutant)	
whereas	for	SabioO	the	KR	values	were	3-fold	higher	for	SaBirA	F123G	relative	to	
the	 wild-type	 protein	 (p	 =	 0.0016	 WT	 vs	 mutant).	 This	 decrease	 in	 activity	 is	
consistent	 with	 a	 3-fold	 higher	 KM	 for	 biotin	 that	 has	 been	 reported	 for	 F123G	
relative	 to	 the	wild-type	enzyme	[25].	For	SabioY,	 an	accurate	estimate	of	 the	KR	
was	not	possible	as	500	nM	was	insufficient	to	completely	inhibit	expression	down	
to	 the	 background	 necessary	 to	 generate	 a	 concentration-dependent	 repression	
curve.	At	the	lowest	biotin	concentration	tested	(1	nM),	β-galactosidase	expression	
from	 the	 bioO	 promoter	 was	 significantly	 lower	 than	 the	 corresponding	 no-
repressor	 control	 implying	 both	 the	wild-type	 and	 F123	mutant	 proteins	 partly	
occupied	the	DNA.	This	was	also	observed	for	SaBirA	with	SayhfS-SayhfT,	but	was	
less	 pronounced	 for	 the	 mutant	 protein.	 Together	 these	 data	 suggest	 that	 an	







cell	 lysates	 containing	 over-expressed	 proteins	 with	 ATP	 and	 a	 biotin-accepting	
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substrate	protein	to	facilitate	protein	biotinylation	and	the	concomitant	loss	of	the	
biotinyl-5ʹ-AMP	 co-repressor	 from	 the	 protein’s	 active	 site	 prior	 to	 the	 IMAC	
purification	 step.	 Confirmation	 of	 the	 apo	 state	 was	 confirmed	 through	 two	




measurement	 of	 protein	 mass.	 The	 native	 nESI-MS	 allowed	 characterization	 of	
both	 apo	 and	 the	 biotinyl-5ʹ-AMP-bound	 proteins	 (i.e.	 holo	 proteins)	 and	 their	
multimeric	states.	A	table	summarizing	the	molecular	weight	detected	in	nESI-MS	
is	 presented	 in	Table	 2.	 	 Mass	 spectrometry	 analysis	 confirmed	 that	 at	 10	 μM	
>95%	of	apo-SaBirA	(wild-type)	was	monomeric,	with	a	molecular	mass	of	37892	
Da	 (theoretical	molecular	mass	37892	Da).	The	addition	of	biotin	 and	MgATP	 to	
the	 apo-SaBirA	 (wild-type)	 resulted	 in	 two	 species,	 both	 consistent	with	 that	 of	
monomeric	wild-type	SaBirA	bound	to	 the	reaction	 intermediate	biotinyl-5ʹ-AMP	
(measured	 38470	 Da,	 theoretical	molecular	mass	 of	 38465	 Da)	 and	 the	 dimeric	
form	 of	 this	 SaBirA	 complex	 (measured	 76930	 Da,	 theoretical	 molecular	 mass	
76925	 Da).	 This	 data	 was	 in	 excellent	 agreement	 with	 the	 wildtype	 protein	
existing	in	a	monomer-dimer	equilibrium	in	solution.		




molecular	 mass	 of	 38373	 Da).	 As	 no	 evidence	 of	 dimer	 was	 seen,	 these	 data	
suggest	 that	 the	 F123G	 mutation	 abolished	 dimerization	 in	 solution,	 but	 that	
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could	 be	 visualized	 after	 fractionation	 by	 reducing	 SDS-PAGE.	 The	 inclusion	 of	
DNA	in	the	reaction	enhanced	protein	dimerization.	A	77	KDa	band	corresponding	
to	 the	 SaBirA	 dimer	 was	 observed	 in	 the	 presence	 and	 absence	 of	 DNA	 for	 the	
wild-type	protein	in	both	apo	and	holo	forms	(Figure	8).	For	SaBirA	F123G,	both	
apo	and	holo	produced	weakly	staining	bands	of	this	size	suggestive	of	a	possible	
transient	 interaction	 in	 solution.	However,	 the	addition	of	SabioO	 in	 the	 reaction	
yielded	a	more	intense	product	at	77	kDa,	implying	that	dimerization	is	intensified	
by	 the	 presence	 of	 DNA.	 The	 DNA	 probes	 containing	 SabioY	 and	 SayhfS-SayhfT	
promoter	sequence	were	also	tested	and	were	able	to	induce	dimerization,	as	seen	









in-solution	 assay	 using	 FITC-labeled	 oligonucleotides	 and	 fluorescence	
polarization	 were	 unsuccessful	 due	 to	 poor	 sensitivity	 at	 low	 protein	
concentrations	and	non-specific	binding	at	higher	concentrations.	For	example,	we	








SaBirA	concentrations	 for	all	promoters	(Fig	 9b-d).	The	result	also	suggests	 that	
the	 interaction	 between	 holo-SaBirA	 and	 its	 target	 promoters	 are	 stronger	
compared	to	the	interaction	between	holo-EcBirA	and	EcbioO	promoter,	as	the	last	
apparent	band	shift	in	holo-EcBirA	EMSA	was	observed	at	an	EcBirA	concentration	
of	 15.6	 nM	 as	 opposed	 to	 1.56	 nM	 observed	 for	 holo-SaBirA.	 A	 control	 reaction	
using	 oligonucleotides	 containing	 mutated	 SaBirA	 binding	 sites	 resulted	 in	 no	
protein	binding	(Fig.9e.),	suggesting	that	binding	events	are	sequence	specific.		
	 In	agreement	with	the	in	vivo	assay	data,	EcBirA	R119W	EMSA	did	not	bind	
to	 the	EcbioO	 promoter	 sequence	 (Fig.	 10a.),	whereas	SaBirA	F123G	did	 indeed	
bind	DNA,	albeit	through	a	weaker	interaction	compared	to	wild-type	SaBirA	(Fig.	






to	 a	 probe	 containing	 only	 one	 functional	 half-site	 and	 found	 no	 binding	 was	
observed	 in	 this	 oligonucleotide	 (sup	 Fig.	 S6).	 This	 suggests	 that	 both	 binding	

































In	 this	 study,	 direct	 comparison	 of	 the	 role	 of	 biotin	 upon	 the	 growth	 of	
prototypical	 bacteria	 E.	 coli	 and	 clinically	 important	 pathogen	 S.	 aureus	 was	
performed.	 We	 have	 shown	 that	 biotin	 is	 a	 growth-promoting	 factor	 in	 biotin-
starved	S.	aureus	but	not	for	E.	coli.	Biotin-starved	S.	aureus	also	exhibited	a	higher	
uptake	 rates	 of	 3H-biotin	 compared	 to	 E.	 coli.	 Additionally,	 transcriptomic	 data	
revealed	 that	 following	 the	 addition	 of	 10	 nM	 biotin	 to	 the	 growth	 media,	 the	
transcript	 level	of	S.	aureus	 biotin	biosynthesis	gene,	SabioD,	 	was	more	 reduced	
compared	to	other	biotin-regulated	genes,	SabioY	and	SayhfS,	as	well	as	compared	
with	 E.	 coli	 biotin	 biosynthesis	 genes.	 This	 data	 is	 in	 agreement	 with	 previous	
studies	where	10-45	nM	of	biotin	was	 found	 to	be	 insufficient	 to	 repress	EcbioO	
operator	 in	 vivo	 [51-53]	 and	 to	 down	 regulate	 biotin	 biosynthesis	 in	
enterohaemorragic	 E.	 coli	 isolated	 from	 the	 mouse	 colon	 [54].	 These	 findings	
suggest	 that	 the	 down	 regulation	 of	 S.	 aureus	 biotin	 biosynthesis	 requires	 less	
exogenous	biotin	compared	to	E.	coli	and	other	S.	aureus	biotin-regulated	genes.		
Furthermore,	 we	 performed	 in	 vivo	 and	 in	 vitro	 analyses	 to	 obtain	 new	
insights	 into	 SaBirA,	 the	 protein	 that	 is	 responsible	 for	 regulating	 biotin	
homeostasis	in	S.	aureus.		We	performed	these	analyses	alongside	the	well-studied	
E.	coli	counterpart	protein,	EcBirA.	We	also	assessed	the	ability	of	the	dimerization	




is	 very	 distinct	 to	 EcBirA,	 since	 EcBirA	 R119W	 was	 unable	 to	 bind	 DNA	 as	
demonstrated	 in	 this	 study	 and	 past	 studies	 [26,	 45].	 Crosslinking	 revealed	
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showed	 that	dimerization	of	 the	SaBirA	F123G	was	 enhanced	 in	 the	presence	of	
DNA.	 This	 data	 suggests	 a	 DNA-mediated	 dimerization	 mechanism	 that	 is	 not	
apparent	 in	E.	 coli.	 Furthermore,	 a	 high	 dimerization	 constant	 reported	 for	 apo-
SaBirA	 (KD2-1	 =	 29	 ±	 0.2	 μM)	 [25]	 suggests	 that	 apo-SaBirA	 is	 likely	 to	 be	
monomeric	 within	 the	 intracellular	 environment.	 Therefore,	 it	 is	 reasonable	 to	
suggest	that	SaBirA	F123G	mimics	the	in	vivo	oligomeric	state	of	apo-SaBirA.		This	
argument	was	 supported	 by	 the	 nESI-MS	 results,	where	 both	SaBirA	 F123G	 and	
apo-SaBirA	were	 found	to	be	monomeric	 in	solution.	The	 fact	 that	SaBirA	F123G	
binds	weakly	 to	 DNA	 is	 also	 in	 agreement	with	 previous	 studies	 on	 apo-SaBirA	
where	binding	to	DNA	exhibited	a	KD	value	that	was	6-fold	lower	compared	to	the	






dimer	 provides	 an	 optimal	 structure	 to	 promote	 strong	 binding	 to	 DNA	 and	
simultaneous	 occupation	 of	 both	 binding	 sites	 on	 the	 target	 operator.	 In	 a	 low	
biotin	 environment,	where	SaBirA	 is	 predominantly	monomeric,	 binding	 to	DNA	
may	proceed	by	 the	 interaction	of	monomers	with	 the	operator	half	 sites,	which	
are	 then	 stabilized	 by	 dimerization	 on	 the	DNA	 (Fig.	11b).	We	 suggest	 that	 this	
proposed	mechanism	contributes	to	the	lower	biotin	threshold	required	to	initiate	
gene	repression	by	SaBirA,	compared	to	higher	biotin	concentrations	required	to	
repress	 EcbioO.	 	 In	 addition,	 the	 arrangement	 of	 target	 promoters,	 including	
variation	 between	 the	 operator	 sequence	 and	 the	 position	 of	 the	 -35	 and	 -10	
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elements	 relative	 to	 SaBirA	 binding	 sites,	 also	 contributes	 to	 the	 different	
magnitude	 of	 repression	 and	 the	 different	 level	 of	 expression	 between	 SaBirA-
regulated	genes.		Future	studies	are	still	required	to	precisely	define	the	position	of	
the	 -35	 and	 -10	 elements	 of	 the	S.	aureus	 promoters	 and	how	binding	of	SaBirA	
affects	the	activity	of	RNA	polymerase.		
This	study	reinforces	 the	 link	between	biotin,	 fatty	acid	synthesis	and	cell	
proliferation.	It	is	known	that	biotin-dependent	ACC	catalyzes	the	first	committed	
step	 in	 fatty	 acid	 synthesis	 [55]	 and	 its	 expression	 is	 controlled	 by	 the	 bacteria	
growth	 rate	 [56,	 57].	 ACC	 also	 plays	 an	 important	 role	 in	 the	 regulatory	 switch	
between	 catalytic	 and	 repressor	 function	 of	 SaBirA	 [21].	 In	 dividing	 cells,	 high	
intracellular	ACC	concentration	leads	to	de-repression	of	SaBirA-regulated	genes.	
This	default	co-ordination	allows	biotin	to	be	obtained	through	de	novo	synthesis	
as	 well	 as	 biotin	 import.	 In	 addition,	 it	 is	 known	 acetyl	 CoA	 acetyltransferase	
encoded	by	SayhfS	is	involved	in	mevalonate	pathway,	which	leads	to	the	synthesis	
of	 important	membrane	 biomolecules	 such	 as	 cholesterol	 [58],	 while	 long-chain	
fatty	 acid	 ligases	 encoded	 by	 SayhfT	 plays	 an	 important	 role	 in	 fatty	 acid	
elongation	 [59,	 60].	 The	 transcriptional	 control	 of	 the	 SayhfS-SayhfT	 operon	 by	
SaBirA	 provides	 a	 molecular	 basis	 to	 coordinate	 biotin-mediated	 membrane	
synthesis	during	active	growth	stage.		
Overall,	 in	 this	 study	we	have	validated	 the	 role	of	SaBirA	as	 a	 functional	
repressor	for	biotin	biosynthesis.	We	have	also	presented	the	first	in	vivo	evidence	
of	SaBirA	as	a	functional	regulator	for	SabioY	and	SayhfS-SayhfT	and	provided	the	
first	direct	comparison	of	biotin-controlled	gene	 transcription	 in	S.	aureus	 and	E.	
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Figure	1:	Outline	of	E.	coli	 and	S.	aureus	 promoter	 region.	BirA	binding	
sequence	 within:	 	 a.)	 EcBioO,	 b.)	 SabioO,	 c.)	 SabioY	 and	 d.)	 SayhfS-SayhfT	
promoters	are	shown.	The	BirA	binding	sites	are	highlighted	 in	yellow.	The	
EcBirA	 binding	 site	 is	 located	 between	 two	 face-to-face	 promoters;	 PB	 (red	
arrow)	that	regulates	the	expression	of	bioB,	bioC,	bioF,	bioD	and	PA	(purple	
arrow)	 for	 bioA	expression.	 The	EcBirA	 binding	 site	 overlaps	 with	 the	 -35	
and	 -10	 element	 of	 PB	 (bold,	 red).	 All	 BirA	 binding	 sites	 are	 composed	 of	
perfect	inverted	repeats,	except	for	the	SayhfS-SayhfT	promoter,	which	is	one	
base	pair	away	 from	 forming	perfect	 inverted	repeat	 (green	highlight).	The	
spacing	between	the	inverted	repeats	is	also	shown.	Blue	highlighted	letters	








































































































a.) E. coli 
       











































            








Figure	 3:	 Biotin	 uptake	 assay	 of	 S.	 aureus	 and	 E.	 coli.	 (a.)	 E.	 coli	
Intracellular	3H-biotin	count	in:	( )3H-biotin	-treated	E.	coli			and	( )	E.	
coli	grown	continuously	 in	the	presence	of	10	nM	3H-biotin	(b.)	S.	aureus	
intracellular	 3H-biotin	 count	 in:	 ( )3H-biotin–treated	 S.	 aureus.	 ( )	 S.	
aureus	grown	continuously	in	10	nM	3H-biotin.	( )	represent	CPM/	CFU	
of	 3H-biotin–treated	 S.	 aureus.	 Intracellular	 3H-biotin	 was	 expressed	
CPM/OD600,	X-axis	represents	minutes	post-	mid-log	phase	(or	post	biotin	









































E. coli (+10nM biotin, continuous growth)
E. coli (+10nM biotin, shock treated)
a.) E. coli


















S. aureus (+10nM biotin, continuous growth)


























Figure	 4:	 Up-regulation	 of	 SaBirA	 regulated	 genes	 in	 biotin-depleted	
media.	 Total	 RNA	 was	 harvested	 from	 S.	 aureus	 during	 mid-log	 phase.	 S.	
aureus	 	 culture	was	 grown	 in	Mueller-Hinton	media	 (black),	 biotin-depleted	
Mueller-Hinton	media	(white)	and	depleted	media	supplemented	with	10	nM	
biotin	(grey).	qRT-PCR	was	performed	to	detect	the	expression	of	(a.)	SabioD,	
(b.)	 SabioY,	 (c.)	 SayhfS	 and	 (d.)	 SaBirA.	 Relative	 expression	 was	 normalized	
against	 16s	 rRNA,	 error	 bars	 represent	 S.E.M	 from	 independent	 biological	































































































































































































































regulated	 genes.	 S.	aureus	 	 and	E.	coli	 	was	grown	 in	biotin-depleted	media	
until	mid-log	phase	was	reached	and	treated	with	10	nM	biotin.	RNA	samples	
were	 collected	 at	 0,15,30	 and	 90	 minutes	 post	 biotin	 addition.	 The	 relative	
expression	 of	 biotin	 biosynthesis	 genes	 (a.)	E.	 coli	bioA	 and	 (b.)	E.	 coli	 	bioB	
were	quantified	and	compared	with	(c.)	S.	aureus	bioD.	The	expression	of	two	
other	SaBirA-regulated	genes,	(d.)	SabioY	and	(e.)	SayhfS	were	also	quantified.	
Transcription	 levels	 were	 corrected	 to	 t	 =	 0,	 after	 internal	 normalization	
against	 16s	 rRNA.	 Error	 bars	 represent	 S.E.M	 from	 independent	 biological	
















































































































































(a.)	 Overview	 of	 E.	 coli	 reporter	 strain	 containing	 integrated	 constructs.	 β-
galactosidase	 assay	validation	 showing:	 (b.)	 the	 loss	of	 repressor	 function	of	
the	 JD26186	birA∷CAT	strain	(red)	compared	to	 the	wild-type	 JD26186	with	
un-modified	 EcBirA	 (black),	 (c.)	 EcBirA	 interaction	 with	 EcbioO.	 The	
interaction	of	SaBirA	with	(d.)	SabioO,	(e.)	SabioY,	(f.)	SayhfS-SayhfT	promoter	
is	 shown.	Wild	 type	proteins	are	shown	 in	 (black)	and	dimerization	mutants	
are	shown	in	(grey).	Strain	with	no	integrated	BirA	was	also	included	to	serve	
as	 control	 (blue).	 A	 control	 strain	without	 integrated	 promoter	was	 used	 to	
measure	the	background	lacZ	activity	at	each	biotin	concentration	(≤	10	units),	
which	 has	 been	 subtracted	 to	 give	 values	 shown	 in	 the	 graphs.	 Error	 bars	
denote	S.E.M	from	independent	biological	replicate	of	at	least	(n	=	6).	
	


















































































Table	1:	 In	vivo	binding	assay	equilibrium	binding	constant	 for	biotin	 (KR).	
The	amount	of	biotin	required	to	achieve	half-maximum	repression	at	equilibrium	
was	 calculated	 from	 the	 graph	 using	 GraphPad	 Prism	 one-site	 specific	 binding	
equation:	Y=	Bmax*X^h	/(KR^h	+	X^h).		Where	Y	=	specific	binding	(LacZ	unit),	X	=	

































Figure	 7:	 	 nESI-MS	 of	 wild-type	 SaBirA	 and	 SaBirA	 F123G.	 Nano-
electrospray	 ionization-mass	 spectrometry	 of	 (a.)	 apo-SaBirA	 (wild-type),	
(b.)	 holo-SaBirA	 (wild-type),	 (c.)	 apo-SaBirA	 F123G	 and	 (d.)	 holo-SaBirA	
F123G	 is	 shown.	Peaks	 representing	 the	oligomeric	 state	of	 the	protein	are	
marked	 by	 the	 sphere	 symbols.	 Monomeric	 apo	 protein	 is	 presented	 by	 a	
single	 solid	 blue	 sphere	 (wild-type	 SaBirA)	 and	 purple	 sphere	 (SaBirA	
F123G).	The	presence	of	ligand	is	presented	by	a	triangle.	Dimeric	protein	is	



























































Apo-F123G	 Monomer	 37800	(-Met)	 37802	 Monomer,	 no	
ligand	








mass	 and	 detected	 mass	 is	 outlined.	 Predicted	 oligomeric	 state	 and	



















Figure	 8:	 DSP	 cross-linked	 SaBirA	 SDS-PAGE.	 Cross-linking	 reactions	
were	 performed	 using	 DSP	 cross	 linker	 as	 described	 in	 materials	 and	
method.	SaBirA	wildtype	and	SaBirA	F123G	were	tested	for	dimerization	in	


































containing	 1mM	ATP	 and	0.1	mM	biotin.	 10	 nM	of	DNA	probe	was	 incubated	
with	protein	for	0.5	hour	at	room	temperature	prior	to	electrophoresis.	Gel	was	




















buffer	 containing	 1mM	 ATP	 and	 0.1	 mM	 biotin.	 10	 nM	 of	 DNA	 probe	 was	
incubated	with	protein	for	0.5	hour	at	room	temperature	prior	to	electrophoresis.	
Gel	was	stained	with	GelRed,	as	outlined	in	materials	and	methods.	The	results	are	





























conditions,	 SaBirA	 (black)	 binds	 biotin	 (blue	 triangles).	 Under	 these	
conditions,	holo-SaBirA	follows	the	same	binding	mechanism	as	holo-EcBirA	
where	pre-formed	dimer	binds	 to	DNA	 (brown	 squares	 represent	 operator	
half-sites).	 (b.)	 Under	 low	 biotin	 conditions,	 SaBirA	monomers	 can	 bind	 to	
















Supplementary	 Fig	 1	 S1:	 Growth	 curve	 of	 E.	 coli	 and	 S.	 aureus	 in	 biotin	
depleted	 media	 and	 biotin	 supplemented	 media.	 Growth	 curve	 of	 (a.)	E.	 coli		
and	 (b.)	 S.	 aureus	 	 were	 obtained	 by	 growing	 bacteria	 in	 100nM	 biotin	
supplemented	 (black),	 30nM	 biotin	 supplemented	 (green),	 10nM	 biotin	
supplemented	(red),	3nM	biotin	supplemented	(blue)	and	depleted	media	is	shown	



















































































+ 100 nM biotin 1.5 ± 0.0 1.2 ± 0.0
+ 30 nM biotin 1.5 ± 0.0 1.2 ± 0.0
+ 10 nM biotin 1.5 ± 0.0 1.2 ± 0.0
+ 3 nM biotin 1.5 ± 0.0 1.2 ± 0.0
Biotin-depleted 1.4 ± 0.0 1.2 ± 0.0
Max. OD600Media Time to reach 1/2 Max. OD600 

















Supplementary	 Fig	 2	 S2:	 Biotin	 uptake	 assay	 results	 showing	 count	 per	
minute	 of	 3H-biotin	 uptake,	 cell	 density	 and	 viability	 assay.	 	 (a.)	 3H-biotin	












































































































































































holo-EcBPL	 incubated	with	 SaPC90,	 (3)	 apo-SaBPL	 incubated	with	 	 SaPC90	
and	 (4)	 holo-SaBPL	 incubated	 with	 	 SaPC90	 	 were	 probed	 using	 Alexa-
Fluor488	 conjugated	 streptavidin,	 to	 detect	 biotinylated	 product.	 The	





























wildtype	 and	 SaBirA	 F123G	 were	 tested	 for	 dimerization	 in	 the	 absence	 or	


















































































































Strain name Genotype Description Source 
JD26186 bioC::Kan 




JD26186 birA::CAT bioC::Kan birA::CAT 
JD28186 strain with N-terminal CAT cassette 







JD26186 birA::CAT strain with SaBioO lacZ 
reporter chromosomally integrated at HK022 att 
site, and placUV5-SaBPL( wildtype) cassette 







JD26186 birA::CAT strain with SaBioY-lacZ 
reporter chromosomally integrated at HK022 att 
site  and placUV5-SaBPL( wildtype) cassette 







JD26186 birA::CAT strain with yHFS-T-lacZ 
reporter chromosomally integrated at HK022 att 
site, and placUV5-SaBPL( wildtype) cassette 







lacZ)HK (placUV5-SaBPL F123G)l 
JD26186 birA::CAT strain with SaBioO-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (monomeric mutant) 








lacZ)HK (placUV5-SaBPL F123G)l 
JD26186 birA::CAT strain with SaBioY-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (monomeric mutant) 







lacZ)HK (placUV5-SaBPL F123G)l 
JD26186 birA::CAT strain with yHFS-T-lacZ 
reporter chromosomally integrated at HK022 att 
site and plac-UV5-SaBPL (monomeric mutant) 




birA bioC::Kan  (EcBioO-lacZ)HK 
JD26186 strain with EcBioO-lacZ reporter 






lacZ)HK (placUV5-birA R119W)l 
JD26186 birA::CAT strain with EcBioO promoter 
and placUV5-birA R119W (monomeric mutant) 
chromosomally integrated at lambda att 
this 
study 
BL21 (λ DE3) 
E. coli B ompT DhsdS (rB–mB–) dcm 







E. coli B F- ompT DhsdS (rB–mB–) 
dcm+TetR gal λ(DE3) endA Hte 
[argU proL CmR] [argU ileY leuW 











































pKD46 AmpR , oriR101, λ-Red  recombinase expression plasmid Datsenko & Warner (2000)
pK(HsBPL ) template for HsBPL to clone into pKD46 (AmpR , pBR322/pUC ori, HsBPL-6xHis, pTac-uV5 ) Mayende, et al (2012)
pKD46(HsBPL ) pKD46 containing HsBPL gene under the control of arabinose promoter this study
pCY216(birA) p15A ori, medium copy plasmid containing CmR and CAT promoter Cronan & Wallace (1995)
pGEMT-SaBPL(6xHis) pGEMT plasmid containing saBPL with 6x his-tag Pendini et al,  (2008)
pGEMT-birA(6xHis) pGEMT plasmid containing birA  with 6x his-tag Soares Da costa, et al (2014)
pIT3_CLlacZ_Trim Chromosomal integration plasmid  (λ-attP, CmR, R6Kγ  ori, lacZ) Cui et al PNAS (2013)
pIT3-SH-152002 Chromosomal integration plasmid  (HK022-attP, SpecR, R6Kγ  ori, ccdB, pUC ori) Shearwin lab, Adelaide university
pIT3_SH_LacZTrim Chromosomal integration plasmid  (HK022-attP, SpecR, R6Kγ  ori, lacZ) this study
pIT4_TL_152002 Chromosomal integration plasmid  (λ-attP, TcR, R6Kγ  ori, ccdB, pUC ori) St. Pierre, et al (2013)
pGEMT-birA R119W  (6xHis) pGEMT plasmid containing birA R119W  (6x his-tag) this study
pGEMT-SaBPL F123G (6xHis) pGEMT plasmid containing saBPL F123G (6xhis-tag) Soares Da costa, et al (2014)
peT16b-birA R119W  (6xHis) pET16b expression vector containing birA R119W(6x his-tag) this study
pET16b-SaBPL F123G (6xHis) pET16b expression vector containing saBPL F123G  with (6xhis-tag) Soares Da costa, et al (2014)
pIT3_SH_SabioO_LacZ SabioO promoter sequence cloned into pIT3_SH_LacZTrim, upstream of the lacZ gene this	study
pIT3_SH_SabioY_LacZ SabioY promoter sequence cloned into pIT3_SH_LacZTrim, upstream of the lacZ gene this	study
pIT3_SH_yHFT_LacZ yHFT promoter sequence cloned into pIT3_SH_LacZTrim, upstream of the lacZ gene this	study
pIT4_TL_SaBPL (WT) plac-UV5 fused with SaBPL (wildtype) sequence cloned into pIT4_TL_152002 this	study
pIT4_TL_SaBPL (F123G) plac-UV5 fused with SaBPL (F123G) sequence cloned into pIT4_TL_152002 this	study
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Target gene Primer name Primer sequence 5'-3'
S. aureus bioD qSA2716_F GCAAGGTGTGGTGATACAGG
qSA2716_R ACACGTGGTCATCGAGTTTG
S. aureus bioY qSA2552_F AATGGCAAGCCAGCAACTAC
qSA2552_R GGATTGGTACCGGTAATTCCA
S. aureus BPL qSA1473_F TCATTCGGCCATTTCACTTT
qSA1473_R AAAGGGCAAGGACTTTGGAT
S. aureus yHFT qSA0557_F AACTAAATGCCCGCATCACT
qSA0557_R TGCCATTTACCTTCCATCATC
S. aureus 16s rRNA qSA0002_F GAACCGCATGGTTCAAAAGT
qSA0002_R CGTAGGAGTCTGGACCGTGT
E. coli 16s rRNA Ec_16s_F GTTAATACCTTTGCTCATTGA
EC_16s__R ACCAGGGTATCTAATCCTGTT 
E. coli bioB Ec_BioB_F ATTACTACAACCACAACCTGGACAC
Ec_BioB_R AATAAAATCAAAGGCATCGACATC
E. coli bioA Ec_BioA_F AGGTGGCGGATATTGAAGTACAG
Ec_BioA_R CAACTGTTGCGGGAGAATAATATAG













Top strand oligo containing sabioO wildtype sequence 
DS-SaBioO oligo 2
CCTTAAATGTAAACTTATTAATTATAAAAGTTTACATTTAAGG 
Bottom strand oligo containing sabioO wildtype sequence 
DS-SabioY oligo 1
AACTTATTGTAAACTTTTCATTTCTTAAAGTTTACAATGGTGCT
Top strand oligo containing sabioY wildtype sequence 
DS-SabioY oligo 2
AGCACCATTGTAAACTTTAAGAAATGAAAAGTTTACAATAAGTT
Bottom strand oligo containing sabioY wildtype sequence 
DS-yHFS-T oligo 1
TTATATAATGTTAACAAGATGTATTTTAAAGTTTACATTGAGTGA
Top strand oligo containing yHFS-T wildtype sequence 
DS-yHFS-T oligo 2
TCACTCAATGTAAACTTTAAAATACATCTTGTTAACATTATATAA
Bottom strand oligo containing yHFS-T wildtype 
DS-HS1m oligo 1
GCCTTACACAGACGATTATTAATTATAAAAGTTTACATTCGGAT
Top strand oligo containing mutated sequence of the first half-site of SaBPL recognition sequence for sabioO
DS-HS1m oligo 2
ATCCGAATGTAAACTTTTATAATTAATAATCGTCTGTGTAAGGC
Bottom strand oligo containing mutated sequence of the first half-site of SaBPL recognition sequence for sabioO
DS-HS2m oligo 1
GCCTTAAATGTAAACTTATTAATTATAAAAAGCAGACACCGGAT
Top strand oligo containing mutated sequence of the second half-site of SaBPL recognition sequence for sabioO
DS-HS2m oligo 2
ATCCGGTGTCTGCTTTTTATAATTAATAAGTTTACATTTAAGGC
Bottom strand oligo containing mutated sequence of the second half-site of SaBPL recognition sequence for sabioO
DS-HSm oligo 1
GCCTTACACAGACGATTATTAATTATAAAAAGCAGACACCGGAT
Top strand oligo containing mutated sequence of both half-site of SaBPL recognition sequence for sabioO
DS-HSm oligo 2
ATCCGGTGTCTGCTTTTTATAATTAATAATCGTCTGTGTAAGGC








	 Colony	 forming	unit	 (CFU)	assays	were	performed	on	S.	aureus	 samples	
collected	at	 time	0,	15,	30	and	90	minutes	post-biotin	 treatment.	50μL	of	 each	
sample	 were	 collected	 and	 serial	 dilutions	 were	 performed	 to	 obtain	 final	











[2]	 and	 cloned	 into	ClaI	 restriction	 site	 of	 pKD46	 [3].	 The	 resulting	 clone	was	
then	transformed	into	E.	coli	JD26816.		
The	 chloramphenicol	 resistance	 gene	 (CmR)	 under	 the	 control	 of	 CAT	






The	 N-terminal	 knockout	 was	 performed	 using	 a	 homologous	
recombination	based	method	previously	described	[3]	Briefly,	electro-competent	
cells	of	the	parent	strain,	JD26186	containing	pKD46(HsBPL),	were	transformed	
with	 1	 μg	 of	 CAT-CmR	 PCR	 product	 flanked	 with	 birA	 N-terminal	 homologous	
sequences.	The	transformation	mixture	was	plated	onto	1.5%	LB	agar	containing	
10	μM	biotin	+	0.2mM	IPTG	+	100μg/mL	chloramphenicol	and	grown	overnight	
at	 30°C.	 The	 resulting	 colonies	 (JD26186	 birA::CAT)	 were	 screened	 using	 PCR	
and	 the	 N-terminal	 knockout	 confirmed	 by	 sequencing.	 The	 abolition	 of	 DNA	
binding	was	 also	 validated	 in	 β-galactosidase	 assay	 (Fig.	 6b).	 	 The	 strain	was	
then	 incubated	 at	 42°C	 to	 eliminate	 the	 pKD46(HsBPL)	 helper	 plasmid,	 which	
carries	a	temperature	sensitive	origin	of	replication.	
	
S.E.3	 :	 Cloning	 of	 repressor	 gene	 and	 operator	 sequence	 into	 integration	
plasmids.	
The	chromosomal	integration	plasmid	pIT3_SH_LacZTrim	was	created	by	
excising	 the	 spectinomycin	 resistance	 gene	 (SmR)	 from	 pIT3-SH-152002	 and	
ligating	 the	SmR	 fragment	 into	 the	NheI	 /	BstBI	backbone	of	 pIT3_CLlacZ_Trim	




steps.	 Firstly,	 a	 double	 stranded	 oligo	 containing	 the	 pLac-UV5	 promoter	
sequence	 and	 lac	 operator	 sequence	upstream	of	 the	 repressor	 gene	 (SabirA	 /	
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EcbirA)	was	inserted	in	the	KpnI	/	PciI	 fragment	of	pGEMT-SaBirA	(6x	his)	and	
pGEMT-birA(6x	 his)	 vector,	 respectively.	 The	 resulting	 pLac-UV5-repressor	




The	 integration	 of	 pLac-UV5-EcbirA	(WT)	 into	 JD26186_birA::CAT	 strain	
did	 not	 yield	 any	 positive	 clones,	 despite	multiple	 attempts.	 As	 an	 alternative,	
parental	strain	E.	coli	JD26186	containing	endogenous	EcbirA	with	non-modified	
N-terminal	 domain	 was	 used	 instead	 of	 JD26186_birA::CAT.	 The	 promoter	
construct	 EcbioO∷lacZ	was	 then	 integrated	 into	 this	 wild-type	 strain	 to	 give	




A	 preliminary	 assay	 was	 conducted	 to	 test	 the	 activity	 of	 pLac-
UV5∷SaBirA(6x	his)	in	the	presence	and	absence	of	IPTG	(data	not	shown).	The	









Protein	 samples	 were	 run	 on	 SDS-PAGE	 and	 transferred	 onto	 Hybond-
PVDF	 membrane	 (Amersham)	 using	 Hoefer	 semiphor	 TE70	 apparatus	
(Pharmacia).	Transfer	were	done	at	80mA	for	1	hour,	all	blocking	was	done	for	1	
hour	at	room	temperature	for	1	hour	in	5%	skim	milk	PBS/0.1%	tween,	followed	
by	 washing	 in	 PBS/0.1%	 tween.	 For	 detection	 of	 6xHis	 recombinant	 protein,	
rabbit-anti-6xHis	 antibody	 (Cell	 Signaling	 Technology)	 was	 used	 as	 primary	
antibody	 and	 detected	 using	 donkey	 anti	 rabbit-CY5	 antibody	 (Jackson	









was	 incubated	 at	 37°C	 for	 1	 hour,	 the	 products	were	 run	 on	 SDS-PAGE	before	
Western	 transfer	 onto	 PVDF	 membrane.	 The	 resulting	 blot	 was	 subsequently	
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	 Antibiotic	 resistance	 evolves	 due	 to	 bacteria’s	 ability	 to	 adapt	 to	 the	
exposure	of	toxic	agents	[1].	It	is	evident	that	the	increasing	resistance	to	current	
antimicrobials	 is	a	serious	problem	and	that	there	 is	an	urgent	need	to	replenish	
the	 current	 antibiotic	 discovery	 pipeline	 with	 new	 chemotherapeutics	 [2].	
Increases	 in	 economic	 burden,	 health	 care	 costs	 and	 mortality	 rates	 are	 all	
attributed	 to	 antibiotic	 resistance	 [3].	 Efforts	 to	 generate	 novel	 classes	 of	
antibiotics	necessary	to	combat	drug	resistance	have	been	disappointing,	with	only	
four	 new	 classes	 of	 antibiotic	 discovered	 in	 the	 past	 forty	 years	 [4].	 Targeting	
essential	 metabolic	 enzymes,	 such	 as	 BPL,	 is	 an	 attractive	 approach	 for	 the	
discovery	of	new	antibiotics	[5].	A	number	of	antiviral	drugs	have	been	discovered	
using	 similar	 approach	 whereby	 new	 drugs	 were	 designed	 as	 analogues	 of	 the	
enzyme’s	natural	ligand	[6].		
	 In	 recent	 years,	 research	 targeting	 S.aureus	BPL	 	 (SaBPL,	 also	 known	 as	
SaBirA)	has	generated	multiple	promising	inhibitors	with	high	selectivity	towards	




to	 give	 rise	 to	 biotinol-5ʹ-AMP	 (Figure	 1,	 structure	 2).	 This	 compound	 lacks	
specificity	 as	 it	 also	 inhibits	 human	 BPL	 (HsBPL)[11].	 Improved	 selectivity	 was	
achieved	by	substituting	the	phosphoanhydride	linker	with	a	1,2,3	triazole	[Figure	
1,	 structure	3].	Moreover,	 further	studies	performed	on	 the	biotin	 triazole	series	




inhibitor	with	whole	 cell	 activity	 against	Mycobacterium	tuberculosis	 (IC50	 =	 140	
nM)[13].	 For	 reasons	 that	 are	 not	 understood,	 this	 compound	 does	 not	 have	
antimicrobial	activity	against	S.	aureus.	We	recently	designed	and	characterized	a	
potent	 SaBirA	 inhibitor	 containing	 the	 acylsulfonamide	 linker	 but	 devoid	 of	 the	
ribose	group	that	was	previously	shown	to	be	dispensable.	This	compound,	known	
as	BPL199	[Figure	 1,	 structure	6],	was	 found	to	be	highly	potent	against	SaBirA		
(Ki	 =	 2.4	 nM),	 and	 demonstrated	whole	 cell	 activity	 against	S.	aureus	 (Minimum	
Inhibitory	 Concentration	 (MIC)	 =	 0.25-0.50	 μg/mL)[12].	 	 A	 crystal	 structure	 of	
SaBirA	in	complex	with	BPL199	has	now	been	determined	(Figure	2).	As	expected,	
the	 compound	 occupies	 the	 biotin	 and	 ATP	 binding	 pockets	 in	 the	 same	 mode	
adopted	by	the	reaction	intermediate,	biotinyl-5ʹ-AMP.	
This	structural	data	reveals	that	BPL199	is	an	inhibitor	due	to	competitive	




metabolic	 pathway	 would	 possibly	 make	 target-based	 resistance	 more	 difficult	
[14].	In	this	chapter,	the	effect	of	the	lead	compound,	BPL199,	on	DNA	binding	and	
gene	expression	was	investigated	using	both	in	vitro	and	in	vivo	methods.	
Furthermore,	 advanced	 resistance	 studies	 have	 been	 performed	 in	 our	
laboratory	 to	 investigate	 possible	 resistance	 mechanisms	 to	 BPL199.	 Here,	 S.	
aureus	NCTC	8325	evolved	resistance	 in	vitro	by	passaging	cultures	continuously	
in	sub-optimal	concentrations	of	BPL199,	as	described	in	previous	literature	[15].	









dimerization	 and	 subsequently,	 DNA	 binding	 and	 transcriptional	 regulation	
activity.	 	As	aspartic	acid	is	chemically	similar	to	glutamic	acid,	with	only	a	single	
carbon	 chain	 length	 difference	 distinguishing	 the	 two	 amino	 acids,	which	 raised	
the	 hypothesis	 that	 the	 effect	 of	 the	 D200E	mutation	 is	 likely	 to	 be	 subtle.	 The	
effect	of	this	single-base	substitution	mutation	on	DNA-binding	activity	of	SaBirA	












Figure	 1:	 Structure	 of	 lead	 compounds	 against	 SaBirA.(1.)	 Reaction	
intermediate	 biotinyl-5ʹ-AMP,	 (2.)	 derivative	 of	 intermediate	 reaction	 with	
non-hydrolysable	phosphodiester	linker,	biotinol-5ʹ-AMP	is	shown	in,	(3.)	next	
generation	of	inhibitor	with	higher	potency	containing	1,2,3	triazole	linker	(4.)	
improved	 stucture	 of	 1,2,3	 triazole	 with	 removed	 ribose	 moeity	 (5.)	 recent	







Figure	2:	 Crystal	 structure	of	BPL199	 in	 complex	with	SaBirA	 .	
BPL199	 (red)	 occupies	 the	 catalytic	 site	 of	 the	 enzyme,	 which	 is	








Alignment	 of	 X-ray	 crystal	 structures	was	 performed	 using	 the	 structural	
analysis	 program,	 UCSF	 Chimera.	 Superimposition	 of	 SaBirA	 in	 complex	 with	











mM	 MgCl2	 and	 5%	 (v/v)	 glycerol.	 Double	 stranded	 oligonucleotides	 (10	 nM)	




final	 volume	 of	 10	 μL	 and	 incubated	 for	 30	 minutes	 at	 room	 temperature.	 For	
analysis	 of	 BPL199,	 100	 μM	 of	 compound	 was	 added	 to	 the	 EMSA	 buffer.	 As	
BPL199	was	 reconstituted	 in	 100%	 DMSO,	 the	 final	 DMSO	 concentration	 in	 the	
binding	buffer	was	2.5%	(v/v).	In	order	to	directly	compare	SaBirA-BPL119	bound	
and	holo-SaBirA	(biotinyl-5ʹ-AMP-bound	SaBirA),	a	control	reaction	was	prepared	
by	 adding	 100μM	 biotin	 and	 2.5%	 (v/v)	 DMSO	 to	 the	 binding	 reaction.	 The	
reaction	was	run	on	4-12%	TBE	gradient	gel	in	0.5x	TBE	buffer	(Life	technologies)	




S.	 aureus	 NCTC	 8325	 was	 grown	 overnight	 at	 37	 °C	 in	 biotin-depleted	
Mueller-Hinton	media.	The	overnight	culture	was	then	used	to	inoculate	10	mL	of	
fresh	 biotin-depleted	 Mueller-Hinton	 media	 and	 	 grown	 until	 mid-log	 phase	
(OD600	=	1.4-1.6).	The	culture	was	then	treated	by	adding	either	10	nM	BPL	199	
or	 3.9	 μM	 (i.e.	 equivalent	 of	 4x	MIC).	 500μL	 of	 culture	was	withdrawn	 at	 time	
point	0,	15,	30	and	90	minutes	post-	BPL199	addition.	The	bacterial	pellet	from	
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each	 time	 point	 was	 then	 treated	 with	 1	 mL	 RNAprotect	 solution	 (Qiagen),	





the	 extracted	 samples	 with	 DNaseI	 enzyme	 (Life	 technologies),	 according	 to	
manufacturer’s	 instructions.	 A	 mixture	 of	 RNA	 template,	 PCR	 primers	 and	
Superscript®	 III	 platinum®	 SYBR®	 1-	 step	 QRT-PCR	 kit	 (Life	 technologies)	 was	
prepared	as	outlined	in	Chapter	2.	QRT-PCR	was	performed	using	QuantstudioTM	
instrument	(ThermoFisher).	Result	was	normalized	against	16s	rRNA	and	relative	
expression	was	 corrected	 against	 t	 =	 0,	 according	 to	 the	 Livak	method	 [18]	 and	
analyzed	using	Graphpad	Prism.		
	
5.2.5	 Cloning	 of	 	 SaBirA	 D200E	 into	 expression	 vector	 pET16b	 and	
integration	vector	pIT4-TL-152002	
	 SaBirA	D200E	was	generated	 in	the	pGEMT-SaBirA	(6x	his)	plasmid	using	
the	Quickchange	 Site	Directed	Mutagenesis	 Kit®	 and	Mutagenesis	 primers,	 B481	
(5ʹ-GGTTGCTAATAATGAAGGTATAGAAGCAATAATATGTGG-3ʹ)	 and	 B482	 (5ʹ-





with	 KpnI	 and	 SpHI	 restriction	 enzymes	 	 and	 ligated	 into	 similarly	 treated	
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	 pET16B-SaBirA-D200E-(6xhis)	 and	 pET16b-SaBirA-wildtype-(6xhis)		
plasmids	 were	 transformed	 into	 the	 expression	 strain	 E.	 coli	 	 BL21(DE3)-RIPL.	
Expression	of	this	protein	was	performed	following	previous	protocols	[16,	19].	To	
generate	apo-BirA,	bacterial	lysate	was	incubated	at	30°C	for	1	hour	with	purified	
biotin	 domain-GST	 fusion	 from	 S.	 aureus	 [20]	 (SaPC90).	 Treated	 lysate	 was	
centrifuged	 at	 17500	 x	 g	 for	 20	minutes	 and	 filtered	 through	 0.45	 μM	ministart	
filter	 disc	 (Sartorius	 stedim,	 Germany)	 prior	 to	 loading	 into	 Nickel	 affinity	
purification	column.	Nickel	affinity	chromatography	was	performed,	according	to	
the	 methods	 outlined	 in	 chapter	 2,	 section	 2.2.17.	 Protein	 concentration	 was	
determined	using	Bradford	assay.	Western	blot	analysis	was	performed	to	confirm	





coli	 reporter	 strain	 containing	-galactosidase	gene	 under	 the	 control	 of	 either	
SabioO	 or	 SabioY	 promoters,	 	 (JD26186_birA∷CAT_SabioO	 and	
JD26186_birA∷CAT_SabioY,	respectively)	was	performed	by	previously	established	






	 β-galactosidase	 assay	was	 performed	on	E.	coli	 reporter	 strain	 containing	
SaBirA	 D200E	 repressor	 in	 order	 to	 analyze	 its	 in	 vivo	 DNA	 binding	 activity.	
Activity	was	 compared	 against	 reporter	 strains	 containing	 SaBirA	wild-type	 and	




Apo-purified	 SaBirA	 D200E	 were	 buffer	 exchanged	 into	 200	 mM	
ammonium	 acetate	 using	 500	MWCO	 10,000	 Vivaspin®	 centrifugal	 concentrator	
(Vivaproducts,	 USA).	 Holo-SaBirA	 D200E	 was	 prepared	 by	 incubating	 the	 apo	
protein	with	500	µM	biotin,	1	mM	ATP	and	1	mM	MgCl2	at	37	°C	for	0.5	hour	prior	
to	 buffer	 exchange.	 Protein	 was	 diluted	 to	 10	 μM	 prior	 to	 analysis.	 MS	
measurements	were	performed	on	a	Synapt	HDMS	system	(Waters,	UK)	with	the	
sample	introduced	by	nano-electrospray	ionisation	in	positive	ion	MS	mode	from	
platinum-coated	 borosilicate	 capillaries	 prepared	 in-house.	 Instrument	
parameters	 were	 optimized	 to	 remove	 adducts	 while	 preserving	 non-covalent	
interactions,	and	were	as	follows;	capillary	voltage,	1.5	kV;	cone	voltage,	60	V;	trap	








5.3.1	 BPL199-bound	 SaBirA	 displayed	 the	 same	 structural	 changes	 as	
biotinyl-5ʹ-AMP-bound	SaBirA		
	 A	 series	 of	well-characterized	 ligand-induced	 conformational	 changes	 are	







residue	 that	 resides	 in	 the	 central	 domain	 of	 the	 neighboring	 subunit.	 Upon	
homodimer	 formation,	 the	 two	 N-terminal	 DNA	 binding	 domains	 are	 optimally	
positioned	for	an	interaction	with	DNA	[22].	In	order	to	compare	the	structure	of	
BPL199-bound	 SaBirA	 with	 the	 structure	 of	 SaBirA	 bound	 to	 biotinyl-5ʹ-AMP,	
structural	 alignment	 between	 the	 two	 available	 x-ray	 crystal	 structures	 was	
performed.	 The	 superposition	 showed	 that	 both	 BPL199-bound	 SaBirA	 and	 the	
holo-enzyme	 are	 perfectly	 aligned	 (RMSD	 =	 1.2Å),	 as	 shown	 in	 Figure3.	 	 This	
indicated	that	the	binding	of	BPL199	to	SaBirA	initiates	the	same	conformational	
changes	 that	 are	 required	 for	 dimerization	 as	 biotinyl-5ʹ-AMP	 and	 resulted	 in									
N-terminal	 position	 that	 is	 receptive	 to	 DNA	 binding.	 Based	 on	 this	 structure	










subunit	 is	 highlighted	 (blue	 and	 red).	 Residues	 located	 in	 the	 dimerization	
interface	 are	 shown	 (boxed	 diagram).	 N-terminal	 domain	 with	 helix-turn-helix	
motif	for	DNA	binding	of	each	subunit	is	highlighted	in	circle	(b.)	The	structure	of	
BPL199-bound	 SaBirA.	 Each	 SaBirA	 subunit	 is	 highlighted	 (gray	 and	 green)	 (c.)	








advance	 resistance	 study.	 These	 purified	 proteins	 were	 then	 used	 in	 EMSA	
analysis.	For	this	work,	it	was	critical	that	both	proteins	were	purified	in	their	apo-
form	as	any	co-purified	biotin	or	biotinyl-5ʹ-AMP	in	the	active	site	might	influence	





spectroscopy	 (nESI-MS)	 and	 Western	 blot	 probed	 with	 alexa488-conjugated	
streptavidin	 in	 order	 to	 assess	 the	 ability	 of	 the	 purified	 enzyme	 to	 biotinylate	
SaPC90.	
	The	result	showed	that	both	wild-type	and	SaBirA	D200E	were	purified	in	
their	 apo-forms,	 as	 co-purified	 biotinyl-5ʹ-AMP	 was	 not	 detected	 by	 nESI-MS	
(Table	1)	and	biotinylation	activity	failed	to	be	detected	by	western	blot	(Figure	
4).	In	addition,	nESI-MS	data	indicated	that	both	wild-type	and	D200E	SaBirA	were	
catalytically	 active,	 as	 biotinyl-5ʹ-AMP	 was	 detected	 when	 the	 apo-purified	
proteins	were	treated	with	biotin	and	ATP	(Table	1,	holo-SaBirA	and	holo-SaBirA	
D200E	respectively).	Furthermore,	nESI-MS	detected	two	different	molecular	mass	
for	 holo-SaBirA,	 which	 correspond	 to	 a	 monomer	 and	 a	 dimer	 form	 of	 SaBirA,	
suggesting	that	the	wild-type	protein	was	able	to	dimerize	in	solution.	In	contrast,	
a	single	molecular	mass	detected	for	holo-SaBirA	D200E,	which	correspond	to	that	














































Apo-D200E		 Monomeric	 37905	(-met)	 Monomeric,	no	ligand	 37910	





SaBirA.	 Summary	 of	molecular	weight	 and	 protein	 species	 detected	 by	 nESI-MS	
for	wild-type	SaBirA	and	SaBirA	D200E.	The	predicted	and	the	detected	molecular	








EMSA	 analysis	 was	 performed	 to	 determine	 the	 co-repressor	 activity	 of	
BPL199.	 The	 EMSA	 reaction	was	 performed	 by	 first	 incubating	 apo-SaBirA	with	
either	 BPL199	 or	 biotin	 and	 ATP	 to	 allow	 the	 synthesis	 of	 biotinyl-5ʹ-AMP	 (i.e.	
Holo-SaBirA).	Since	BPL199	was	reconstituted	in	100%	DMSO,	dilution	of	BPL199	
in	 the	 reaction	 buffer	 give	 a	 final	 DMSO	 concentration	 of	 2.5%	 (v/v).	 A	 control	
reaction	containing	biotin,	ATP	and	2.5%	(v/v)	DMSO	was	performed	in	parallel	to	
adjust	 for	 these	 binding	 conditions.	 DNA	 binding	 was	 tested	 against	 double	
stranded	 DNA	 probes	 containing	 either	 SabioO	 or	 SabioY	 promoter	 sequences,	
representing	the	promoters	that	regulate	the	biotin	biosynthesis	operon	and	biotin	
transporter,	 respectively.	 A	 control	 of	 the	 SaBirA-SabioO	 and	 SaBirA-SabioY	
interaction	in	the	presence	of	biotinyl-5ʹ-AMP	performed	in	binding	buffer	lacking	
DMSO	 obtained	 from	 separate	 experiment	 (as	 described	 in	 chapter	 4),	 was	 also	
included	in	the	figure	as	a	comparison	(Figure	5a-b)	
By	comparing	the	SaBirA-SabioO	interaction	in	binding	buffer	lacking	DMSO	




exact	 mechanism	 of	 how	 DMSO	 affects	 SaBirA-DNA	 interaction	 has	 not	 been	
investigated	 previously.	 However,	 the	 ability	 of	 DMSO	 to	 change	 the	 topological	
structure	of	DNA	has	been	well	documented	[23-25].		Therefore,	the	discrepancy	in	
binding	 affinity	 between	 the	 two	 buffers	 was	 not	 surprising,	 as	 the	 DNA	
confirmation	might	be	different	in	the	two	different	buffers.		
	 179	
Furthermore,	 	 the	 data	 also	 showed	 that	 BPL199-bound	SaBirA	 exhibited	
equipotent	 DNA	 binding	 to	 that	 of	 biotinyl-5ʹ-AMP-bound	 SaBirA	 (Figure	 5c-f).	
SaBirA	binding	 to	SabioO	 exhibit	 100%	binding	 at	 156	nM	SaBirA	 concentration	
for	 both	 BPL199	 and	 biotinyl-5ʹ-AMP	 (Figure	 5c-d).	 SaBirA	 binding	 to	 SabioY	
probe	 was	 2-fold	 weaker	 compared	 to	 SabioO,	 as	 the	 lowest	 concentration	 of	
protein	 required	 to	 produce	 maximum	 binding	 was	 312	 nM	 for	 both	 ligands	
(Figure	5e-f).	This	observation	confirmed	the	hypothesis	that	BPL199	induced	the	




and	 SabioY	 exhibit	 similar	 affinity	 (Figure	 5a-b).	 This	 result	 indicated	 that	 the	
change	 in	DNA	topology	caused	by	 the	DMSO	might	be	different	between	SabioO	
and	SabioY,	which	resulted	in	weaker	binding	of	SaBirA	to	SabioY.			
Overall,	 the	 binding	 affinities	 displayed	 by	 BPL199-bound	 SaBirA	 was	
similar	 to	 that	 of	 biotinyl-5ʹ-AMP-bound	 SaBirA	 under	 these	 conditions,	 which	










Figure	 5:	 EMSA	 of	 BPL199-bound	 SaBirA	 vs	 biotinyl-5ʹ-AMP-bound	 SaBirA.	
EMSA	was	 performed	 using	 10	 nM	 of	 44	 bp	 double	 stranded	 oligo	 and	 titrated	
wild-type	SaBirA	as	indicated,	in	strandard	binding	buffer	containing	50	mM	Tris	
pH	8.0,	50	mM	NaCl	and	5%	(v/v)	glycerol.	(a.)	Binding	reaction	of	SaBirA–SabioO	
and	 (b.)	 SaBirA-SabioY	 in	 the	 absence	 of	 DMSO	 were	 performed	 in	 separate	
experiment	as	comparisons	to	 the	binding	reaction	containing	2.5%	(v/v)	DMSO.	
Gel	shift	assay	in	standard	buffer	containing	2.5%	DMSO	is	outlined	in	(c.)	biotinyl-












(biotin	 transporter	 gene)	 using	 qRT-PCR.	 All	 data	 was	 normalized	 against	 16S	
rRNA.	 Relative	 mRNA	 expression	 was	 quantified	 and	 corrected	 against	 t	 =	 0,	
according	 to	 the	 Livak	method	 [18].	 The	 results	were	 then	 compared	with	 qRT-
PCR	 results	 from	 S.	 aureus	 treated	 with	 10	 nM	 biotin,	 obtained	 from	 separate	
experiment,	as	presented	in	Chapter	4.		
	 As	discussed	 in	Chapter	 4,	S.	aureus	 treated	with	10	nM	biotin	 showed	a	





level	 of	 repression	 was	 maintained	 throughout	 the	 time	 course.	 This	 results	











4x	 MIC,	 with	 the	 P	 values	 indicating	 a	 significant	 difference	 (p	 <	 0.0001).	 In	
addition,	 the	 results	 also	 indicated	 BPL199	 dose-dependent	 repression,	 as		
increasing	 the	 concentration	 of	 BPL199	 also	 resulted	 in	 increase	 in	 repression.	
This	 result	 confirmed	 that	 the	 mode	 of	 action	 of	 BPL199	 was	 consistent	 with	
BPL199	 binding	 to	 SaBirA	 and	 that	 BPL199	 is	 an	 active	 co-repressor	 in	 vivo.		

























gene	 expression.	 	 S.	 aureus	 	 treated	 with	 (a.)	 10	 nM	 biotin	 as	 previously	
presented	 in	chapter	4,	 	 (b.)	10nM	BPL199	and	(c.)	4x	MIC	or	3.9	μM	of	BPL	
199.	Relative	expression	was	calculated	by	using	the	Livak	method	[18].	Error	




was	 presented.	 10	 nM	 biotin	 only	 yielded	 2-fold	 repression	 at	 15	 minutes																			
(p	<	 0.01),	 5–fold	 at	 30	minutes	 (p	 <	 0.01)	 and	 6-fold	 at	 90	minutes	 (p	 <	 0.01)	
(Figure	7a).	The	effect	of	BPL199	on	SabioY	gene	expression	was	also	tested	at	10	
nM	 and	 compared	 to	 the	 repression	 induced	 by	 biotin.	 The	 result	 showed	 that	
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the	 rate	 of	 uptake	 between	 BPL199	 and	 biotin	 could	 be	 different,	 which	 could	
influence	 the	 level	 of	 repression	 observed.	 	 Nonetheless,	 these	 results	 further	
indicated	that	BPL199	was	clearly	able	to	act	as	a	co-repressor	and	promote	gene	
















Figure	 7:	 qPCR	 analysis	 to	 determine	 the	 effect	 of	 BPL199	 on	 SabioY	 gene	
expression.	 	S.	aureus	 	 treated	with	;	(a.)10	nM	biotin	as	previously	presented	in	
chapter	4	and	(b.)	10	nM	BPL199.	Relative	expression	was	calculated	by	using	the	

















































EMSA.	 DNA-binding	 of	 holo-SaBirA	 D200E	 was	 carried	 out	 in	 binding	 buffer	
containing	 1mM	 ATP,	 1mM	 MgCl2	 and	 100	 μM	 biotin.	 For	 analysis	 of	 the	 apo-
enzyme	 biotin	 was	 omitted	 from	 the	 binding	 buffer.	 These	 EMSA	 results	 are	
presented	 in	 Figure	 8	 and	 compared	 to	 the	 EMSA	 analysis	 of	 wild-type	 SaBirA	
presented	in	Figure	5a-b.	From	the	data,	it	was	clear	that	apo-SaBirA	D200E	binds	
weaker	to	both	SabioO	and	SabioY,	compared	to	the	holo-protein.		This	result	is	in	
agreement	with	wild-type	 SaBirA,	where	weaker	 interaction	with	 DNA	was	 also	
observed	for	apo-SaBirA,	compared	to	holo-SaBirA	[16,	30].		
The	 results	 also	 indicated	 that,	 for	 both	 apo	 and	 holo	 SaBirA	 D200E,		
complete	 binding	 to	 SabioY	 failed	 to	 be	 obtained	 at	 the	 highest	 protein	
concentration,	 as	 indicated	 by	 the	 appearance	 of	 the	 unbound	 DNA	 (Figure	 8b	
and	8d).	Conversely,	100%	binding	was	observed	to	the	SabioO	probe	at	625	nM	
and	78	nM	for	apo	and	holo-SaBirA	D200E,	respectively.	This	result	suggested	that,	
unlike	 the	 wild-type	 protein	 that	 has	 equivalent	 affinity	 for	 SabioO	 and	 SabioY	
(Chapter	 4,	 Figure	 9),	 the	 SaBirA	 D200E	 interaction	 with	 SabioY	 was	
compromised.	 The	 consequence	 of	 this	 is	 that	 bacteria	 harboring	 the	 D200E	
mutation	 would	 have	 greater	 expression	 of	 BioY,	 allowing	 the	 bacteria	 to	
accumulate	biotin	from	the	environment	more	readily	compared	to	the	wild-type	
strain.	It	is	possible	that	this	mechanism	contributed	to	the	bacteria’s	resistance	to	
BPL199.	 	 Furthermore,	 by	 comparing	 the	 EMSA	 results	 of	 holo-SaBirA	 D200E	
binding	 to	 SabioO	 and	 SabioY	 (Figure	 8c-d),	 to	 the	 EMSA	 results	 of	 wild-type	
SaBirA	 binding	 to	 the	 same	 probes	 (presented	 in	 chapter	 4,	 Figure	 9b-c,	
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Overall,	 these	 results	 showed	 that	 the	 binding	 of	 SaBirA	 D200E	 to	 both	
SabioO	 and	 SabioY	 generated	 a	 weaker	 interaction	 compared	 to	 the	 wild-type	






























	 To	 determine	 the	 DNA	 binding	 activity	 of	 SaBirA	 D200E	 in	 vivo,	 an	
integration	 vector	 containing	 the	 gene	 encoding	 SaBirA	 D200E	was	 constructed	
(Figure	 9a)	 and	 integrated	 into	 the	 chromosome	 of	 E.	 coli	 reporter	 strains	
JD26186_birA::CAT_SabioO	and		JD26186_birA::CAT_SabioY,	containing	SabioO	and	
	 188	
SabioY	 regulated	 lacZ	 reporter	 genes,	 respectively.	 	-galactosidase	activity	was	
then	 measured	 to	 assess	 in	 vivo	 DNA	 binding	 activity	 of	 SaBirA	 D200E	 and	
compared	 to	 wild-type	 SaBirA	 and	 SaBirA	 F123G.	 The	 expression	 of	 β-
galactosidase	 from	 each	 reporter	 strain	 was	 normalized	 by	 subtracting	 the	
background	 values	 generated	 by	 the	 control	 strain	 containing	 no	 promoter	
sequence.	The	results	were	then	graphed	(Figure	9b-9c)	and	the	concentration	of	
biotin	 required	 to	 generate	 half-maximum	 repression	 (KR)	 was	 calculated	 and	
presented	 in	Table	 2.	 The	 result	 showed	 that	wild-type	SaBirA	 interaction	with	
SabioO	promoter	was	the	strongest	(KR		=	4.3	±	1.9	nM)	and	about	2-fold	weaker	
interaction	was	observed	for	interaction	with	SabioY	(KR		=	8.2	±	0.7	nM).	SaBirA	
D200E	 exhibited	 a	 similar	 repression	 profile	 as	 SaBirA	 F123G	 (Figure	 9b-9c).	
SaBirA	F123G	interaction	with	SabioO	exhibited	a	3.6-fold	lower	KR	value	(15.3	±	
3.5	 nM)	 compared	 to	 the	wild-type	 (p	<	0.01).	 This	 result	was	 similar	 to	SaBirA	
D200E	binding	 to	SabioO,	where	 the	KR	value	 (13.9	±	3.4	nM)	was	3.2-fold	 lower	
compared	to	the	wild-type	(p	<	0.01).	In	stark	contrast,	binding	of	SabioY	 to	both	
SaBirA	F123G	and	SaBirA	D200E	 failed	 to	give	KR	values	with	 the	concentrations	
tested	 in	 this	 assay	 (KR	≥	 500nM).	This	 suggested	 that	 the	biotin	 requirement	 to	
generate	full	repression	is	higher	for	these	mutants.	Overall,	 these	data	 indicated	
that	 both	 SaBirA	 mutants	 required	 higher	 biotin	 concentration	 to	 generate	 full	
repression	 of	 SabioO	 and	 SabioY	 and	 that	 the	 biotin	 level	 required	 to	 repress	
SabioY	is	significantly	higher	compared	to	SabioO.	
	 Based	 on	 the	 in	 vivo	 data	 obtained,	 I	 proposed	 that	 the	 weaker	 DNA	
interaction	 displayed	 by	 both	 SaBirA	 mutants	 is	 an	 indication	 of	 higher	 biotin	
requirement	of	these	mutants	to	form	the	reaction	intermediate.	It	 is	known	that	







D200E	 would	 be	 apparent	 at	 higher	 biotin	 concentrations,	 higher	 than	 500	 nM	
tested	 in	 this	assay.	This	hypothesis	 is	 supported	by	 the	EMSA	result,	where	 the	
concentration	of	biotin	 in	 the	binding	buffer	was	 fixed	at	100	μM,	 the	binding	of	
SaBirA	D200E	to	DNA	was	evident	as	indicated	by	the	band	shifts	on	the	gel.		
	 Furthermore,	EMSA	analysis	of	the	apo-SaBirA	D200E	indicated	that	DNA-
binding	 also	 occurred	 in	 the	 absence	 of	 biotin.	However,	 in	 the	 in	vivo	 assay,	 no	
repression	was	observed	at	low	biotin	concentrations	(≤1	nM).	It	is	possible,	that	




expression	 of	 SaBirA	 in	 the	 in	 vivo	 system	 produces	 similar	 concentration	 of	
protein	 as	 the	 predicted	 BirA	 concentrations	 it	 was	 not	 surprising	 that	 no	
repression	 at	 lower	 biotin	 concentration	 (≤1	 nM)	was	 observed.	 Therefore,	 it	 is	
reasonable	 to	 conclude	 the	 repression	 generated	 by	 this	mutant	 is	 a	 function	 of	
repressor	 concentration	 and	 biotin	 concentration.	 Experiments	 determining	 the	







Figure	9:	 In	vivo	 β-galactosidase	 assay	 of	SaBirA	D200E	 compared	 to	Wild-
type	SaBirA	and	SaBirA	F123G.	In	vivo	assay	was	carried	out	in	E.	coli	reporter	
strain	as	described	in	chapter	3.	(a.)	Integration	vector	containing	SaBirA	D200E.	
-galactosidase	 assay	 showing	 the	 repression	 of	 (b.)	 SabioO	 and	 (c.)	 SabioY	 by	
SaBirA	 D200E	 (green),	 SaBirA	 F123G	 (black)	 and	 SaBirA	 wild-type	 SaBirA	






















to	 reach	 half-maximum	 repression	 (KR)	 ±	 S.E.M	was	 calculated	 from	 the	 results	






repressor	 function	of	SaBirA	was	 investigated.	EMSA	analysis	 indicated	that	both	
biotinyl-5ʹ-AMP	 and	 BPL199	 was	 able	 to	 induce	 DNA-binding	 and	 generated	
similar	affinity,	as	seen	in	Figure	5.	In	addition,	qRT-PCR	analysis	indicated	that	S.	
aureus	 treated	 with	 biotin	 exhibited	 stronger	 SabioD	 and	 SabioY	 repression	
compared	to	S.	aureus	treated	with	BPL199,	suggesting	that	although	BPL199	was	
an	active	 co-repressor	 in	vivo,	 the	 level	 of	 repression	generated	by	 this	 inhibitor	
was	still	less	compared	to	biotin.	Overall,	in	this	chapter,	the	co-repressor	ability	of	
BPL199	has	been	validated	both	in	vitro	and	in	vivo.	
Furthermore,	 in	 this	 chapter,	 the	 transcriptional	 repressor	 activity	 of	
SaBirA	 D200E	 mutant	 generated	 from	 the	 advance	 resistance	 study	 was	 also	
investigated	 and	 compared	 to	 the	 wild-type	 protein.	 The	 EMSA	 result	 indicated	










Furthermore,	 the	KR	value	generated	by	SaBirA	D200E	 	binding	 to	SabioO	
was	 lower	 by	 3.2-fold	 compared	 to	 the	KR	 value	 generated	 by	wild-type	 protein	
binding	to	the	same	probe	(p	≤	0.01).	This	suggests	that	binding	of	SaBirA	D200E	
to	SabioO	 is	weaker	 compared	 to	 the	wild-type.	Based	on	 this	 data	 and	 the	data	
described	 above,	 it	 was	 reasonable	 to	 conclude	 that	 S.	 aureus	 BPL199-resistant	
mutant	 bearing	 the	 SaBirA	 D200E	 mutation	 would	 have	 a	 higher	 rate	 of	
transcription	of	both	biotin	biosynthesis	and	biotin	 transporter,	compared	to	 the	




in	 S.	 aureus	 is	 similar	 to	E.	 coli,	 the	mutant	 strain	 containing	 the	 SaBirA	 D200E	
would	 have	 to	 accumulate	 biotin	 at	 ≥	 5-fold	 higher	 concentration	 than	 the	




interface	of	SaBirA,	 (D200E)	weakens	 the	 repressor-DNA	 interaction,	possibly	 to	
facilitate	 the	 S.	 aureus	 resistant	mutant	 to	 acquire	more	 biotin	 through	 both	 de	
	 193	
novo	 synthesis	 and	 biotin	 transport,	 compared	 to	 the	wild-type	 strain.	 The	 data	
also	suggested	that	biotin	transport	was	the	preferred	mechanism	to	obtain	biotin	
over	de	novo	synthesis.	Further	studies	are	still	required	 in	order	to	validate	this	
hypothesis	 further,	 for	 example,	 by	 comparing	 the	 level	 of	 intracellular	 biotin	
between	wild-type	SaBirA	and	D200E	mutant,	as	well	as	biotin	uptake	studies	and	
transcriptomics	 studies	 comparing	 the	 level	 of	 biotin	 biosynthesis	 transcripts	
between	 the	 two	 strains.	 The	 accumulation	 of	 intracellular	 biotin	 may	 be	
necessary	to	outcompete	the	toxic	compound	(in	this	case,	BPL199)	in	occupying	
the	 active	 site	 of	 SaBirA.	 This	 competitive	 binding	 mechanism	 was	 common	 in	
resistance	development	 involving	vitamin	biosynthesis,	as	suggested	by	previous	
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	 The	 role	 of	 EcBirA	 as	 a	 transcriptional	 repressor	 has	 been	 well	
characterized	 (reviewed	 in	 [1,	 2]).	 In	 contrast,	 the	 transcriptional	 repressor	
function	of	SaBirA	has	not	been	explored	as	extensively	as	EcBirA.	Previously,	a	
computational	study	performed	by	Rodionov	et	al	[3]	predicted	that	as	opposed	
to	 EcBirA,	 which	 only	 regulates	 biotin	 biosynthesis	 operon,	 SaBirA	 regulates	
multiple	 genes	 including	 the	 biotin	 biosynthesis	 operon	 (SabioO),	 biotin	
transporter	(SabioY)	and	homologs	of	long-chain	fatty	acid	CoA	ligase	and	acetyl	
CoA	acetyltransferase	(SayhfS-SayhfT).	Since	then,	few	studies	have	investigated	
the	 interaction	 between	 SaBirA	with	 SabioO	 [4-6].	 However,	 the	 interaction	 of	
SaBirA	with	SabioY	and	SayhfS-SayhfT	has	not	been	elucidated	experimentally.	In	
this	 study,	 I	 have	 confirmed	 the	 role	 of	 SaBirA	 as	 a	 biotin-responsive	
transcriptional	 repressor	 for	 SabioO,	 SabioY	 and	 SayhfS-SayhfT,	 using	 both	 in	
vitro	 and	 in	 vivo	 analyses.	 The	 results	 obtained	 from	 this	 study	 suggest	 a	
hierarchy	 of	 SaBirA-regulated	 genes,	 with	 biotin	 biosynthesis	 as	 the	 most	
stringently	 controlled	 over	 the	 other	 targets,	 possibly	 to	 conserve	 energy	 as	
biotin	synthesis	is	metabolically	costly	[7].		
	 The	molecular	interaction	of	SaBirA	with	DNA	was	also	investigated	and	
compared	 to	 that	 of	 EcBirA.	 Extensive	 studies	 on	 EcBirA	 revealed	 that	
homodimerization	is	a	pre-requisite	 for	DNA	binding	(reviewed	in	[1]	and	[8]).		





These	 authors	 also	 showed	 that	 the	 F123G	 mutation	 within	 the	 dimerization	
interface	abolished	dimerization	of	SaBirA	and	resulted	in	a	3-fold	lower	Km	for	
biotin	compared	to	the	wild-type.	
	 In	vivo	 and	 in	vitro	 data	 obtained	 from	 this	 present	 study	 revealed	 that	
SaBirA	F123G	was	able	to	bind	DNA	and	dimerize	(chapter	4,	Figure	6,	8	and	10).	
Interestingly,	 native	 nESI-MS	 data	 confirmed	 that	 this	 mutant	 is	 primarily	




bind	DNA,	 as	 shown	 in	 cross-linking	 experiments.	 Given	 the	 high	 dimerization	
constant	 of	 apo-SaBirA	 (KD2-1	 =	 29.0	 μM),	 it	 was	 predicted	 that	 in	 a	 cellular	
context,	 apo-SaBirA	 is	 largely	monomeric.	 Therefore,	 SaBirA	 F123G	 could	 also	
represent	 the	 apo-protein	 in	 the	 in	 vivo	 environment.	 Therefore,	 it	 was	 not	
surprising	 that	both	apo	and	SaBirA	F123G	exhibited	 the	same	outcome	 in	 the	
native	nESI-MS	and	cross-linking	experiments.	Although	apo-SaBirA	could	bind	




6.1.2	 SaBirA	 ability	 to	 bind	 as	 apo	 and	 holo-form	 is	 similar	 to	 other	
transcription	factors.	




their	 holo	 forms	 (37%	 holo-repressor,	 42%	 by	 holo-activators	 vs.	 15%	 apo-
repressor	and	3.25%	by	apo-activators).	Similar	work	on	S.	aureus	transcription	
factors	has	not	been	reported.	However,	it	is	possible	that	apo-regulators	might	
be	 common	 in	S.	aureus.	 It	 is	 also	possible	 that	 transcription	 factors	 can	act	 in	
both	apo	and	holo-form	such	as	SaBirA.	Moreover,	certain	transcription	factors,	
such	 as	 the	 acyl-CoA–responsive	 activator,	 FadR,	 displays	 the	 ability	 to	 act	 as	
apo-repressor.	 	 FadR	 interaction	with	 ligand	acyl-CoA	disrupted	 the	apo-dimer	





the	 expression	 of	 the	 virulence	 gene	 prfA.	 Like	 SaBirA,	 CodY	 regulates	 the	
synthesis	of	its	own	co-repressor,	by	regulating	the	ilvD	operon	that	encodes	for	
isoleucine	 synthesis	 [11].	 Lobel	et	al	 showed	 that	Listeria	monocytogenes	CodY	
was	able	to	bind	a	DNA	probe	containing	the	promoter	sequence	as	both	apo	and	
holo-forms	with	different	affinity.	These	authors	revealed	that	when	isoleucine	is	
abundant,	 holo-CodY	 binds	 to	 the	 ilvD	 operon	 and	 codY,	 to	 act	 as	 a	 repressor.	
However,	when	isoleucine	is	scarce,	apo-CodY	binds	to	the	prfA	promoter	to	act	
as	 an	 activator.	 These	 authors	proposed	 that	during	host	 invasion,	 the	 level	 of	
branch	amino	acids,	such	as	isoleucine	is	limited.	This	is	the	cue	for	the	bacteria	
to	 activate	 its	 virulence	 gene,	 prfA.	 	 Although	 there	 was	 no	 evidence	 of	 apo-
SaBirA	 to	 act	 as	 a	 transcriptional	 activator,	 both	 CodY	 and	 SaBirA	 show	 the	





Furthermore,	 recent	 work	 on	 MerR	 family	 of	 transcription	 factors	
revealed	a	novel	mechanism	 involved	 in	apo	and	holo	protein	 interaction	with	
DNA.	 A	 study	 conducted	 by	 Philips	 et	 al	 on	 CueR	 protein,	 a	 member	 of	 MerR	
family,	 showed	 that	 in	 a	 repressor	 conformation,	 apo-CueR	 binds	 DNA	 and	
causes	DNA	bending	that	prevents	contact	between	the	-10	elements	and	the	σ2	
domain	of	RNA	polymerase	(RNAP)	by	 forcing	the	-10	elements	away	from	the	
σ2	 domain	 by	 40Å	 [14].	 Upon	 ligand	 binding,	 the	 protein	 undergoes	 further	
conformational	change	and	introduces	major	kinks	to	the	DNA,	bringing	the	-10	
elements	 closer	 to	 the	 σ2	 subunit	 of	 RNAP,	 completing	 the	 transformation	 of	
CueR	from	transcriptional	repressor	to	an	activator	[14].	Counago	et	al	provided	
similar	 findings	 from	 their	 work	 on	 another	 MerR	 protein,	 HiNmlR.	 These	
authors	 revealed	 that	 apo-HiNmlR	binds	 to	 sequence	between	 the	 -10	 and	 -35	
sites	of	the	operator	region	to	act	as	a	repressor.	Ligand	binding	to	the	protein	
induced	DNA	twisting	leading	to	re-arrangement	of	the	-10	and	-35	orientation,	
allowing	 access	 for	 RNA	 polymerase	 to	 bind	 on	 the	 opposite	 face	 of	 the	 DNA	
helix	to	HiNmlR	and	form	a	complex	to	activate	transcription	[15].		





bent	 in	 solution	but	became	 linearized	upon	SaBirA	binding	 [4].	However,	 this	
SAXS	 experiment	 was	 confined	 to	 SabioO	 and	 did	 not	 include	 the	 SabioY	 or	
	 202	
SayhfS-SayhfT	 DNA	 probes.	 Given	 the	 different	 binding	 hierarchy	 exhibited	 by	
SaBirA	towards	these	three	target	promoters,	and	that	the	sequence	comprising	
these	 promoters	 are	 different,	 similar	 SAXS	 experiment	 should	 also	 be	
performed	 on	 SabioY	 and	 SayhfS-SayhfT	 probe.	 Future	 experiments	 involving	
SAXS	 analysis	 on	 these	 probes	would	 determine	whether	 the	 changes	 in	 DNA	
conformation	 exhibit	 by	 sabioY	 and	 SayhfS-SayhfT	 is	 the	 same	 as	 SabioO,	 or	
whether	 DNA	 conformation	 varies	 between	 these	 probes.	 The	 consequence	 of	





	 	High-resolution	molecular	 structure	will	provide	crucial	 information	on	
the	SaBirA-DNA	interaction,	including	details	on	DNA	bending.	To	date,	a	crystal	
structure	 of	 class	 II	 BPL	 in	 complex	 with	 DNA	 has	 not	 been	 reported.	 Our	
laboratory,	 in	collaboration	with	Prof.	Matthew	Willce	(Monash	University)	has	
attempted	 to	grow	crystals	of	SaBirA	 in	 complex	with	SabioO,	without	 success.	
Hundreds	 of	 crystallization	 conditions	 were	 trialed	 with	 only	 two	 yielding	
crystals.	 However,	 these	 crystals	 produced	 either	 weak	 or	 no	 diffraction	 data	
[17].	 	 Increasing	 the	 stability	 of	 the	 protein-DNA	 complex	 may	 enhance	 the	
crystallization	of	the	complex	[18].	Future	studies	should	focus	on	improving	the	
stability	of	 the	protein-DNA	complex	 such	as	 shortening	 the	 length	of	 the	DNA	
probe	and	using	alternative	DNA	sequence	from	SabioY	and	SayhfS-SayhfT.	
	In	 addition,	 the	 recent	 discovery	 of	 a	 EcBirA	 super-repressor	 mutant	
(EcBirA	G154D)	by	Chakravarrty	and	Cronan	suggested	that	this	super-repressor	
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mutant	 could	 increase	 the	 chances	 of	 obtaining	 stable	 complexes	 for	
crystallization	[19].	An	equivalent	mutation	to	generate	super-repressor	SaBirA	
could	 also	 be	 used	 in	 future	 crystallization	 trials	 in	 order	 to	 improve	 the	
diffraction	of	the	crystals.	In	this	study,	I	have	predicted	the	equivalent	mutation	
in	 SaBirA	 to	 be	 A158D,	 using	 structural	 alignment	 and	 sequence	 alignment.	 I	
have	 generated	 this	 mutant	 protein	 using	 site-directed	 mutagenesis	 and	
successfully	 purified	 this	 protein.	 However,	 the	 purified	 protein	 did	 not	 show	
any	super-repressor	activity,	as	tested	in	EMSA	(data	not	shown).	Future	studies	
should	 focus	 on	 generating	 SaBirA	 super-repressor	 mutants	 by	 using	 other	
techniques,	such	as	random	mutagenesis.		
	 Furthermore,	 in	 addition	 to	 high-resolution	 molecular	 structure	 data,	
crucial	 information	 that	 is	 still	 lacking	 in	 the	 experimental	 validations	 is	 the	
identification	of	 the	-35	and	-10	promoter	site	of	SaBirA	target	promoters.	The	
location	 of	 EcBirA	 binding	 sites	 within	 the	 promoter	 region	 has	 been	 well-
defined.	 It	 is	 known	 that	 EcBirA	 binding	 sites	 overlap	 with	 the	 -35	 and	 -10	
elements	 of	 two	 face-to-face	 promoters	 that	 regulate	 the	 biotin	 biosynthesis	




delineate	 the	 -35	 and	 -10	 elements	 of	 the	 promoter	 site	 relative	 to	 SaBirA	








	 It	 is	 known	 that	 the	 biotin-dependent	 enzyme,	 ACC,	 catalyzes	 the	 first	
limited	 step	 in	 fatty	 acid	 biosynthesis	 [2,	 22].	 At	 the	 same	 time,	SaBirA	 is	 also	




ATP-dependent	 process	 that	 requires	 fatty	 acids	 [23]	 (encoded	 by	 SayhfS,	
http://www.genome.jp/kegg-bin/show_pathway?ec00061+6.2.1.3).	 The	 SayhfS	
gene	 is	 located	 within	 the	 same	 operon	 as	 another	 enzyme,	 acetyl	 CoA	
acetyltransferase,	 an	 enzyme	 that	 is	 involved	 in	 many	 metabolic	 pathways,	
including	fatty	acid	degradation	and	amino	acid	metabolism	(encoded	by	SayhfT,	
http://www.genome.jp/dbget-bin/www_bget?2.3.1.9).	 Therefore,	 a	 certain	
dynamic	 has	 to	 exist	 between	 maintaining	 the	 level	 of	 biotin	 and	 fatty	 acid	
biogenesis,	 with	 SaBirA	 being	 the	 central	 regulator	 of	 these	 events.	 Further	
studies	 are	 therefore	 required	 to	 elucidate	 the	 correlation	 between	 biotin	 and	
fatty	acid	metabolism.	
	 Furthermore,	 the	 ability	 of	 bacteria	 to	 modify	 their	 membrane	
composition	 through	the	altered	synthesis	of	various	 fatty	acids	can	contribute	
to	a	successful	infection	[24,	25].	Considering	the	intimate	role	of	biotin	in	fatty	
acid	 biosynthesis,	 future	 work	 should	 focus	 on	 metabolomics	 profiling	 of	 S.	
aureus	 fatty	 acid	 composition,	 from	 bacteria	 that	 are	 subjected	 to	 biotin-




was	 performed	 as	 part	 of	 this	 project.	 However,	 the	 results	 obtained	 from	 a	
sample	 size	of	n	=	3	were	 inconclusive	 (data	not	 shown).	A	 larger	 sample	 size	
would	be	required	to	obtain	more	definitive	data.	In	addition,	as	the	composition	
of	 fatty	acids	will	 influence	the	fluidity	of	the	bacterial	membrane,	experiments	
measuring	membrane	 fluidity	 of	 S.	 aureus	 grown	 in	 these	 biotin-depleted	 and	
biotin-replete	conditions	should	also	be	conducted	to	provide	insights	into	how	
biotin	 affects	 viscosity	 of	 the	membrane	 and,	 subsequently	 the	 function	 of	 the	
membrane,	 such	 as	 passive	 permeability,	 active	 transport	 and	 protein:protein	
interactions	 [24].	 This	 knowledge	 would	 then	 aid	 in	 understanding	 the	 rapid	
adaptation	ability	of	S.	aureus	during	pathogenesis	[26-28].		
	 Evidence	of	the	association	between	biotin	and	virulence	in	other	bacteria	
have	 been	well	 documented	 [29-32].	 Therefore,	 future	 studies	 should	 address	
the	relationship	between	biotin	and	virulence	 in	S.	aureus.	The	use	of	S.	aureus	
mutants	with	a	deleted	SabioY	gene	(ΔSabioY)	or	a	deleted	biotin	synthesis	gene	
(for	 example,	 ΔbioC)	 will	 be	 useful	 to	 aid	 these	 future	 studies.	 In	 addition,	 S.	
aureus	with	deleted	SayhfS	and	SayhfT	genes	should	also	be	utilized	in	order	to	
gain	more	understanding	of	 the	roles	of	 these	proteins	 in	S.	aureus	metabolism	
and	how	they	contribute	to	virulence.		Comparing	the	ability	of	these	mutants	to	
establish	an	infection	in	animal	models	should	be	performed.	Moreover,	the	use	
of	 biotin-deficient	mice	 [33,	 34]	 can	 also	 be	 considered	 in	 order	 to	 assess	 the	











As	 an	 alternative	 to	 S.	 aureus	 transformation,	 E.	 coli	 reporter	 strains	 were	
generated	 in	 this	 study,	 as	 described	 in	 chapter	 3.	 These	 reporter	 strains	
provided	 an	 efficient	 tool	 to	 study	 SaBirA	 repressor	 function,	 in	 vivo.	 The	
integration	 vectors	 generated	 in	 this	 study	 were	 modified	 by	 introducing	
particular	 restriction	 sites	 to	 enable	 cloning	 of	 other	 target	 promoters	 and	
repressors.	 In	 addition,	 chromosomal	 integration	 procedures	 used	 to	 integrate	
these	vectors	into	the	genome	has	also	been	validated	to	be	highly	efficient	[39].	
Therefore,	 the	 assembly	 of	 reporter	 strain	 provided	 by	 this	 system	 is	
straightforward	 and	 offers	 high	 transformation	 efficiency	 of	 site-specific	
genomic	integration.	This	system	can	therefore	be	applied	to	study	other	biotin-
regulated	 transcription	 factors.	 For	 example,	 transcription	 factors	 from	
organisms	 with	 class	 I	 BPL	 such	 as	 BioR	 from	 Brucella	 melitensis	 [40],	 other	





There	 has	 been	 much	 interest	 in	 understanding	 vitamin	 synthesis	
pathways	in	bacteria,	especially	as	drug	targets	for	new	antibiotics.	For	example,	
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thiamine	 (vitamin	 B1),	 folic	 acid	 (vitamin	 B9)	 and	 nicotinic	 acid	 (vitamin	 B3)	
have	 all	 been	 the	 subject	 of	 antibiotic	 development	 [44].	 Just	 like	 biotin,	 these	
vitamins	are	essential	requirements	to	support	bacterial	growth	and	deprivation	
of	 these	 vitamins	 could	 be	 detrimental.	 Therefore,	 targeting	 the	 utilization	 of	
biotin	through	the	inhibition	of	protein	biotinylation	is	also	an	attractive	target	
for	 new	 antibiotic	 development.	 One	 compound	 discovered	 in	 our	 laboratory,	
BPL199,	 is	a	promising	pre-clinical	candidate	 for	antibiotic	discovery	against	S.	
aureus.	BPL199	binds	SaBirA	with	 a	 low	nM	Ki	 value,	 inhibits	 the	 growth	 of	S.	
aureus	with	an	MIC	of	0.5	μg/mL	and	exhibits	low	toxicity	towards	mammalian	
cells	 and	 a	 mouse	 model	 (unpublished	 data).	 However,	 whilst	 extensive	
biochemical	 and	 structural	 analysis	 of	 BPL199	 as	 an	 enzyme	 inhibitor	 on	 the	
catalytic	 function	 has	 been	 performed	 in	 our	 laboratory	 (unpublished	 result),	
BPL199	function	as	a	co-repressor	has	not	been	previously	explored.	
	In	 this	 study,	 the	 effect	 of	BPL199	on	SaBirA’s	DNA-binding	 ability	 and	
consequently,	 gene	 regulation,	 was	 investigated	 using	 in	 vitro	 and	 in	 vivo	
methods.	 Comparison	 of	 BPL199-bound	 SaBirA	 and	 biotinyl-5ʹ-AMP-bound	
SaBirA	revealed	a	high	degree	of	structural	homology	(RMSD	=	1.2Å),	suggesting	
that	 the	SaBirA-BPL199	 complex	would	 be	 receptive	 to	 binding	DNA.	 Gel-shift	
assays	 indeed	confirmed	 the	DNA-binding	activity	of	BPL199-bound	SaBirA.	 In	
addition,	qPCR	analysis	performed	on	S.	aureus	treated	with	BPL199,	confirmed	
that	 BPL199	 could	 down	 regulate	 the	 expression	 of	 biotin	 biosynthesis	 gene,	
SabioD,	as	well	as	the	gene	encoding	biotin	transporter	protein,	SabioY.		Based	on	




enzyme	 inhibitor	 and	 a	 co-repressor,	 the	 development	 of	 resistance	 to	 this	
inhibitor	 potentially	 is	 more	 difficult	 compared	 to	 other	 inhibitors	 that	 only	









of	 S.aureus	were	 generated	 by	 serial	 passage	 in	 sub-optimal	 concentrations	 of	
BPL199.	 The	 genome	 of	 one	 isolated	 mutant	 was	 sequenced	 and	 the	 result	




performed	 by	 incorporating	 SaBirA	 D200E	 into	 the	 in	 vivo	 reporter	 assay,	
alongside	the	wild-type	SaBirA	and	SaBirA	F123G.	




SaBirA	 dimer	 [5].	 Therefore,	 it	 was	 proposed	 that	 these	 two	 mutants	 would	
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behave	 similarly	 in	 the	 in	 vivo	 reporter	 assay.	 Both	 SaBirA	D200E	 and	 SaBirA	
F123G	did	indeed	exhibit	higher	requirements	for	biotin	compared	to	the	wild-







to	 outcompete	 the	 binding	 of	 the	 toxic	 compound	 to	 the	 proteins	 [46-48].	 For	
example,	 resistance	 to	 the	 thiamanine	 analogue,	 pyrithiamine,	 in	 Bacillus	
subtillis,	 E.	 coli	 and	 Aspergillus	 oryzae	 was	 shown	 to	 have	 occurred	 by	 de-
repression	of	thiamine	biosynthesis	[46].	In	another	example,	high	intracellular	
concentration	 of	 thiamine	 accumulated	 through	 thiamin	 import	 and	 de	 novo	
synthesis	 reversed	 4-amino-2-trifuloromethyl-5-hydroxymethylpyrimine	 (CF3-
HMP)	 inhibition	 on	 thiamine	 biosynthesis	 enzyme,	 ThiE	 [47].	 Likewise,	
resistance	 to	 roseoflavin,	 an	 inhibitor	of	 riboflavin	 (vitamin	B2)	 synthesis,	was	
through	 the	 over-production	 of	 riboflavin	 [48].	 Based	 on	 the	 previous	 studies	
outlined	above,	it	is	possible	that	high	intracellular	levels	of	biotin	are	required	
to	reverse	the	effect	of	BPL199	by	outcompeting	the	binding	of	this	compound	to	
the	 SaBirA	 target.	 It	 is	 therefore	 logical	 that	 the	 D200E	 resulted	 in	 weaker	






	 Overall,	 this	 study	has	 confirmed	 the	 role	of	SaBirA	as	 a	 transcriptional	
repressor	 that	 regulates	 biotin-related	 genes,	 as	 well	 as	 the	 SayhfS-SayhfT	
operon	involved	in	fatty	acid	metabolism.	In	this	study,	I	have	also	developed	an	
in	vivo	 reporter	 assay	 that	 could	be	used	as	 a	 tool	 to	 study	other	DNA-binding	
proteins.	 Future	 studies	 on	 solving	 the	 structure	 of	 SaBirA-DNA	 complex	 still	
needs	to	be	performed	in	order	to	provide	detail	understanding	of	the	molecular	
interaction	 between	 this	 transcriptional	 repressor	 and	 DNA.	 This	 study	 also	
revealed	 that	 the	 resistance	mechanism	 to	BPL199	 involves	 a	mutation	within	
the	 dimerization	 interface,	 of	 SaBirA,	which	 result	 in	 reduced	 affinity	 for	 DNA	
and	higher	requirement	for	biotin.	Experiments	to	determine	determining	the	Km	
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